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The Nuclear Receptor Co-repressor (N-CoR) is a key component of the 
generic multi-protein co-repressor complex involved in transcriptional control 
mediated by various transcription factors. Our laboratory previously demonstrated 
an important role of the misfolded conformational dependent loss (MCDL) of N-
CoR in Acute Promyelocytic Leukemia (APL). Encouraged by the results in APL, 
we analyzed the status of N-CoR in other AML subtypes and identified an APL- 
like MCDL of N-CoR in primary patient specimens and secondary leukemic cell 
lines derived from Acute Monocytic Leukemia (AML designated as M5 in the 
FAB-classification-AML-M5). Here we report the in depth analysis of the 
molecular mechanism underlying the MCDL of N-CoR and its implication in the 
malignant growth and transformation of AML-M5 leukemic cells. We also 
explored the potential of the MCDL of N-CoR as a therapeutic target in AML-
M5.  
The MCDL of N-CoR was found in AML-M5 derived cell lines and an 
APL-like N-CoR cleaving activity was observed in both AML-M5 primary 
patient specimens and secondary leukemic cell lines. Activation of Akt inversely 
correlated with the status of MCDL of N-CoR in a comparative protein kinase 
array analysis. These observations implied a possible role of Akt in the MCDL of 
N-CoR in AML-M5. Akt is an important regulator of cell survival and initiates 
tumourigenesis by its aberrant serine/threonine kinase activity.  A constitutively 
active Akt promoted N-CoR misfolding while therapeutic and genetic inhibition 
of Akt activity blocked the misfolding of N-CoR in AML-M5. Moreover, N-CoR 
misfolding was found to be triggered by Akt induced phosphorylation at Serine 
1450 of N-CoR. These observations clearly indicated the importance of Akt 
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dependent phosphorylation in the misfolding and subsequent loss of N-CoR 
protein. 
Given N-CoR’s documented roles in hematopoiesis and as a 
transcriptional co-repressor, the functional consequence of Akt mediated MCDL 
of N-CoR in AML-M5 was next studied. Expression analysis of genes involved in 
hematopoiesis led to the identification of Flt3 as a transcriptional target of N-
CoR. N-CoR status in various AML deived cell lines was found to be inversely 
related to Flt3 expression. N-CoR effectively repressed the activity the Flt3 
promoter driven luciferase reporter and was found to be associated with the Flt3 
promoter in ChIP assay. N-CoR loss facilitated the IL3-independent growth of 
BA/F3 cells through the de-repression of the Flt3 gene, and N-CoR loss was 
augmented by Flt3 ligand stimulation. Enforced N-CoR expression in immature 
hematopoietic cells inhibited their growth and promoted myeloid lineage 
commitment, while blocking the N-CoR loss with Genistein; an inhibitor of N-
CoR misfolding, significantly down regulated Flt3 level and promoted 
differentiation of AML-M5 derived cell lines. These findings indicated that 
aberrant expression of Flt3 in AML-M5 was a consequence of the loss of N-CoR 
repressive function due to its MCDL.  This suggested that N-CoR may have a 
potential tumour suppressive role in AML-M5 pathogenesis through unmasking 
the growth promoting potential of Flt3.   
In this study, we identified and characterized the importance of the MCDL 
of N-CoR in the growth of AML-M5 leukemic cells through the in depth analysis 
of its mechanism and functional consequence. We also demonstrated that 
therapeutic inhibition of the N-CoR MCDL pathway in AML-M5 leukemic cells 
led to growth arrest. Together, these findings illustrate the potential of targeting 
the N-CoR MCDL pathway as an effective therapeutic strategy in AML-M5.	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1.1 Acute Myeloid Leukemia 
The term Acute Myeloid Leukemia (AML) is used to describe a cluster 
of neoplastic disorders characterized by the clonal expansion of immature 
blood cells of the myeloid lineage in the bone marrow (BM), blood or in other 
tissue 1,2. This accumulation is a result of increased cell proliferation and 
survival coupled with a block in the ability of the hematopoietic progenitor 
cells to differentiate3. These progenitor cells include cells of the granulocytic, 
monocyte/macrophage, erythroid and megakaryocytic lineages. 
Diagnosis and classification of AML is made primarily on the basis of 
morphology and cytochemical analysis. Using the widely adopted French-
American-British (FAB) classification system4, AML can be broadly 
classified into 8 subtypes as determined based on morphology, cellularity, 
blast percentage and cytochemistry. These subtypes are distinguished based on 
both the degree of differentiation and cell lineage. Cytochemical stains, 
including myeloperoxidase, nonspecific esterase and Sudan black B are used 
in conjunction with morphology in the identification of the subtypes5,6. Table 
1.1 depicts the various AML subtypes as classified under the FAB system and 
their associated morphological and cytochemical presentations. 
Although the FAB classification has been widely used in AML 
classification in the past three decades, the discovery that many AMLs are 
associated with recurring genetic aberrations prompted the World Health 
Organization (WHO) to come up with a new classification of AML. This new 
classification system stratifies AMLs based on the recurring molecular 
parameters associated to the various AMLs as diagnosed by cytogenetics, 
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molecular genetics and immnophenotyping in addition to their morphological 
presentations2. The different classes of AML and the criteria associated to 
each subclass as first defined by WHO in 2001 is listed in Table 1.2. This 
classification was published with the knowledge that it will be constantly 
modified with increasing information about the various genetic anomalies 
associated with AML pathogenesis. A revised classification was published by 
WHO in 2009 with the genetic information acculmulated after the first 
publication205. 
Although each subtype of AML may differ vastly in their genetic 
backgrounds regardless of the classification system used, a hallmark of all 
AMLs is the severe block of myeloid differentiation. Thus it is thought that 
aberrations involving key transcription factors and its associated co-activators 
and co-repressors which are essential for the differentiation process is a major 











[Reproduced with permission from LÖwenberg, et al., Acute Myeloid Leukemia. 
NEJM  341(14): 1051-1062 (1999)] 
 
Table 1.1: The French-American Classification of Acute Myeloid Leukemia. 
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AML with characteristic genetic 
abnormalities 
This category includes: 
1) Acute myeloid leukemia with 
t(8;21)(q22;q22), (AML1/ETO) 
2) Acute myeloid leukemia with abnormal bone 
marrow eosinophils and inv(16)(p13q22) or 
t(16;16)(p13;q22), (CBFβ/MYH11) 
3) Acute promyelocytic leukemia with 
t(15;17)(q22;q12), (PML/RARα) 
4) variants of Acute myeloid leukemia with 
11q23 (MLL) abnormalities 
  
 
AML with multilineage dysplasia 
Following MDS or MDS/MPD. 
Without antecedent MDS or MDS/MPD, but with 





AML and MDS, therapy-related 
This category includes: 
1) Alkylating agent/radiation–related type 
2) Topoisomerase II inhibitor–related type 








AML not otherwise categorized 
Classify as: 
1) Acute myeloid leukemia, minimally 
differentiated 
2) Acute myeloid leukemia without 
maturation 
3) Acute myeloid leukemia with maturation 
4) Acute myelomonocytic leukemia 
5) Acute monoblastic/acute monocytic 
leukemia 
6) Acute erythroid leukemia 
(erythroid/myeloid and pure 
erythroleukemia) 
7) Acute megakaryoblastic leukemia 
8) Acute basophilic leukemia 






[adapted from Vardiman et al, The World Health Organization (WHO) classification 








1.1.1. Acute Monoblastic/Monocytic Leukemia  
Acute Monoblastic/Monocytic leukemia (AML-M5) is a class of AML 
classified under the M5 subtype in the FAB classification. It is one of the most 
common subclass of AML found in young children, representing 18 percent of 
all pediatric AML; and in children below 2 years the proportion rate of AML-
M5 is about 40 to 50 percent7.  In adults, AML-M5 makes up about	  5 to 10 
percent of all AML cases and AML-M5 with MLL1 abnormalities is also a 
common secondary AML developed after chemotherapy treatment. 
AML-M5 is classified as a group of malignant disorder characterized 
by an abnormal accumulation of immature cells of myelo-monocytic lineage 
in the bone marrow and peripheral blood8,9 . It can be further sub classified in 
to two classes, AML-M5a (also known as Acute Monoblastic Leukemia) 
where greater than 80 percent of the monocytic cells are monoblasts and 
AML-M5b where less than 80 percent of monocytic cells are monoblasts with 
the rest showing (pro) monocytic differentiation. Under the newer World 
Health Organization (WHO) classification of AML, AML-M5 was classified 
under Acute Myeloid Leukemia with 11q23 (MLL1) abnormalities with the 
presence of the fusion product between the MLL1 and AF9 genes 
[t(9;11)(p22;q23)], MLL1-AF9 presenting the highest occurrence rates in  the 
disease10,11. Although MLL1-AF9 is mainly associated with AML-M5, it is not 
the only genetic anomaly present. Other diverse genetic aberrations have also 
been reported in the disease12. However, despite the varied genetic background 
of the disease, the phenotypic presentation is almost identical, characterized by 
the differentiation arrest at the monoblast and/or promonocytic stage coupled 
with increased survival and proliferation capacities. 
5	  
	  
1.1.2. Current treatment strategies for AML-M5. 
 To date, AML-M5 and AMLs in general remain a difficult disease to 
treat and the most common therapeutic strategies in current clinical practice 
include aggressive multi-drug chemotherapy using anthracyclins, cytarabine 
and etoposide. However these current strategies have severe side effects with 
non negligible mortality and morbidity rates. Although the availability of other 
treatment options such as allogenic bone marrow transplantation and 
radiotherapy have greatly improved the outcome of patients, these options 
remain highly specialized with a treatment related mortality and morbidity rate 
of approximately 10 to 15 percent13. 
Despite the difficulties in treatment, some small progress has been 
made in the recent decade which improved the outcome of AMLs and AML-
M5. Identification of new therapeutics such as new nucleoside analogues 
(Fludarabine, Cladribine, Cyclopentenyl, Cytosine and Clofarabine) and 
monoclonal antibodies against CD33 labeled with radionuclide or toxic 
compounds; as well as targeted therapies such as imatinib meslyate (Glivec®), 
Flt-3 inhibitors and farneysal transferase inhibitors which target tumor specific 
cellular pathways with less cytotoxicity can hopefully increase anti-tumor 
activity with less toxicity compared to conventional chemotherapy14. 
The mechanisms underlying AML-M5 pathogenesis and the 
difficulties in treating patients with AML-M5 have only been partially 
unraveled. Various mechanisms regarding the transformation event and drug 
resistance play a role in the moderation of disease outcome in patients with 
AML-M5. Thus it is prudent that more knowledge regarding the molecular 
6	  
	  
pathology be collected so as to better devise targeted therapeutic approaches to 
hopefully improve the outcome of patients with AML-M5. 
 
1.2. The Nuclear Receptor Co-repressor (N-CoR), a component of the 
transcriptional repression machinery and its role in AML pathogenesis. 
1.2.1. The importance of the transcription machinery in the regulation of 
hematopoiesis. 
 The transcription machinery plays a critical role in the control of 
normal hematopoiesis by having a major influence on the differentiation of the 
hematopoietic stem cell (HSC) to cells of the various hematopoietic lineages15-
18. In normal hematopoiesis, the hematopoietic precursor/stem cell (HSC)  
matures into more committed multi-potential progenitors and finally to 
specific cell types of the different lineages. This process of growth and 
maturation of hematopoietic cells is regulated during normal hematopoiesis 
through a balance between its capacity to self renew and proliferate versus 
lineage commitment and differentiation. Regulation is achieved via the 
controlled expression or repression of certain genes that are involved in self 
renewal, proliferation and differentiation as well as cell survival. This control 
is exerted via the cell’s transcription machinery and its associated cofactors 
which include the various co-activator and co-repressor proteins. Figure 1.1 






Figure 1.1. Role of the transcription machinery in the control of hematopoiesis. 
As the hematopoietic precursor/stem cells progress towards the more mature 
phenotype, there is a stepwise co-operation between the transcription repressors 
which represses the expression of self-renewal genes and the transcriptional 
activators which activates the expression of the lineage specific genes. 
 
A number of members of the transcription machinery (mainly 
transcriptional activators) have been identified to be crucial in the commitment 
of HSCs to the specific lineages. While factors such as RUNX1/AML119-21 
have been reported to be important for the proper development for all lineages, 
the role of other transcription factors are more specific to particular lineages. 
These include Ikaros22, tal-1/SCL23 and Pax5/BSAP24 which are essential for 
the development of lymphoid lineage cells as well as GATA-125 and LMO226 
which are critical for erythropoiesis. 
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In the recent years, transcription factors critical for the development of 
myeloid lineage cells have also been identified and studied. The importance of 
the various members of the  CCAAT/enhancer binding protein (CEBP) family 
such as CEBPα/β/ε in myeloid development have been suggested in mice 
models where various abnormalities in myeloid lineage development have 
been observed in CEBPα/β/ε knockouts27-30. Another transcription factor 
reported to be essential in myeloid lineage cell commitment is the ETS-
domain transcription factor PU.1/SPI1which activates gene expression during 
myeloid and B-cell development. It is thought that PU.1 and CEBPα work in 
tandem to regulate the myelopoiesis pathway, determining the final 
phenotypic fates of the common myeloid progenitors31.  Recent studies 
conducted in normal hematopoiesis and leukemogenesis have emphasized that 
these factors which are involved in transcription, have a major influence on 
these two processes32-34; especially when mutated or dysregulated, these 
factors become key initiators of AML pathogenesis. 
1.2.2. The Nuclear Receptor Co-Repressor (N-CoR). 
The nuclear receptor co-repressor N-CoR is a 270 kDa protein which is 
a key component of the multi-protein co-repressor complex involved in 
transcriptional control mediated by various transcriptional factors. It mediates 
gene repression by binding to unliganded nuclear receptors (NR) such as the 
retinoic acid and thyroid hormone receptors35 (Fig 1.2) and consists of both the 







Figure 1.2. Transcriptional repression by N-CoR is mediated by binding of N-
CoR to nuclear receptors. Transcriptional repression is brought about by the 
recruitment of N-CoR/SMRT to the gene promoter region by nuclear receptors. 








Figure 1.3. The domains of N-CoR/SMRT. Repression domains (RI, RII, RIII) and 
SANT domains (A and B) are indicated, as are interaction domains for HDACs, 
nuclear receptors (I and II), PML and Ski and other transcription factors. 
(Reproduced with permission from Jepsen K, Rosenfeld M G J Cell Sci 
2002;115:689-698) 
  
N-CoR mediates gene repression by recruiting histone deacetylases 
(HDACs) to the promoter region of genes which utilizes it for repression. 
When associated to the promoter region, the N-CoR/HDAC complex promotes 
the deacetylation of histones at these regions, changing the conformation of 
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the chromatin. This makes the chromatin less accessible to transcription 






Figure 1.4. Mode of action of N-CoR mediated gene repression. Recruitment of 
the N-CoR/HDAC complex to the promoter region of genes by nuclear receptors 
(NR), results in a change in the conformation of the chromatin by deacetylation of the 
histone tails in these regions. (Reproduced with permission from T Alenghat, J Yu & 
M A Lazar EMBO J 2006; 25:3966-3974).  
 
 
 Other than HDAC, N-CoR also recruits other factors such as 
Transducin B-Like 1 (TBL1), the TBL1-related protein (TBLR1)40 and G 
Protein Pathway Suppressor 2 (GPS-2)41 which together mediates the 
repression by multiple nuclear receptors such as the unliganded thyroid 
hormone receptor(TR)42 as well as the retinoic acid receptor (RAR), the 
peroxisome-proliferator-activated receptors (PPARs) PPARα, PPARβ (also 
known as PPARδ) and PPARγ, and the liver X receptors (LXRs) LXRα and 
LXRβ243,44. Other than the nuclear receptors, N-CoR was also found to 
interact with the mammalian switch-independent 3 protein (mSin3)45-47. It was 
suggested that the interaction between N-CoR and mSin3 is involved in the 




1.2.2.1. N-CoR in normal development. 
Physiologically, N-CoR is important in many developmental processes 
such as proliferation, differentiation and apoptosis. Its importance was 
underscored by the fact that N-CoR -/- knockout mouse models produced an 
embryonically lethal phenotype with severe anemia due to defects in definitive 
erythropoiesis as well as defects in thymocyte and neural development36. N-
CoR had been reported to be important in neural stem cell differentiation to 
astrocytes where the PI3K/Akt mediated cytosolic export of N-CoR via its 
phosphorylation resulted in the concomitant loss of N-CoR nuclear function48, 
promoting differentiation. Recently, N-CoR’s role in erythroid differentiation 
was also established with it being important in the regulation of the heme 
biosynthesis enzyme 5-aminolevulinate synthase (ALA-S2) in K562 cells49. A 
role for N-CoR in the differentiation of pituitary cells50 as well as in 
myogenesis51 had also been cited, highlighting the critical role of N-CoR in 
regulating differentiation of multiple cell types. 
Other than the regulation of differentiation, a novel role for N-CoR in 
the regulation of circadian metabolic physiology was recently published. 
Genetic disruption of the N-CoR/HDAC3 interaction in mice resulted in the 
aberrant regulation of clock genes. This caused the mice to exhibit abnormal 
circadian behavior. The loss of the functional N-CoR/HDAC3 complex altered 
the oscillatory patterns of several metabolic genes. This indicated that 
activation of HDAC3 by N-CoR was critical in the epigenetic regulation of 





1.2.2.2. N-CoR in Carcinogenesis. 
N-CoR being a key component of the transcriptional repression 
machinery; its expression and function is tightly regulated in normal 
development. Deregulations of N-CoR function due to changes in expression 
or aberrant nuclear export have been reported to contribute to carcinogenesis. 
For example, N-CoR had been shown to be important in the repression of the 
PI3K/Akt signaling pathway in thyrocytes and its observable loss of 
expression in thyroid cancer cells was thought to enhance the survival of these 
cells by activating the PI3K/Akt kinase signaling pathway53. N-CoR’s role in 
the transcriptional control of POZ/zinc finger transcription factor BCL-6 was 
also reported to be essential for the survival of tumor cells in diffuse large B-
cell lymphomas54. In glioblastoma multiforme (GBM), tumor cells with 
nuclear localization of N-CoR demonstrate an undifferentiated phenotype. 
However upon exposure of these cells to agents which promoted N-CoR 
phosphorylation and subsequent cytosolic translocation, astroglial 
differentiation was observed55. It was also observed that in colorectal cancer 
primary patient specimens, N-CoR displayed aberrant cytosolic localization. 
This was due to its phosphorylation by IKKα and this was thought to result in 
the de-repression of genes which promote the proliferation and survival of 
these cancer cells56. 
1.2.2.3. N-CoR in AML Pathogenesis.  
Although N-CoR has been reported to contribute to the pathogenesis of 
various types of cancers, it is most widely implicated in the pathogenesis of 
AML, especially in AMLs involving the AML1-ETO fusion protein and in 
Acute Promyelocytic Leukemia (APL/ AML-M3).  
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In AML1-ETO positive myeloid leukemia, it was observed that 
aberrant recruitment of the N-CoR/HDAC3 complex to ETO in the fusion 
oncogene repressed gene transcription and inhibited differentiation in 
hematopoietic precursors57. 
In APL, N-CoR’s role in the pathogenesis of the disease has been 
extensively studied. It is believed that in APL, N-CoR recruited by the fusion 
oncogene PML-RARα acts as a repressor for the genes that respond to 
Retinoic Acid (RA). These RA responsive genes are also the genes that are 
essential for myeloid cell maturation. By dissociating N-CoR from PML-
RARα in RA and Genistein treatment, the repression for these genes is lifted 
which leads to myeloid cell maturation and differentiation58-61. Recently a 
different role for N-CoR in the pathogenesis of APL was proposed. It was 
shown that PML-RARα mediated the accumulation of a non-functional, 
misfolded and insoluble form of N-CoR in the endoplasmic reticulum (ER)62. 
In APL, this misfolded N-CoR was subsequently modified in the golgi 
through glycosylation and was selectively cleaved by an aberrant protease 
activity induced or activated by the Unfolded Protein Response (UPR)63.   
With these new findings, a bi-functional model for the role of the 
association between PML-RARα and N-CoR in the pathogenesis of APL was 
proposed. It was suggested that in APL cells, there exists two forms of N-CoR, 
a natively folded and stable nuclear residing form and a misfolded and 
unstable form preferentially localized to the cytosol62,63. Similarly, nuclear and 
cytosolic forms of PML-RARα were thought to exist and it was proposed that 
each form of PML-RARα engaged the respective form of N-CoR to regulate 
the two different arms of the transcriptional mechanism, eventually leading to 
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the dysregulation of both transcriptional activation and repression in APL64 
(Fig 1.5).  Based on this new model, the mode of action for RA and Genistein 
had been redefined to include its effects on the non-functional form of N-CoR 







Figure 1.5. Mode of action of bi-functional role of N-CoR in APL pathogenesis. 
The nuclear and cytosolic forms of PML-RARα possibly engage N-CoR protein in a 
bi-functional manner with two opposing outcomes. Nuclear PML-RARα represses 
RA target genes by recruiting native nuclear N-CoR to the promoter regions of RA 
responsive genes thus repressing the expression of these genes. On the other hand, the 
self-renewal genes which were originally repressed by N-CoR could be re-expressed 
due to the loss of functional N-CoR as a result of PML-RARα induced misfolding 
and cytosolic export. (Reproduced with permission from M Khan Expert Rev. 









Figure 1.6. Mode of action of Retinoic Acid (RA) and Genistein. RA and 
Genistein inhibit the association of PML-RARα and N-CoR by inhibiting the aberrant 
phosphorylation of N-CoR at the N-CoR box. This releases and refolds N-CoR 
resulting in the restoration of N-CoR function. This dissociation is accompanied by 
the concurrent degradation of the PML-RARα fusion oncogene. (Reproduced with 
permission from M Khan Expert Rev. Proteomics 2010; 7(4):501-600).  
 
 
1.3. Protein Misfolding and its role in AML pathogenesis. 
1.3.1. Protein folding and the Unfolded Protein Response (UPR). 
 The normal function of proteins is determined by its three dimensional 
structure which is acquired through the folding of the polypeptide chain 
encoded by the genome. Any changes in the polypeptide chain either via 
abnormal amino acid modifications or aberrant post-translational 
modifications may result in changes of the folding process causing protein 
misfolding65. 
 In a normal mammalian cell system, the amino acid sequence in the 
polypeptide chain contains all the necessary information to determine the 
conformation of the protein it encodes. However, there are a vast number of 
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permutations for the way the polypeptide can be folded, thus creating the 
possibility of the formation of proteins which have a misfolded conformation. 
Therefore, mammalian cells have evolved a robust protein quality control 
(PQC) system which utilizes the aid of molecular chaperones to facilitate this 
folding process and prevent misfolding66,67. This system also comprises the 
Unfolded Protein Response (UPR) which acts to eliminate misfolded or 
damaged proteins. This UPR is initiated when there is an accumulation of 
unfolded or misfolded proteins in the endoplasmic reticulum (ER). 
 The UPR consist of two arms, the first arm known as cytoprotective 
UPR is the cell’s first response to misfolded proteins. This arm utilizes 
molecular chaperones to first attempt to correct the conformation of the 
damaged proteins or activate the ubiquitin-proteasome system to eliminate 
these misfolded proteins before they can exert their cytotoxic effects. In the 
event where the load of misfolded protein is too high to be cleared by the 
cytoprotective arm which usually occurs under conditions of disease, the 
second arm known as cytotoxic UPR is activated. This results in the 
accumulation of cytotoxic protein aggregates which ultimately eliminates the 
cells through programmed cell death. A simplified schematic of the dynamic 
protein folding/misfolding process is represented in Figure 1.7. 






Figure 1.7. A simplified schematic of the dynamic protein folding/misfolding 
process. After synthesis, the polypeptide chain mediated by molecular chaperones is 
modified to fold to its final functional native conformation. In the process, misfolding 
of the polypeptide chain may occur and this may be refolded, degraded or they may 
form toxic aggregates. (Adapted from Bross & Gregerson Protein Misfolding and 
Disease, Methods in Molecular Biology Vol 232, Humana Press 2003)  
 
1.3.2. Protein Misfolding and Disease. 
 Traditionally, protein misfolding has been linked to the pathogenesis of 
neurological diseases such as Alzheimer’s disease and Parkinson’s disease68-
70, however recent studies are beginning to reveal new evidences of the 
involvement of protein misfolding in a multitude of other diseases such as in 
lung diseases71,72, ophthalmic tissue diseases73-78, skeletal muscle diseases79-83, 
connective tissue diseases84-86, Atherosclerosis87-89 as well as in cancers. 
The basis for pathogenesis of most of these conformational diseases is 
the cellular inability to degrade these misfolded proteins resulting in the 
formation of cytotoxic aggregates. In these diseases, pathology is 
predominantly determined by cell damage associated with protein aggregation 
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thus exhibiting what is considered a ‘gain-of-function’ pathology90. This group 
of disease includes the neurological disorders Alzheimer’s, Parkinson’s and 
Huntington’s disease91-93. In another group of disease, which includes cystic 
fibrosis94, phenylketonuria95 and fatty acid oxidation defects96, the misfolded 
proteins are highly unstable and degraded rapidly resulting in what is termed a 
‘loss-of-function’ pathology related to the decrease in the steady amount of the 
protein92,97. 
1.3.2.1. Protein Misfolding in Carcinogenesis 
In normal conditions, tumor suppressors play a critical role in the 
regulation of cell division and survival. Tumourigenesis often arises due to the 
inhibition of the proper function of these proteins as a result of genetic or post-
translational aberrations. In some cases, these misfolded tumor suppressors are 
inactivated resulting in a subsequent loss of function, while in certain cases, 
these mutated proteins may adopt an aberrant conformation which is regulated 
differently from its wild-type counterparts. 
p53 is a good example of a protein that links the loss of function 
phenotype due to a misfolded protein conformation to carcinogenesis. p53 is a 
tumor suppressor protein which is commonly found to be deregulated in 
multiple cancers due to genetic aberrations. It has been demonstrated that 
mutations involving the core domain (p53C), which are found in more than 
50% of all cancers contributes to p53 misfolding98,99. This misfolded variant of 
p53 was found to be inactive and observed to have a dominant negative effect 
on normal wild type p53100. The loss of functional p53 resulted in the 
accumulation of mutations in the genome due to the inability of the cell to 
effectively repair DNA lesions. This inactive conformational variant of p53 
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had been described to be aggregated in the nucleus and cytoplasm of multiple 
cancers such as neuroblastomas, retinoblastomas, breast cancers and colon 
cancers99,100.   
In recent years, more proteins where the loss of function due to a 
misfolded conformation resulted in the cancer phenotype had been identified. 
These include proteins such as the WT1 zinc-finger transcription factor where 
the tumourigenic WT1 inactivation mutation (WT/AR) (a result of improper 
splicing) was thought to have a role in the development of Wilms’ Tumour a 
pediatric cancer of the kidney101-103. Mutations in the von Hippel Lindau 
(VHL) tumor suppressor, a 213 amino acid protein which assembles with 
elongins B and C to form the VBC complex104, triggered misfolding (as 
observed in multiple tumourigenic mutants of this protein)105, hence 
compromising its ability to form the VBC complex and resulted in the 
development of tumors associated with VHL syndrome. Merlin is another 
example of a protein where misfolding had been reported to result in a loss of 
function phenotype that led to the development of tumors associated with 
Neurofibromatosis type II. A missense point mutation in the N-terminus of 
this 65 kDa protein disrupts the native conformation of Merlin, thus affecting 
its ability to dimerize for proper function106. 
1.3.2.2. Protein Misfolding in AML.  
Acute Promyelocytic Leukemia (APL) or AML of the M3 subtype 
under the FAB classification is regarded as a model disease where a definitive 
link between protein misfolding and leukemogenesis has been established. 
PML-RARα, the fusion oncogene associated with more than 95 
percent of the known cases of APL was traditionally thought to induce 
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differentiation arrest through the induction of transcription inhibition of RA 
target genes61, via the recruitment of the transcriptional co-repressor N-CoR. 
However recent studies have revealed a novel mechanism in PML-RARα-
induced APL pathogenesis. These new studies have demonstrated the direct 
role of PML-RARα in the misfolding of N-CoR. These studies suggested that 
when expressed with PML-RARα, N-CoR displayed several characteristics of 
misfolding, including its accumulation in the ER as insoluble protein 
aggregates, aberrant post-translational modifications and destabilization62-64 . 
PML-RARα which is a de novo misfolded protein by itself, apparently acted 
as a nucleating event to trigger the conformational re-arrangement of N-CoR 
resulting in its misfolding. The misfolded N-CoR in the APL was highly 
unstable and was rapidly degraded by a non-regulated protease activity 
selectively activated in APL cells. This resulted in the loss of N-CoR protein 
and thus created a loss of function effect, contributing to the pathogenesis of 
APL by abrogating the repression of N-CoR target genes62-64. 
Other than abrogating N-CoR’s repression on its target genes through 
N-CoR degradation, the non-regulated protease activity contributed to APL 
pathogenesis by allowing these cells to escape UPR induced cell death 
triggered by the accumulation of misfolded N-CoR63 . It was reported that in 
the normal cellular environment, PML-RARα induced aggregation of 
misfolded N-CoR resulted in the amplification of ER stress to a level which 
ultimately triggered cell death. However in APL, the cells evolved a ‘late’ 
cytoprotective arm of UPR via the activation of a non-regulated, protease-
mediated clearance of this misfolded N-CoR. This kept the ER stress level 
below the threshold required to initiate cell death and conferred a survival 
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Figure 1.8. The activation of a third proposed cytoprotective arm of UPR in APL 
promotes cell survival. In the normal cellular environment, misfolded N-CoR is 
accumulated and ultimately results in cell death (A). However in APL, the activation 
of cytoprotective UPR negated the effects of misfolded N-CoR accumulation leading 
to cell survival (B). (Reproduced with permission from M Khan Expert Rev. 










1.4. Akt and its role in transcription factor mediated carcinogenesis. 
1.4.1 Akt  
 Akt is a serine/threonine kinase which has major roles in the regulation 
of multiple cellular processes. These processes include glucose metabolism, 
apoptosis, cell proliferation, transcription and cell migration. Currently, three 
mammalian Akt family members have been identified. They are Akt1107,108, 
Akt2109,110 and Akt3111-113. These members of the Akt family are reported to be 
differentially expressed at both the protein and mRNA levels114-116. Members 
of the Akt family of proteins are structurally similar with all members 
containing a pleckstrin homology (PH) domain in the N-terminus and a 
proline rich hydrophobic region in the C-terminal end117,118. Members of this 
family also contain a central kinase domain with specificity for serine or 









Figure 1.9. Schematic representation of various domains in the Akt family of 
proteins. All Akt family members contain three distinct functional domains namely 
the PH (Pleckstrin Homology) domain at the N-terminus, a centrally located kinase 
domain and the C-terminal regulatory/ hydrophobic domain (HD). The key 






1.4.2. Akt activation. 
 The activation of Akt kinase activity is a multistep process which 
involves membrane translocation and phosphorylation120. Upon the 
stimulation of growth factors, growth factor receptor tyrosine kinases signal 
the production of 3’-phosphorylated phosphoinositides 3,4,5-triphosphate (PI-
3,4,5-P3) and PI-3,4-P2 produced by phosphatidylinoditol 3-kinase (PI3K). 
The binding of these phospholipids to the PH domain of Akt triggers the 
translocation of Akt to the plasma membrane where it is phosphorylated.  Akt 
is phosphorylated by the PI-3,4,5-P3-dependent protein kinase ( PDK1) at 
Threonine 308/309/305 (for Akt1/2/3 respectively) located in the kinase 
activation loop and at Serine 473/474/472 (for Akt1/2/3 respectively) which is 
located in the carboxy-terminal tail by the once elusive PDK2. The identity of 
PDK2 has recently been identified to be the mammalian Target Of Rapamycin 
Complex 2 (mTORC2) comprising of mTOR, rapamycin-insensitive 
companion of mTOR (Rictor), GβL, and mammalian stress-activated protein 
kinase interacting protein 1 (mSIN1)121,122. Phosphorylation of Akt at the 
Serine 473/474/472 residue occurs before and facilitates the phosphorylation 
at Threonine 308/309/305.  The phosphorylation at Threonine 308/309/305 is 
thought to be essential for the activation of Akt while Serine 473/474/472 is 
required for maximal activity of Akt kinase123. Figure 1.10 represents a 
simplified schematic of the activation pathway of Akt by its upstream 







Figure 1.10. The pathway of Akt activation. PI3K is activated by extracellular 
stimulus. This results in the synthesis of PI-3,4,5-P3 and PI-3,4-P2. Binding of these 
phospholipids to the PH domain of Akt triggers the translocation of Akt to the plasma 
membrane where it is phosphorylated  by PDK1 at Thr 308/309/305 and PDK2/ 
mTORC2 at Ser 473/474/472. Akt is first phosphorylated at Ser473/474/472 and this 
in turn facilitates the phosphorylation of the Thr308/309/305 residue for complete 
activation of Akt. Activated Akt translocates from the plasma membrane to the 
cytosol or to the nucleus, where it phosphorylates a wide array of downstream 
effector proteins. Signal termination is mediated by several inositol polyphosphate 
phosphatases, including PTEN, SHIP, and SHIP2. The activation cycle ends with 
dephosphorylation of Akt by protein phosphatases. (Adapted from K Du and P N 




After activation, Akt translocates from the membrane to the cytosol or 
the nucleus where it phosphorylates its multitude of substrates. Termination of 
the signaling cascade occurs with the dephosphorylation of PI-3,4,5-P3 and PI-
3,4-P2 by the inositol polyphosphate phosphatases which include PTEN, 






1.4.3. Identification and regulation of Akt substrates 
 The importance of Akt as a key regulator of multiple cellular events 
has fuelled the search for its substrates to better understand the plethora of 
roles it plays in normal cell survival as well as in disease. This search for 
substrates of Akt relevant to its survival promoting effects had been 
significantly aided by the identification of the preferred phosphorylation 
consensus motif RxRxx S/T-bulky hydrophobic in vitro125,126. This consensus 
RxRxx S/T-bulky hydrophobic sequence where Akt preferentially 
phosphorylates the serine or threonine residue exists in a large number of 
mammalian proteins including transcription factors and components of the 
apoptotic machinery127. The identification of the Akt consensus 
phosphorylation motif in proteins which participate in the apoptotic pathway 
emphasized the importance of Akt in the regulation of survival in cells via its 
direct phosphorylation of components of the cell death apparatus. Due to the 
particular focus of our work on transcription factors and the vast amount of 
information available with regards to the mammalian cell death machinery and 
their relationship with Akt, only the regulation of transcription factors via 
phosphorylation by Akt will be discussed here.  
1.4.3.1. Regulation of transcription factors by Akt 
 The possible involvement of Akt in the regulation of transcription 
factors was first suggested by the observation that within 30 minutes of their 
activation by growth factors, both Akt1 and Akt2 detach from the cell surface 
membrane and translocates to the nucleus128,129. Subsequent work performed 
by various groups identified that the Forkhead family of transcription factors 
interacted with the insulin-response sequence (IRS)130,131 which had been 
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identified in the promoter of genes such as the IGF-binding protein 
(IGFBP1)132, phosphoenol pyruvate kinase (PEPCK)133, apoplipoprotein 
CIII134 and glucose-6-phosphatase135. Various reports also demonstrated 
Foxhead family of transcription factors mediated Akt-dependent 
transcriptional repression of these genes135-138. Concurrent work performed on 
DAF-16 (a Foxhead family member) and the discovery of Akt in the 
C.elegans model revealed that the PI3K/Akt pathway was a key regulator of 
nematode DAF-16 function139-141. In mammalian cells, 3 members of the 
Foxhead family of transcription factors were identified as likely DAF-16 
orthologs (FKHR, FKHRL1/AF6q21 and AFX)142-144. Analysis of the amino 
acid sequence of all 3 orthologs and DAF-16 revealed that in all the 
sequences, there exist 3 sites corresponding to the Akt phosphorylation 
consensus sequence127. Evolutionary conservation of these sequences 
suggested the importance of these sequences in the function of the 
transcription factors. It was also reported that all 3 orthologs as well as DAF-
16 could be effectively phosphorylated by Akt in vitro145-148.  
Akt was thought to mediate the function of these transcription factors 
by regulating their subcellular localization145,146. In the absence of Akt 
activity, FKHR and FKHRL1 translocates to the nucleus. However when Akt 
is activated, phosphorylation of these factors at the Akt consensus motif 
promotes their cytoplasmic retention, thus sequestering them from their 
nuclear targets. Recent work by Menghini and colleagues also reported a 
similar mechanism of functional inhibition of the transcription factor GATA2 
in adipocytes149. Here it was reported that Akt phosphorylation of GATA2 at 
the Serine 401 residue located within the Akt phosphorylation consensus motif 
retained GATA2 in the cytoplasm of preadipocytes, modulating its DNA 
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binding activity and aided preadipocyte differentiation preventing its ability to 
exert inflammatory function.  Another transcription factor which function was 
reported to be regulated by Akt phosphorylation is the transcriptional activator 
CREB150. It was reported that phosphorylation of CREB at Serine 133 by Akt 
enhanced the binding of CREB to CBP thus facilitating CREB-mediated 
transcription.  
 In carcinogenesis, deregulations in Akt activity have been widely 
reported and many tumours have been reported to display Akt hyper-activity. 
Given Akt’s role in the regulation of the survival signalling pathway, Akt 
hyper-activity have been widely associated with the enhanced survival 
advantage of tumour cells. There is increasing evidence from multiple protein 
databases suggesting that a large number of transcription factors contain the 
putative Akt phosphorylation consensus motifs in their amino acid sequences. 
This suggests that transcription factors could be potential substrates of Akt and 
any deregulation in Akt activity could possibly contribute to cancer 
progression by affecting the normal function of these factors, leading to 
differentiation arrest, the hallmark of cancer. 
 
 
1.5. The FMS-Like Tyrosine Kinase 3 receptor (Flt3) 
1.5.1. Receptor Structure 
Flt3 is a membrane bound receptor tyrosine kinase (RTK) essential for 
normal haematopoiesis and mutations in the FLT3 gene is one of the most 
frequent genetic aberration found in haematological malignancies. 
Located on chromosome13q12, the human Flt3 has an 85% amino acid 
homology to its mouse counterpart151. It belongs to the RTK subclass III 
family which also includes other members such as the macrophage colony-
stimulating factor (M-CSF) receptor, Steel Factor Receptor (KIT) and the 
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receptor for platelet-derived growth factors A and B (PDGFRA and 
PDGFRB)152. Two forms of the human Flt3 have been identified- the 160 kDa 
membrane bound N-glycosylated form and the intracellular non-glycosylated 
130 kDa form153,154.  The mature membrane bound form of the Flt3 receptor 
consist of a extracellular binding domain which have 5 immunoglobulin loops, 
a juxtamembrane domain, an ATP-binding pocket, an activation loop and a 
Kinase insert155 (Fig 1.11). 
 
 
Figure 1.11. A simplified schematic of the Flt3 receptor. The Flt3 receptor 
monomer consist of multiple domains including the extracellular binding domain 
which have 5 immunoglobulin loops, a juxtamembrane domain, an ATP-binding 
pocket, an activation loop and a Kinase insert (Reproduced with permission from K 
Shami et al, Expert Rev Hematol 2008; 1: 153-160) 
1.5.2. Role of Flt3 in normal haematopoiesis. 
Flt3 is expressed mainly in the early myeloid and lymphoid 
progenitors156 but not in the more matured erthyroid cells157, 
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megakaryocytes158 or mast cells159. Expression of the Flt3 receptor in normal 





Figure 1.12. Expression of Flt3 in normal haematopoiesis. The figure indicates 
expression of Flt3 (green) in various classes of hematopoietic stem and progenitor 
cells as well as mature blood cells. Symbols: (−) most/all cells appear to lack Flt3 
expression; (+) most/all cells appear to express Flt3; (+/−) the cell type appears to 
consist of significant receptor-positive as well as receptor-negative populations; (?) 
sufficient expression or functional data not available. Abbreviations: BFU, burst-
forming units; CFU, colony-forming units; E, erythroid; Mk, megakaryocyte; G, 
neutrophilic progenitor; M, monocyte/macrophage; DC, dendritic cell; Baso, 
basophil; RBC, red blood cell; NK, natural killer cell. (Reproduced with permission 
from Lyman S D et al, Blood 1998; 91: 1101-1134) 
In normal cells, binding of the Flt3 ligand to the Flt3 receptor activates 
the Flt3 signal transduction pathway which promotes the growth of early 
progenitor cells. Flt3-mediated responses differ greatly for various cell types 
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and specific responses are dependent on the combination of other growth 
factors. For example, Flt3 receptor activity stimulated by the Flt3 ligand in the 
absence of other growth factors promoted the monocytic differentiation of 
early progenitors without any marked differences in proliferative response160 
while in the presence of other growth stimulating cytokines such as 
interleukin-3 (IL-3), G-CSF, CSF1, GM-CSF, EPO and KIT ligands the cells 
showed an enhanced proliferative response and increased the development of 
granulocytic-monocytic colony formation units157,160,161. However, Flt3 
stimulation via the Flt3 ligand had no marked effect on erythropoiesis and 
megakaryopoiesis as these cell lineages do not express Flt3157. 
Preferential expression of Flt3 in primitive hematopoietic cells 
suggested a role of Flt3 in the regulation of differentiation. It was reported that 
Flt3 ligand activation of the wild-type Flt3 transfected 32D cells inhibited 
their progression towards neutrophils, however a complete block of 
differentiation was not observed162.  Although Flt3 expression is widespread in 
the hematopoietic system, it was surprising to observe that the Flt3-/- 
knockout mouse had relatively normal haematopoiesis with the only defect 
being a small decrease in the size of the pro-B and pre-B cell compartments163. 
Transplantation experiments in mice with either non-functioning Flt3 or wide-
type Flt3 led to the reconstitution of the bone marrow containing mostly cells 
which expressed the wide-type receptor suggesting a selective growth 
advantage of these cells. The selective advantage was found in all cell lineages 
indicating a global effect of Flt3 disruption in the hematopoietic system163. 
Additionally, the lethal phenotype was only observed when Flt3 was knocked 
out in combination with Kit. Thus it was suggested that Flt3 is important but 
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not absolutely required for normal haematopoiesis and works together with 
other growth factors to enhance proliferation and differentiation of myeloid 
and lymphoid cells. Recent studies by Kikushige et al also reported that Flt3 
expression in human HSCs, Granulocyte/Macrophage Progenitor stages 
promoted and maintained cell survival in these cells. In their experiments, it 
was observed that activation of the Flt3 signalling pathway in the HSCs and 
progenitors prevented spontaneous apoptotic cell death via the up regulation of 
the important pro survival protein MCL-1. This suggested that the human Flt3 
signalling pathway has a critical role in the survival of the stem and progenitor 
cells and present as important targets for AML transformation164. 
1.5.3. Flt3 in leukemogenesis 
It was previously suggested that leukemia arise from LSCs which have 
re-acquired or retained the abilities of self-renewal and unlimited growth and 
proliferation. Involvement of Flt3 in the proliferation of HSCs and early 
progenitor cells suggested that Flt3 expression and activation of the Flt3 
signaling pathway had possible oncogenic potentials. Evidence from clinical 
studies had indicated that Flt3 had the capacity to enhance the survival and 
proliferation of leukemic blasts, with 70% to 100% of AMLs expressing wild-
type Flt3165-167. Aberrant activation of the Flt3 signaling pathway via tyrosine 
kinase gain-of-function mutations of the Flt3 receptor are also observed in 
about 30% of patients with AML. Patients who present with Flt3 receptor 
activating mutations are reported to have a worse prognosis compared to 
patients with the wild-type receptor168,169. Two types of activating mutations 
have been identified to contribute to the deregulation of the Flt3 receptor.  
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The first and most common mutation is the in-frame internal tandem 
duplication (ITD) in the juxtamembrane (JM) domain of the Flt3 receptor. 
This FLT3-ITD mutation has been reported in 17 to 26 percent of known 
AML cases170,171. The mutation is an insertional mutation within exon 14 and 
can vary in length from 3 to more than 400 base pairs172. Current knowledge 
of the cause of this mutation is still vague although it was proposed that the 
cause could be a failure in the slippage or mismatched pair repair mechanism 
during the DNA replication process173,174. The ITD mutation results in the 
constitutive activation of Flt3 kinase as it disrupts the JM domain mediated 
regulation of kinase catalytic activity175. The FLT3-ITD mutation has been 
observed in all subtypes of AML but has been reported to appear most 
frequently in AML of the M3 and M5 subtypes and has the lowest frequency 
of occurrence in the M2 subtypes176-182. 
The second type of genetic defect is the single-amino acid mutation in 
the Flt3 sequence. These are usually missense point mutations in the kinase 
domain of the Flt3 RTK which can also confer constitutive activity to Flt3. 
The most reported point mutation is the substitution of tyrosine for aspartic 
acid at position 835 within the activation loop of the Flt3 kinase domain. Other 
point mutations at positions 836 and 841 which also result in the constitutive 
activity of the Flt3 receptor have also been reported183-185. The FLT3-D835 
mutation is found in 7 percent of AML cases and it is thought that the 
mechanism of RTK activation is most likely similar to that of other members 
of the RTK family where the substitution stabilizes the ‘open’ ATP-binding 
conformation of the activation loop186. 
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Despite the involvement of Flt3 in proliferation, self-renewal and anti-
apoptosis, over expression of Flt3 and its mutants alone are not able to induce 
the complete leukemic phenotype in vivo187. The FLT3-ITD mutant was 
observed to induce myeloproliferative phenotype in transduced mouse models 
but lacked induction of the necessary block in differentiation, a hallmark of 
AML. Thus the Knudson 2 hit hypothesis of cancer progression seemed to be 
supported by this observation where a second oncogenic event may be needed 
to work in tandem with Flt3 deregulation to bring about complete 
transformation. This was later supported in a study where the transduction of 
FLT3-ITD into the bone marrow cells of PML-RARα transgenic mice 
displayed the complete penetrance and rapid progression of APL162. This 
indicated that although aberrant Flt3 signaling may affect differentiation, a 
more potent mechanism must work in tandem to effect transformation. 
Nevertheless, the importance of Flt3 in the maintenance of the survival 
and proliferative capabilities of the leukemic blasts cannot be denied and 
aberrant or enhanced Flt3 signaling due to activating mutations or over 
expression of the receptor may be crucial in providing the leukemic blasts with 







1.6. Hypotheses and Aims of this project. 
Recently, our laboratory reported the role of misfolded conformation 
dependent loss (MCDL) of N-CoR protein in the pathogenesis of APL58,62,63. 
In APL, we reported that the fusion oncoprotein PML-RARα induced 
misfolding of N-CoR as characterized by N-CoR’s detergent insolubility and 
aberrant cytosolic location. The accumulation of misfolded N-CoR in the 
endoplasmic reticulum (ER) resulted in the induction of ER stress62. This 
misfolded N-CoR was subsequently found to be cleaved by O-
sialoglycoprotein endopeptidase (OSGEP) a heat liable protease63 which 
selectively cleaves O-sialyated proteins. This cleavage contributed to the 
survival of APL cells by preventing the ER stress levels from reaching the 
threshold where ER stress induced cell death is initiated. We also reported that 
Genistein, a kinase inhibitor isolated from soy was able to restore native N-
CoR function leading to the differentiation and proliferation block in APL58. 
 The transcriptional control imparted by N-CoR have been reported to 
be important for the growth suppressive functions of several tumor suppressor 
proteins including Mad and Rb188,189.  Also, N-CoR being a key component of 
the generic multi-protein co-repressor complex involved in the transcriptional 
control mediated by various transcription factors has also been suggested to be 
important in the normal development and maturation of the hematopoietic 
system, with reports indicating that N-CoR knockout mice are embryonically 
lethal and appear to die from anemia due to defects in definitive 
erythropoiesis36. Loss of N-CoR protein via MCDL could thus be a key event 
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in malignant transformation not only in APL but in other AML subtypes as 
well.  
In light of the findings from our laboratory based on the APL model 
and the essential role of N-CoR in the normal maturation and development of 
the hematopoietic system, this project was conceived to investigate if MCDL 
of N-CoR could also contribute to the malignant growth and transformation of 
other FAB subclasses of AML such as in Acute Monocytic Leukemia (AML 
designated as M5 in the FAB classification system-AML-M5).  Specifically, 
our aim was to (1) identify the molecular mechanism behind the misfolding of 
N-CoR in AML-M5, (2) elucidate the physiological and functional 
consequences of N-CoR MCDL in the pathogenesis of AML-M5 and (3) 
devise new therapeutic strategies for AML-M5 through targeting the N-CoR 











2. MATERIALS AND EXPERIMENTAL PROCEDURES 
2.1. Materials 
2.1.1. General Reagents 
Table 2.1: List of Chemicals, Reagents and Kits  
Chemicals/Reagents/Kits Company Country 
	  2-­‐Mercaptoethanol 	  Bio-­‐Rad 	  CA,	  USA 
4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) 
Merck Darmstadt,	  Germany 
4’,6-diamidino-2-phenylindole (DAPI) Sigma Aldrich MO,USA 
1 kb DNA ladder Promega WI,USA 
30% Acrylamide-Bis Solution Bio-Rad CA, USA 
Accuprime Taq Polymerase System Invitrogen CA,USA 
Agarose Bio-Rad CA,USA 
Akti-X  Merck Darmstadt, 
Germany 
Ammonium Persulfate Bio-Rad CA,USA 
Ampicillin Sigma Aldrich MO,USA 
Annexin V-FITC Apoptosis Detection Kit BD Pharmingen CA,USA 
Bovine Serum Albumin (BSA) Sigma Aldrich MO,USA 
Cell Proliferation Kit I [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; (MTT) 
Roche Germany 
ChIP-IT Kit Active Motif CA,USA Diethylpyrocarbonate	  (DEPC)	  	   Sigma Aldrich MO,USA Dimethyl	  sulfoxide	  (DMSO) Sigma Aldrich MO,USA Dulbucco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	   Sigma Aldrich MO,USA 
Ethanol Merck Darmstadt,	  Germany 
Fetal Bovine Serum (FBS) Hyclone  Logan, UT Fugene	  6	  	   Roche Germany GeneTailor™	  Site-­‐Directed	  Mutagenesis	  System Invitrogen CA,USA 
Giemsa Azur Eosin Methylene Blue Solution Merck Darmstadt,	  Germany	  
Glacial Acetic Acid Merck Darmstadt,	  Germany 
Glycine Bio-Rad CA,USA	  
Human Phospho-kinase Array Kit (Proteome Profiler-
Antibody Array) 
R&D Systems MN,	  USA	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Chemicals/Reagents/Kits Company Country 
  	  
Isocove’s Modified Dulbocco’s Medium (IMDM) Life 
Technologies 
Gaithersburg,	  MD	  
Isopropanol Merck Darmstadt,	  Germany Kanamycin	   Sigma Aldrich MO,USA Lipofectamine	  2000	   Invitrogen CA,USA 
 Luciferase Assay System (Dual) Promega WI,USA 
May-Grunwald Solution Roche Germany 
Methanol Sigma Aldrich MO,USA Murine	  Reverse	  Transcriptase,	  MMLV Promega WI,USA Normal	  Goat	  IgG	   Santa Cruz 
Biotechnologies 
CA,USA 
Normal	  Mouse	  IgG	   Santa Cruz 
Biotechnologies 
CA,USA 
Normal	  Rabbit	  IgG	   Santa Cruz 
Biotechnologies 
CA,USA 
Nucleofector	  Kit	  V	  	   Amaxa, Lonza Cologne, 
Germany One	  Shot®	  DH5ά™-­‐T1	  Competent	  Cells Invitrogen CA,USA 
Paraformaldehyde Sigma Aldrich MO,USA 
Phosphatase Inhibitor Cocktails 1 and 2 Sigma Aldrich MO,USA 
Precision Dual Color Standard Protein Marker Bio-Rad CA,USA 
Prolong Gold Antifade Reagent Invitrogen CA,USA 
Protein G Sepharose Breads  Roche Germany 
PVDF Membrane Bio-Rad CA,USA 
Qiagen plasmid DNA purification Kit (maxi and miniprep 
kit) 
Qiagen GmBH Hilden, 
Germany 
Qiagen Gel Extraction Kit Qiagen GmBH Hilden, 
Germany 
Qiagen RNasey RNA extraction Kit (RNA miniprep kit) Qiagen GmBH Hilden, 
Germany 
Recombinant Mouse EPO R&D systems MN,USA 
Recombinant Mouse Flt3 Ligand R&D systems MN,USA 
Recombinant Mouse G-CSF R&D systems MN,USA 
Recombinant Mouse IL-3  R&D systems MN,USA 
Recombinant Mouse SCF R&D systems MN,USA 
Recombinant Human Flt3 Ligand R&D systems MN,USA 
Recombinant Human IL-3 R&D systems MN,USA 
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Chemicals/Reagents/Kits Company Country 
   




Skim Milk powder Sigma Aldrich MO,USA 
SMART-PCR cDNA Synthesis Kit Clontech CA,USA Sodium	  Dodecyl	  Sulfate	  (SDS) Bio-Rad CA,USA 
Sodium Fluoride Sigma Aldrich MO,USA 
SuperScript II RT First-Strand kit Invitrogen CA,USA TaqMan	  Gene	  Expression	  Assay	  (Real	  time	  PCR)	   ABI systems CA,USA Tetramethylethylenediamine	  (TEMED) Bio-Rad CA,USA 
Tris-Base Bio-Rad CA,USA 
Trizol Sigma Aldrich CA,USA 
Tween 20 Sigma Aldrich MO,USA 
   
 
2.1.2. Antisera 
2.1.2.1. Western Blotting (WB) 
Table 2.2: List of Primary Antibodies (WB) 
Target Company Description Dilution Incubation 
Conditions 
     
β-Actin Sigma Aldrich Mouse Monoclonal 1:10000 Overnight at 4
0C 
Akt Cell Signaling Technologies Rabbit Polyclonal 1:5000 Overnight at 4
0C 
Flag Sigma Aldrich 
Mouse 
Monoclonal 1:10000 Overnight at 4
0C 
Flt3 Santa Cruz Biotechnologies Rabbit Polyclonal 1:1000 Overnight at 4
0C 
GRP 78 Santa Cruz Biotechnologies Goat Polyclonal 1:1000 Overnight at 4
0C 
N-CoR Santa Cruz Biotechnologies Goat Polyclonal 1:500 Overnight at 4
0C 
N-CoR Upstate Technologies Rabbit Polyclonal 1:1000 Overnight at 40C 












Rabbit Polyclonal 1:1000 Overnight at 40C 




Table 2.3 : List of Secondary Antibodies (WB) 
Description Company Dilution Incubation 
Conditions 
    
HRP-Goat anti-Rabbit Zymed Laboratories 1:10000 
1 hr, Room 
Temperature 
HRP-Goat anti-Mouse Zymed Laboratories 1:10000 
1 hr, Room 
Temperature 
HRP-Rabbit anti-Goat Zymed Laboratories 1:10000 
1 hr, Room 
Temperature 
    
 
2.1.2.2. Immnofluorescence Staining (IF) 
Table 2.4: List of Primary Antibodies (IF) 
Target Company Description Dilution Incubation Conditions 
     
Akt Cell Signaling Technologies 
Rabbit 
Polyclonal 1:200 Overnight, 4
0C 
Flag Sigma Aldrich Mouse Monoclonal 1:1000 2 hr, Room Temp 
GRP 78 Santa Cruz Biotechnologies 
Goat 
Polyclonal 1:100 2 hr, Room Temp 
N-CoR Santa Cruz Biotechnologies 
Goat 
Polyclonal 1:100 2 hr, Room Temp 
N-CoR Santa Cruz Biotechnologies 
Rabbit 
Polyclonal 1:100 2 hr, Room Temp 
PDI Santa Cruz Biotechnologies 
Rabbit 











Table 2.5: List of Secondary Antibodies (IF) 
Description Company Dilution Incubation Conditions 
    
Alexa Flour Chicken Anti-Goat 
488 
Invitrogen 1:200 1 hr, Room Temperature 
Alexa Flour Chicken Anti-Goat 
594 
Invitrogen 1:200 1 hr, Room Temperature 
Alexa Flour Chicken Anti-Mouse 
488 
Invitrogen 1:200 1 hr, Room Temperature 
Alexa Flour Chicken Anti-Mouse 
594 
Invitrogen 1:200 1 hr, Room Temperature 
Alexa Flour Chicken Anti-Rabbit 
488 
Invitrogen 1:200 1 hr, Room Temperature 
Alexa Flour Chicken Anti-Rabbit 
594 
Invitrogen 1:200 1 hr, Room Temperature 
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2.1.2.3 Flow Cytometry Analysis 
Table 2.6: List of antibodies used in Flow Cytometry Analysis 
Target Company Conjugation Incubation Conditions 
    
CD14 BD Pharmingen FITC 
1 hr, Room 
Temperature 
Annexin V BD Pharmingen FITC 15 mins, 40C 
    
 
 
2.1.3. Primer Sequences 
2.1.3.1. Semi-Quantitative RT-PCR primers 
Table 2.7: List of semi-quantitative RT-PCR primers 
Gene  Sequence  Annealing Temperature (0C) Cycles 
    
GATA-1  Forward: 5’-ATATGCCGGCTGGGCCTACG-3’  Reverse: 5’-GGTGGTCGTCTGGCAGTTGG-3’  60 30 
GATA-2  Forward: 5’-TCATCTTCCGCGGGGGGTAG-3’  Reverse: 5’-GGACATCTTCCGGTTCCGAGTC-3’  60 30 
C/EBPα  Forward: 5’-CAAGCGGGTGGAACAGCTGAG-3’  Reverse: 5’-TGCTCCCCTCCTTCTCTCATGG-3’  60 30 
PU.1  Forward: 5’-CGTGCACAGCGAGTTCGAGAG-3’  Reverse: 5’-GCGCGCCATCTTCTGGTAGG-3’  60 30 
IL5Rα  Forward: 5’-CCTGCAGAACGACCACTCACTAC-3’  Reverse: 5’-CACTCTCTCAAGGGCTTGTGTTC-3’  60 30 
MBP  Forward: 5’-GCGCTCAACCAGGGTCAAGTC-3’  Reverse: 5’-AAGAGAACTAGCTGAGCCCATTCC-3’  60 30 
MCP-5  Forward: 5’-GCCTACCTGGAAATTGTAACTTCC-3’  Reverse: 5’-CAGCTGAAGATTGTGGTCAAAGTC-3’  60 35 
EoPO  Forward: 5’-TATGGCAGTGAGGTCTCCCTCTC-3’  Reverse: 5’-GGTACTGACTGTCCAAGCGGAAC-3’  60 30 
FCεRIα  Forward: 5’-GTGTTAGCAGTCCCTCAGAAACC-3’  Reverse:5’-TACAGTAATGTTGAGGGGCTCAG-3’  60 35 
Notch-1  Forward: 5’-TACTACGGCCGCGAGGAGGA-3’  Reverse: 5’-TGGCAGACATGCGCAGGTCA-3’  60 30 
FOG-1  Forward: 5’-CCTCCCAGCGCAGATGTTAACTC-3’  Reverse: 5’-GGTCTCTTTGGGCTTCTCGTCTG-3’  60 35 
PAX-5 Forward: 5’-AGAGCGGGTGTGTGACAATGAC-3’  Reverse: 5’-GCACACTGCTCCCGATGTCAG-3’ 60 35 
EBF Forward: 5’-TGGCCCGGGCTCACTTTGAG-3’  Reverse: 5’-GAGCAAGACTCGGCACATTTCTG-3’ 60 35 
HoxA9 Forward: 5’-ATCCCAATAACCCAGCAGCCAAC-3’  Reverse: 5’-ACACACAGCTATCAGCACTAATGC-3’ 60 30 
HoxA10 Forward: 5’-GATTCCCTGGGCAATTCCAAAGG-3’  Reverse: 5’-CCCAGGAGATGGCGAGTGTG-3’ 60 30/40 
β-catenin  
 
Forward: 5’-GTAGAAGCTGGTGGAATGCAAGC-3’  
Reverse: 5’-ATAGTGAAGGCGAACTGCATTCTGG-3’ 60 30/40 
Flt3 Forward: 5’-TCAGGGGCAATGCCCGTCTG-3’  Reverse: 5’-CTGCATCTGCCAGCTGACATCC-3’ 60 30/40 
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JunB Forward: 5’-GCCTCCACCTTCAAGGAGGAAC-3’  Reverse: 5’-GGGCAGGGGACGTTCAGAAG-3’ 60 30 
Plakoglobin Forward: 5’-ACGAGGGCACTGCCACCTAC-3’  Reverse: 5’-AGGCCGTCGCTGTAGGTGTC-3’ 60 30 
Scl/Tal1 Forward: 5’-CTCGGCAGCGGGTTCTTTGG-3’  Reverse: 5’-CATTGAGCAGCTTGGCCAAGAAG-3’ 60 30 
Stat5A Forward: 5’-GGAAGTTTGACTCCCCGGAACG-3’  Reverse: 5’-CTGGCCACATCCATGGTCTCATC-3’ 60 30 
N-CoR1 Forward: 5’-GACTCTGATATGGCAGCTGCTCAG-3’  Reverse: 5’-GCTGAGCATCCGCATAGTCAGAG-3’ 60 30 
HPRT Forward: 5’-GAAGGAGATGGGAGGCCATCAC-3’  Reverse: 5’-CAACAATCCGCCCAAAGGGAAC-3’ 60 30 
    
 
2.1.3.2. Real Time PCR Primer Assays (Taqman) 
Table 2.8: List of Taqman Assays used in Real Time PCR Analysis 




C/EBP alpha  HS02915002_s1 
C/EBP gamma  HS00156454_m1 
PU.1 HS02786711_m1 





















2.1.3.3. ChIP Assay Primers 
Table 2.9: List of Primers used in ChIP assay 
Gene  
Promoter Sequence  
Annealing 
Temperature (0C) Cycles 
    
CD36 Forward: 5’-AAGACAGGAAAACCTGAGCCTTCC-3’  Reverse: 5’-CTCACTCATTTTGGGCCTCAGTTG-3’  60 25 
Flt3  Forward: 5’-ACCTCCCTAATTGCCTTGGTTGAC-3’  Reverse: 5’-GGATCTTTGAGGCCCTGAGAAAGG-3’  60 25 
Scl/Tal1  Forward: 5’-AAAAGAGGTCTTCGCTCCCTTTCC-3’  Reverse: 5’-ATCCCACCGCATGCACACAAC-3’  60 25 
    
 
2.1.3.4. siRNA sequences 
Table 2.10: List of siRNA sequences used in siRNA mediated gene knockdown 
Target Sequence  
  




2.1.3.5 Site directed mutagenesis sequences 
Table 2.11: List of primers used in Site Directed Mutagenesis 


















Table 2.12: Primers used for analysis of base pair mutations  









2.1.4.1. pACT –N-CoR-Flag 
            The non-viral mammalian expression vector, carrying the ampicillin 
bacterial resistant gene and the CMV promoter, pACT was purchased from 
Promega, USA. The pACT-N-CoR-Flag consist of 2 tandem repeats of the 
Flag sequence, linked to the C-terminal end of the mouse N-CoR sequence. It 
was cloned into the vector site at the Nco1 and Xba1 restriction sites.  
2.1.4.2. pEGFP-MLL1-AF9 
          The non-viral mammalian expression vector, carrying the kanamycin 
bacterial resistant gene, the gene encoding the Enhanced Green Fluorescent 
protein (GFP) variant of the Aequorea victoria and the CMV promoter, 
pEGFP-C1 was purchased from Clontech, USA. The MSCV-MLL1-AF9-MIG 
plasmid was a kind gift from Dr Scott. A. Armstrong from the Harvard 
Medical School, Boston, Massachusetts, USA. The MLL1-AF9 sequence was 
excised via Eco1 blunt end restriction digestion and cloned into the pEGFP-C1 
vector. The pEGFP-MLL1-AF9 plasmid contains the GFP tagged at the N-
terminus of the MLL1-AF9 sequence. 
2.1.4.3. pECFP-myr-Akt 
         The pECFP-myr-Akt plasmid was a kind gift from Dr Koichi Okumura 
from the Cancer Science Institute, National University of Singapore.  pECFP-
C1 plasmid encodes an Enhanced Cyan Fluorescent (CFP) variant of the 
Aequorea victoria Green Fluorescent Protein (GFP) gene. It is a non-viral 
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mammalian expression vector carrying the kanamycin bacterial resistant gene 
and the CMV promoter.  
2.1.4.4. Luciferase reporter plasmids. 
          The Flt3 (-901)-luciferase reporter plasmids were kind gifts from Dr 
Shinichiro Takahashi from the Division of Hematology, Kitasato University 
School of Allied Health Science, Kanagawa, Japan. The Flt3 promoter region 
(up to 901 basepairs upstream of the Flt3 transcriptional start site) was cloned 
into the pGL3 Luciferase reporter Vector from Promega, USA. The pGL3 
vector contains a modified coding region for the firefly (Photinus pyralisi) 
luciferase gene. It carries an ampicillin bacterial resistant gene and lacks the 
eukaryotic promoter and enhancer sequences to allow for the cloning of 
putative regulatory sequences. 
2.1.5. Cell Lines  
2.1.5.1. AML-M5 cell lines 
         The AML-M5 cell lines, THP-1, SigM5 and Mono-Mac-1 were obtained 
from DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH (German Collection of Microorganisms and Cell Cultures). The AML-
M5 cell lines Nomo-1 and MV-4-11 were kind gifts from Dr Motomi Osato 
from the Cancer Science Institute of Singapore and Dr Chien Shing Chen from 
Loma Linda University, California, USA. The cell lines THP-1, Mono-Mac-1 
and Nomo-1 carry the t (9:11) (p22; q23) translocation resulting in the 
expression of the fusion protein MLL1-AF9. While both THP-1and Nomo-1 
are known to express the wild type Flt3 receptor, Mono-Mac-1 is known to 
carry a constitutively active Flt3 receptor due to an activating point mutation 
at tyr594 in the kinase domain of the Flt3 receptor.  The cell line MV-4-11 
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carries a t (4:11) (q21; q23) translocation resulting in the expression of the 
fusion protein MLL-AF4 and is known to carry the Flt3-ITD mutant receptor. 
The cell line SigM5 has no reported chromosomal translocations and no 
known Flt3 receptor status. 
2.1.5.2. AML cell lines from other FAB subtypes 
         The AML-M2 cell line HL60 was purchased from the American type 
Culture Collection.  
2.1.5.3. Non AML cell lines 
         The non-AML cell lines U937 (Histiocytic Lymphoma), K562 (Chronic 
Myelogenous Leukemia) and HEK 293T (Human Embryonic Kidney) cells 
were obtained from the American type Culture Collection. The mouse pro B-
cell line BA/F3 was obtained from DSMZ - Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (German Collection of 
Microorganisms and Cell Cultures). 
2.1.6. AML primary patient specimens. 
          A total of 12 AML primary patient specimens and were used in this 
study. Primary leukemic specimens used in this study were obtained at the 
time of diagnosis. Diagnoses of AML were made from the morphology and 
cytochemistry according to the French–American–British (FAB) classification 
as well as immunophenotypic and cytogenetic analyses. Mononuclear cells 
were isolated from peripheral blood or bone marrow samples. This study was 
approved by the Institutional Review Boards and informed consent was 
obtained from the patients in accordance with the Declaration of Helsinki. The 
samples were obtained from Dr Norio Asou from Kumamoto University, 
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Japan, as well as from Dr Chng Wee Joo from the Department of Hematology-
Oncology, National Cancer Institute of Singapore. 
2.2. Experimental Procedures 
2.2.1. Tissue Culture and Techniques 
2.2.1.1. Mammalian cell culture maintenance. 
          All Cells were cultured in either RPMI 1640, IMDM, α-MEM or 
DMEM supplemented with heat in-activated Fetal Bovine Serum (FBS), in a 
humidified atmosphere of 5% CO2 at 370C. Detailed culture conditions and 
cytokine requirements of the various cell lines are listed in Table 2.13. Cells 
were split at a ratio of 1:10 every 2 to 3 days. 
Table 2.13: List of cell lines and culture medium composition. 
Cell Line Description/ Species Culture Medium Composition 
   
HL60 FAB-M2/Human RPMI1640 + 10%FBS 
NB4 FAB-M3/Human RPMI1640 + 10%FBS 
Mono-Mac-
1 
FAB-M5/Human RPMI1640 + 10%FBS 
MV-4-11 FAB-M5/Human RPMI1640 + 10%FBS 
Nomo-1 FAB-M5/Human RPMI1640 + 10%FBS 
SigM5 FAB-M5/Human IMDM + 20%FBS 
THP-1 FAB-M5/Human RPMI1640 + 10%FBS 
BA/F3 Pro-B/ Mouse RPMI1640 + 10%FBS+10ng/ml rmIL-3 
HEK293T Embryonic Kidney/ Human DMEM + 10% FBS 
K562 CML/Human RPMI1640 + 10%FBS 
U937 Histiocystic Lymphoma/ Human RPMI1640 + 10%FBS 
   
 
2.2.1.2. Storage of cells. 
        Suspension cells were pelleted directly at 200 g for 5 minutes while 
adherent cells were first trypsinized before pelleting. Cell pellets were 
resuspended in freezing medium (10% DMSO v/v in FBS) at a density of 1 X 
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106 cells/ml of freezing medium. 1 ml aliquots were stored in polypropylene 
cryovials and tubes were frozen slowly at 10C per minute in -800C overnight. 
Vials were then transferred and stored in -800C for short-term storage or in 
liquid nitrogen for long term storage. 
2.2.1.3. Revival of frozen cells. 
         Frozen cell stocks were thawed rapidly in a 370C water bath and 
transferred to an appropriate volume of culture media (pre-warmed to 370C). 
Cells were pellet at 200 g for 5 minutes and resuspended in fresh culture 
media to remove traces of DMSO. The cells were then transferred to a sterile 
culture flask and incubated at 370C in a humidified atmosphere of 5% CO2. 
2.2.1.4. Treatment of cells with drug compounds, cytokines and 
antibodies. 
2.2.1.4.1. Treatment of THP-1 cells with AEBSF. 
         THP-1 cells were seeded at a density of 2 x 105 cells/ml and appropriate 
amounts of either vehicle or AEBSF (to final concentrations of 50, 100, 200 
and 400 µM) were added and incubated at 370C in a humidified atmosphere of 
5% CO2 for 48 hours before harvesting for protein expression analysis. 
2.2.1.4.2. Treatment of THP-1 cells with Genistein. 
           THP-1 cells were seeded at a density of 2 x 105 cells/ml and appropriate 
amounts of either vehicle or Genistein (to final concentrations of 12.5, 25, 50 
and 100 µM) were added and incubated at 370C in a humidified atmosphere of 






2.2.1.4.3. Treatment of THP-1 cells with Akti-X. 
      THP-1 cells were seeded at a density of 2 x 105 cells/ml and 
appropriate amounts of either vehicle or Akti-X (to final concentrations of 1, 
2.5, 5 and 10 µM) were added and incubated at 370C in a humidified 
atmosphere of 5% CO2 for 24 hours before harvesting for protein expression 
analysis. 
2.2.1.4.4. Treatment of THP-1 cells with Kaletra. 
THP-1 cells were seeded at a density of 2 x 105 cells/ml and 
appropriate amounts of either vehicle or Kaletra (to final concentrations of 1, 
2.5, 5 and 10 µM) were added and incubated at 370C in a humidified 
atmosphere of 5 % CO2 for 24 hours before harvesting for protein expression 
analysis. 
2.2.1.4.5. Treatment of THP-1 cells with anti-Flt3 antibody. 
           THP-1 cells were serum starved overnight and seeded at a density of 4 
x 105 cells/ml in 3 mls of serum free media in a 6-well plate. Anti-Flt3 
antibody or control IgG was added in various amounts (1, 0.5, 2.5,5 µg) and 
cells were incubated for 60 minutes at 370C in a humidified atmosphere of 5 % 
CO2. Cells were then stimulated with 30 ng/ml of rh-Flt3 ligand for 4 hours 
before harvesting for protein expression analysis. 
2.2.1.4.6. Treatment of BA/F3 cells with rm-Flt3 ligand. 
           BA/F3 cells which were electroporated with either 2 µg of N-CoR 
siRNA or 2 µg of control siRNA were allowed to recover in IL-3 containing 
growth medium for 48 hours to allow for Flt3 receptor expression. Cells were 
then washed once in 1X PBS, resuspended in IL-3 free culture medium or Flt3 
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ligand (100 ng/ml) supplemented media and seeded at 2000 cells/100 µl in 96-
well plate. Cells were assayed for growth proliferation over duration of 4 days. 
2.2.1.4.7. Treatment of HEK293T cells with rh-Flt3 ligand 
          HEK293T cells were transfected with either 6 µg of MSCV-GFP-Flt3 
(WT) expression vector or 6 µg MSCV-GFP-Empty vector and incubated for 
24 hours. After which cells were serum starved overnight and stimulated with 
30 ng/ml of rh-Flt3 ligand for 4 hours before cells are assayed for SDS-PAGE 
and Western Blotting Analysis. 
2.2.1.5. Transfection of cells. 
2.2.1.5.1. Transfection in HEK293T cells using Fugene 6. 
       HEK293T cells were transfected using the lipid base transfection 
reagent Fugene 6 (Roche, Germany) according to the manufacturer’s 
instructions. Briefly cells were seeded at 1 x 105 cells/ml in a sterile 10 cm TC 
dish and incubated for 18-22 hours at 370C in a humidified atmosphere of 5% 
CO2. On the day of transfection, 18 µl of Fugene 6 was mixed in 150 µl of 
serum free-DMEM and incubated for 5 minutes. 6 µg of DNA was then added 
and incubated for 15 minutes. The transfection mix was then added drop wise 
to the cells. Cells were grown for 48 hours before being assayed. 
2.2.1.5.2. Transfection in HEK293T cells using Lipofectamine 2000. 
       HEK293T cells were transfected with Lipofectamine 2000 reagent 
(Invitrogen, US) according to the manufacturer’s protocol. Briefly, cells were 
seeded into at 1 x 105 cells/ml in 3 mls of DMEM in a 6-well plate and grown 
overnight (until 80-90% confluency). 
      On the day of transfection, DNA/siRNA and Lipofectamine 2000 were 
prepared separately in 250 µl of serum free-DMEM and incubated for 5 
50	  
	  
minutes at room temperature. Diluted DNA was combined with the 
Lipofectamine 2000 and the mix was incubated for 20 minutes at room 
temperature. The transfection complexes were added drop wise to the cells and 
incubated for 4 hours at 37ºC before replacing the medium with fresh DMEM. 
Cells were then grown for 48 hours before being assayed. 
2.2.1.5.3. Transfection in AML cell lines and BA/F3. 
       The AML cell lines THP-1 and HL60 were transfected via 
electroporation using the Amaxa Cell line Nucleofector Kit (Amaxa, Cologne, 
Germany) and the Nucleofector II system. Briefly, cells were pelleted at 90 g 
for 10 minutes and resuspended in 100 µl of Nucleofector solution. Cells were 
then electroporated using the Nucleofector II system set to cell line specific 
programs. Cells were then immediately added to pre-warmed culture media 
and transferred to a sterile TC dish and grown for 48 hours before being 
assayed. Cell line specific Nucleofector solution and program requirements 
can be accessed at the Amaxa website. 
2.2.1.5.4. siRNA mediated gene knockdown 
       All siRNA (Qiagen, Hilden, Germany) were synthesized as fully 
annealed oligonucleotide duplexes. The lyophilized siRNA were reconstituted 
in 1ml of sterile water as suggested by the manufacturer. For siRNA-mediated 
knockdown of N-CoR in HL60 and BA/F3 cells and siRNA mediated Akt 
knockdown in THP-1 cells, 2 µg of siRNA was transfected by electroporation 
using the Cell Line Nucleofector kit V (Amaxa, Cologne, Germany) according 
to the manufacturer’s optimized protocol. In case of HEK293T cells, siRNA 
was transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 
A mock siRNA targeting the luciferase sequence, which is not found in the 
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mammalian genome, was used as control. All siRNA sequences used are 
depicted in Table 2.10 in section 2.1.3.4. 
2.2.2. Protein Assays. 
2.2.2.1. Direct Lysis of cells. 
           Cell lysates were prepared by pelleting cells at 200 g for 5 minutes. 
Cell pellets were washed using ice cold 1X PBS and was lysed directly with 
5X pellet volume of 1X SDS sample buffer (50 mM Tris pH 6.8, 10% 
Glycerol, 2% SDS, 0.1% Bromophenol Blue, 5% β-mercaptoethanol). Lysates 
were sonicated briefly at 5W for 10 seconds using the Branson Sonifier150 
and this was repeated twice. Cell lysates were then heat inactivated at 500C for 
10 minutes. Lysates were stored at -800C for analysis by SDS-PAGE and 
Western Blotting.  
            For primary patient specimens that arrived as frozen cell pellets, the 
pellets were lysed directly with 2X SDS sample buffer and prepared and 
stored as mentioned above. 
2.2.2.2. In Vitro Cleavage Assay 
           Crude cellular extracts of cell lines and primary patient specimens were 
prepared in RSB buffer (10 mM Tris pH 8.0, 10 mM NaCl, 3 mM MgCl2, 
0.1% NP-40) incubated on ice for 15 minutes and nuclei were removed by 
centrifugation at 800 g for 5 minutes. N-CoR substrate was prepared from 
HEK293T cells transfected with N-CoR and PML-RARα expression plasmids 
in 2X NT buffer (40 mM Tris pH 8.0, 1.2 M NaCl). Optimized cleavage 
assays were performed at 370C in buffer containing 300 mM NaCl, 50 mM 
Tris pH 8.0. The reaction was stopped by heating the samples at 500C in SDS 
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sample buffer and proteins were resolved with SDS-PAGE and transferred to 
PVDF membranes for western blotting. 
2.2.2.3. Protein Solubility Assay 
           Cellular extracts were prepared in NET buffer (20 mM Tris pH 8.0, 300 
mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 tablet/10 ml Complete Mini protease 
inhibitor tablet [Roche, Germany]) and rotated at 40C for 45 minutes. The 
insoluble fraction was separated from the soluble fraction by centrifugation at 
20000 g for 10 minutes. SDS sample buffer was then added to the fractions 
and fractions were heat inactivated at 500C for 10 minutes. Proteins were 
resolved with SDS-PAGE and transferred to PVDF membranes for western 
blotting. 
2.2.2.4. Immunoprecipitation 
           For Immunoprecipitation (IP), 4 X 108 cells were pelleted at 200 g for 5 
minutes, washed once in ice cold PBS and lysed in 1 ml of  IP buffer (20 mM 
Tris pH 7.4, 300 mM NaCl, 0.5% NP-40, 1 mM EDTA, 200 µM AEBSF, 1 
tablet/50 ml Complete protease inhibitor tablet [Roche, Germany], 1 mM NaF, 
20 mM β-Glycerolphosphate, 10 ul/ml Phosphatase Inhibitor Cocktail I 
[Sigma, USA], 10 µl/ml Phosphatase Inhibitor Cocktail II [Sigma, USA]). The 
lysate was sonicated at 5 W for 10 seconds twice using the Branson 
Sonifier150. Lysate was then centrifuged at 850 g for 5 minutes and a fraction 
of the supernatant was taken and inactivated by adding 4X SDS sample buffer 
to a final concentration of 1X and heated at 500C for 10 minutes this will be 
analyzed by SDS-PAGE and Western Blotting as input controls. The 
remaining supernatant was then subjected to immunoprecipitation by rotating 
with 10 µg of anti-N-CoR antibody or 10 µg of normal goat IgG for 2.5 hours 
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at 40C. 50 µl of Protein G sepharose beads (Roche, Germany) resuspended in 
IP buffer was then added to each reaction and rotated for another 1.5 hours. 
Protein bound to the Protein G beads were then pelleted at 850 g for 5 
minutes. The supernatant was carefully removed and protein bound beads 
were washed 4 times with IP buffer. Bound protein was released from the 
beads by addition of 2 X SDS sample buffer and supernatant was collected 
after centrifugation at 850 g for 5 minutes. The supernatant consisting of 
mainly immunoprecipitated protein was heat inactivated at 500C for 10 
minutes and stored at -800C for analysis by SDS-PAGE and Western Blotting. 
2.2.2.5. In Vitro Phosphorylation Assay 
      HEK293T cells were transfected with pAct-N-CoR-Flag and incubated for 
48 hours. Flag-tagged N-CoR was immunoprecipitated from HEK293T cells 
using the Affinity Flag M2 resin (Sigma Aldrich, MO, USA). Purified flag-
tagged N-CoR was eluted from the resin using 3X flag peptide (Sigma 
Aldrich, MO, USA).   
      Active Akt kinase was purified from pCFP-Myr-Akt transfected HEK293T 
cells and immunoprecipitated using anti-pAkt (Ser473) immobilized beads 
(Cell Signaling Technologies, CA, USA).  
       In vitro phosphorylation assay was performed using the non-radioactive 
Akt kinase assay kit (Cell Signaling Technologies, CA, USA) as describe by 
the manufacturer. Briefly, purified active Akt kinase was resuspended in 50 µl 
of 1X kinase buffer supplemented with 1 µl of 10 mM and 4 µg purified flag-
tagged N-CoR. The mixture was incubated at 300C for 30 minutes for the 




       In vitro phosphorylation of N-CoR was analyzed via western blotting 
assay with anti-phospho Akt substrate (RxRxx pS/pT) antibody. Amount of N-
CoR added to the reaction was detected using anti-Flag antibody while Akt 
kinase was detected using the pAkt (Ser 473) antibody. 
2.2.3. Protein expression analysis 
2.2.3.1. SDS-PAGE 
      Cell lysates were resolved on SDS-PAGE. Denaturing polyacrylamide gels 
of 6, 8 or 10% acrylamide (Components are listed in 2.14) were cast using a 
mini-Protean gel caster (BioRad). Gels were poured into the caster, overlaid 
with water and allowed to set for 1 hour. Once set, water was removed and 
stacking gel (5% acrylamide mix, 125 mM Tris [pH 6.8], 1% SDS, 4 mM 
EDTA) was poured. Both reservoirs were then filled with 1x SDS-PAGE 
running buffer (25 mM Tris-Base, 192 mM glycine, 0.1% SDS w/v). Protein 
samples (Concentration dependent on protein to be visualized) were loaded 
and run through the stacking gel at 10 mA before separating at 17 mA at 40C. 
Gels were then either stained with Coomassiee Blue staining solution for 30 











Table 2.14: Components of Gels used in SDS-PAGE 
COMPONENTS GEL PERCENTAGE (%) 
 6 8 10 
    
Water (ml) 5.3 4.6 4.0 
30% acrylamide mix 
(ml) 
2.0 2.7 3.3 
1.5 M Tris-pH 8.8 (ml) 2.5 2.5 2.5 
10% APS (µl) 100 100 100 
10% SDS (µl) 100 100 100 
TEMED (µl) 8 6 4 
Total Volume (ml) 10 10 10 
    
 
2.2.3.2. Western Blotting 
      Resolved proteins were transferred onto PVDF membrane using the wet 
transfer system (Bio-Rad, US) in cold 1X transfer buffer (48 mM Tris-base, 37 
mM Glycine, 0.037% SDS w/v) with 10% methanol. Transfer was carried out 
at a constant current of 60 mA for 2.5hrs at 40C. Membrane was then blocked 
for non-specific interactions with 5% skimmed milk powder (Sigma Aldrich, 
MO, USA) in PBS 0.01% Tween-20 at room temperature for 1 hour. The 
membrane was then incubated with the primary antibody (see Table 2.2 in 
section 2.1.2.1 for dilution and incubation times). Following 3 washes of 10 
minutes each in PBS; 0.01% Tween-20, the appropriate peroxidase-conjugated 
secondary antibody was added to the membrane for 1 hour at room 
temperature (concentration specified in Table 2.3 in section 2.1.2.1). 
Membranes were again washed 5 times for 10 minutes each in PBS 0.01% 
Tween-20 and finally visualized by using enhanced chemiluminescent 
reagents (Amersham) and exposure to Fuji X-Ray film. To reprobe the 
membrane with another primary antibody, antibodies were stripped by 
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incubating the membrane for 15 to 45 minutes (depending on the antibody) at 
room temperature in stripping buffer (200 mM glycine, 1% SDS, pH 2.5). The 
membrane was then re-blocked in 5% skimmed milk before being incubated 
with a new primary antibody. 
2.2.4. Cell Based Assays 
2.2.4.1. May-Grunwald-Giemsa Staining 
          Cells were cytospun onto glass slides at 1000 rpm for 5 minutes. Fixing 
was then performed using May-Grunwald solution (Merck, Germany) for 5 
minutes at room temperature and stained with Giemsa stain diluted in 1XPBS 
for 30 minutes. Slides were washed with distilled water and cell morphology 
was observed using light microscopy. 
2.2.4.2. Immnofluorescence Staining 
           Cells were cytospun onto glass slides and fixed with 3% 
paraformaldehyde at 370C and permeabilized with 0.2% Triton-X-100 in PBS 
for 5 minutes at 40C. After blocking with 5% Bovine Serum Albumin (BSA), 
the cells were stained with primary antibody at 1:100 dilution in 5% BSA for 2 
hours followed by fluorescence labeled secondary antibodies at 1:200 dilution 
in 2.5% BSA for 1 hour. The cell nuclei were then stained with 4’, 6-
diamidino-2-phenylindole (DAPI) at 1:3000 dilution in 5% BSA for 10 
minutes. Slides were visualized using confocal microscopy. 
2.2.4.3. Cell Proliferation Assay 
          The cell proliferation assay was carried out using the Cell Proliferation 
Kit I [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; (MTT)]	  
(Roche, Germany) as described by the manufacturer. Briefly, cells were 
seeded into 96-well plates at 8 x 103 cells per well in 100 µl of culture medium 
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containing various concentrations of AEBSF, Genistein, Kaletra or Akti-X.  
The plates were then incubated at 370C at 5% CO2 for the durations stated. 
After the incubation period, MTT labeling reagent was added and incubated at 
370C for 4 hours. This was followed by the addition of the solubilization 
solution and the reaction was then allowed to stand overnight at 370C. The 
spectrophotometric absorbance was measured using a microplate reader 
(Ultramark, Biorad) at wavelength 595 nm with a reference wavelength of 655 
nm.  For statistical analysis, the results of the proliferation assays were 
reported as mean ± SD. Statistical analysis was performed using unpaired t-
test. P value less than 0.05 was considered to be statistically significant. 
2.2.4.4. Apoptosis Assay  
      Detection of phosphatidylserine (PS) on the outer leaflet of apoptotic cells 
was performed using FITC conjugated Annexin V (Pharmingen, San Diego, 
CA) and Propidium Iodide (Pharmingen, San Diego, CA) according to the 
manufacturer’s recommendations. Briefly, cells were pellet and washed once 
with ice cold 1X PBS. Cell pellets were then resuspended in 1X Annexin V 
binding buffer and FITC conjugated anti-Annexin V antibody and Propidium 
Iodide were added at 1:20 dilution. Mixture was then allowed to incubate for 
15 minutes in the dark at room temperature. Flow cytometry was performed 
using fluorescence activated cell sorting (NUMI core facility and CSI flow 
Cytometry Unit, National University of Singapore). 
2.2.4.5. Determination of Cell Differentiation 
          THP-1 cells were grown with various concentrations of Genistein or 
vehicle and incubated for 72 hours at 370C at 5% CO2. Cells were then 
collected, washed twice with PBS + 0.5% bovine serum albumin and 
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incubated for 60 minutes on ice in 500 µl of PBS + 0.5% bovine serum 
albumin with PE conjugated monoclonal mouse anti-human CD14 antibody or 
control IgG ((Pharmingen, San Diego, CA). Antibody conjugated cells were 
washed with PBS + 0.5% bovine serum albumin and analyzed using 
fluorescence activated cell sorting (NUMI core facility and CSI Flow 
Cytometry Unit, National University of Singapore). 
2.2.4.6. Colony Assay 
         1×104 GFP and c-Kit positive cells purified from bone marrow (BM) 
cells infected with MSCV-IRES-GFP-N-CoR or empty vector were cultured 
in 35-mm plates in 1 ml Methocult M3131 methylcellulose medium (StemCell 
Tec., Canada) containing 1% antibiotic-antimycotic supplemented with 10 
ng/ml recombinant murine IL-3, 10 ng/ml SCF, 100 ng/ml G-CSF and 10 
ng/ml EPO. Morphology of MSCV-IRES-GFP-N-CoR or vector infected cells 
was determined by May-Grunwald-geimsa staining. 
2.2.4.7. Long-Term Culture-Initiating Cell (LTC-IC) Assay 
           1×104 GFP and c-Kit positive cells were cultured for 18 days in a 6-
well plate on an OP9 stromal cell layer in 2 ml αMEM medium supplemented 
with 10% FBS, 1% antibiotic-antimycotic and 10 ng/ml recombinant murine 
IL-3, 100 ng/ml G-CSF, 10 ng/ml SCF and 10 ng/ml EPO (Pepro Tech EC 
Ltd). Hematopoietic cells were then harvested and subjected to Wright-
Giemsa staining for morphological analysis. 
2.2.5. In vivo Transplantation Assay in Mice 
      5 x 105 transfected BM cells were transplanted intravenously into sub 
lethally irradiated C57BL/6 mice (8 Gy). The recipient mice were examined at 
week 3,6 and 10 for blood cell counts and GFP positivity in peripheral blood. 
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Phoenix-Eco packaging cell line was kindly provided by A/Prof Motomi 
Osato (Cancer Science Institute, Singapore). 
2.2.6. Gene expression analysis 
2.2.6.1. Reverse Transcription PCR (RT-PCR) analysis 
       Total RNA was isolated using the RNeasy® Mini Kit protocol for 
isolation from mammalian cells using a table top centrifuge (Qiagen GmBH, 
Hilden, Germany). Briefly, Cells were lysed using 350 µl of Buffer RLT 
which is a highly denaturing guanidine-thiocynate containing buffer (which 
inactivates RNases) supplemented with 0.01% 2-mercaptoethanol using gentle 
syringing (5 times through a blunt 20-guage needle). Next 350 µl of 70% 
ethanol was added and sample was mixed by gentle pipetting. The sample was 
then applied to the RNeasy spin column for binding of the RNA to the resin. 
The resin was washed with DNase1 containing buffer RW1 to remove protein 
and DNA contaminants. The resin was again washed with ethanol containing 
buffer RPE and RNA was eluted from the resin using 30 µl of DEPC treated 
water. 
	  	  	  	  	  	  	  	   From each sample, 2 µg of RNA was aliquoted into a sterile 
microcentrifuge tube with 3 pmoles of oligo-dT (18-mer) and DEPC-treated 
water added to a final volume of 21 µl. The mixture was incubated at 65°C for 
15 minutes and immediately quenched on ice. A mastermix of 10 µl of 5 X RT 
buffer, 1 µl of 25 mM dNTPs, 0.5 µl of RNasin Inhibitor, 1 µl of murine 
reverse transcriptase and sterile water was prepared to a total volume of 29 µl 
for each sample. The mastermix was added to the RNA and mixed. The 
sample was incubated at 42°C for 1 hour for the generation of cDNA. PCR 
amplification was carried out in 50 µl volumes (1 µl of 10 X or 100 X diluted 
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template, 1X PCR reaction buffer, 200 nM of each dNTP, 0.8 µM of each 
primer and 1.5 units of DNA polymerase were used for each reaction). List of 
genes and their corresponding primers used are listed in Table 2.7 in section 
2.1.3.1. 
       Gene expression analysis was carried by agarose gel electrophoresis 
where PCR products were resolved in 1% w/v agarose gel (1 g of 
electrophoretic grade agarose powder in 100 ml 1X TAE buffer [40 mM Tris-
acetate (pH 7.8), 1 mM EDTA]) stained with Gel Red (Life Technologies, 
Delhi, India) at a 1:10000 dilution and expression levels visualized using 
Trans UV on the Gel Doc System (Bio-Rad, CA, USA). 
2.2.6.2. Real time PCR (qRT-PCR) analysis 
       For cell lines, total RNA was isolated using the RNeasy Mini Kit 
(Qiagen GmBH, Hilden, Germany). From each sample, 2 µg of RNA was 
converted into cDNA as described in section 2.2.6.1. 
      For analysis of gene expression normal mouse hematopoietic cells, 
each type of hematopoietic cells was purified from mouse bone marrow cells 
by FACS using cell specific antibodies. About 5000 cells from each 
population were lysed using Trizol, and total RNA was purified according to 
the manufacturer's instructions (Life Technologies, Rockville, MD). First-
strand cDNA was synthesized using SMART-PCR cDNA Synthesis Kit 
(Clontech). 
       qRT-PCR analysis was carried out using the Taqman® Gene 
Expression Assay System (Applied Biosystems, CA,USA) and Ct values were 
recorded using the ABI Prism 7300 Real Time PCR system (Applied 
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Biosystems, CA, USA).  The PCR reaction and PCR conditions were as 
follows, 
Table 2.15: qRT- PCR Reaction set up using the Taqman® Gene Expression 
Assay System. 
Component Volume used per reaction (µl) 
  
2X Taqman Universal PCR master mix 12.5 
20X Primer Mix 1.25 
Nuclease Free Water 10.25 
cDNA 1 
Total Volume 25 
  
 
Table 2.16: qRT-PCR conditions using the ABI Prism 7300 system. 
Step Temperature (0C) Time  Number of 
Cycles 
    








Elongation 60 10 mins 1 
    
       For gene expression analysis in human leukemic cell lines, list of genes 
and assay used are listed in Table 2.8 in section 2.1.3.2. Expression of the 
housekeeping gene HPRT was used as the endogenous control. 
       For gene N-CoR and Flt3 gene expression analysis in mouse 
hematopoietic cells, the Taqman® Gene expression Assays (Mm 
00448681_m1 for N-CoR and Mm00439016_m1 for Flt3) were used and 
expression of housekeeping gene GAPDH was used as an endogenous control. 
Analysis of the data was carried out as follows. 
       For gene expression in cell lines, data was analyzed using the 
comparative Ct method where the cell line HL60 was used as the reference 
sample and the HPRT gene was used as the endogenous gene control. 
       For gene expression in mouse hematopoietic cells, the same 
comparative Ct method was applied with the expression levels in the total 
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bone marrow fraction used as the reference sample and the expression of the 
GAPDH gene used as the endogenous gene control. 
       Briefly, in qRT-PCR the cycle number at which the increase in 
fluorescence (and there for the amount of cDNA) is logarithmic. The point at 
which the fluorescence crosses the preset threshold is called the Ct. In the 
comparative Ct method, relative gene expression is compared based on an 
assumption that the primer efficiencies are relatively similar. In this method 
the need to generate a standard curve is omitted.	  The Comparative Ct method 
involves comparing the Ct values of the samples of interest with a reference 
sample or calibrator .The Ct values of both the reference sample and the 
samples of interest are normalized to an endogenous housekeeping gene. The 
comparative Ct method is also known as the 2-∆∆Ct method, where 
∆∆Ct = ∆Ct,sample - ∆Ct,reference 
Here, ∆CT,sample is the Ct value for any sample normalized to the 
endogenous housekeeping gene and ∆Ct, reference is the Ct value for the 
reference sample also normalized to the endogenous housekeeping gene. Data 
representation is in the form of a bar graph plotted on a log scale with a base 
of 10, where expression level in the reference sample for all genes will be set 
to 0 while genes which are up-regulated relative to expression levels in the 
reference sample will be given a positive value and those which are repressed 
relative to expression levels in the reference sample will be given a negative 
value. 
       Raw Ct values which were undetermined were set to 40. Data 




2.2.7. Promoter Studies 
2.2.7.1. Dual Luciferase Reporter Assay 
       For analysis of N-CoR repression of the Flt3 promoter, suspension 
leukaemia cell lines HL60, THP-1, K562 and U937 were co-transfected with 1 
µg of Flt3 full-length promoter / firefly luciferase reporter plasmid or 
promoter-less pGL3-basic vector and 5 ng of CMV / renilla luciferase plasmid 
(as internal control to normalize firefly luciferase signal) by electroporation, 
using the Cell Line Nucleofector kit (Amaxa, Cologne, Germany). The cells 
were harvested for luciferase assay, 48 hours post-electroporation, as 
described by the Dual Luciferase Assay kit (Promega, WI, USA).   
In this Assay system, the activities of firefly (Photinus pyralis) and 
Renilla (Renilla reniformis or sea pansy) luciferases are measured sequentially 
from a single sample. The firefly luciferase reporter is measured first by 
adding 20 µl of Luciferase Assay Reagent II (LARII) to 20 µl of cell lysate to 
generate a signal which lasts for at least 1min. After quantification of the 
firefly luminescence using the luminometer, this reaction is quenched via the 
addition of 100 µl of the Stop & Glo® Reagent to the same sample and a 
second reading which records the Renilla luciferase activity is then taken. For 
data analysis, the ratio between the readings for the firefly luciferase activity 
and the Renilla activity is taken and normalised to the readings obtained from 
the corresponding control samples expressing the promoter-less pGL3-basic 
vector. 
       Adherent HEK293T cell line was co-transfected with 50 pmol of N-
CoR-targeting siRNA, 1 µg of Flt3 full-length promoter / firefly luciferase 
reporter plasmid or promoter-less pGL3-basic vector, 5 ng of CMV / renilla 
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luciferase plasmid and various dosages of pAct-Flag / N-CoR or its empty 
vector, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The cells 
were harvested and reporter activity determined 72 hours post-transfection, as 
specified by the Dual Luciferase Assay kit. 
2.2.7.2. ChIP Assay 
       Chromatin Immunoprecipitation (ChIP) was carried out with the 
commercially available ChIP-IT kit (Active Motif, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. In this method, intact cells are 
fixed using formaldehyde, which cross links and preserves protein-DNA 
interactions. The DNA is then sheared into small uniform fragments via 
sonication at 5 W using the Sonifier150. Prior to precipitation, an aliquot of 
the chromatin isolated from HL60 was taken as input DNA control. Chromatin 
linked to N-CoR was precipitated with either 3 µg of ChIP-grade N-CoR C-20 
antibody (Santa Cruz Biotechnology, CA, USA) or 3 µg of non-specific goat 
IgG (Santa Cruz Biotechnology, CA, USA). 
       Following immunoprecipitation, cross-linking is reversed and the 
proteins are removed by Proteinase K treatment and the DNA is purified as 
described by the kit’s manual. The purified immunoprecipitated chromatin 
was subject to RT-PCR analysis, using the Accuprime Taq polymerase system 
(Invitrogen, Carlsbad, CA, USA). The sequences of the primers used in ChIP 
assay are presented in Table 2.9 in section 2.1.3.3. The priming site for the 






Figure 2.1: Flt3 promoter sequence and ChIP primers priming sites. The Flt3 
promoter sequence up to -901 base pairs upstream of the transcriptional start site in 
exon 1(highlighted). The forward and reverse primers are indicated in bold font and 
grey highlights. The primers prime in a region upstream of known transcription factor 






2.2.8. Creation of N-CoR mutants. 
2.2.8.1. Site Directed mutagenesis 
       Identification of Akt phosphorylation consensus site RxRxx S/T- bulky 
hydrophobic in the human N-CoR sequence was identified using the online 
motif identification software Human Protein Kinase Database. 
       Site directed mutagenesis of pAct-N-CoR-Flag to generate the mutant 
which cannot be phosphorylated and the phosphomimetic mutants were 
carried out using the GeneTailor™ Site-Directed Mutagenesis System 
(Invitrogen, CA, USA) using the primers listed in Table 2.11 in section 
2.1.3.5.  A brief workflow of the GeneTailor™ Site-Directed Mutagenesis 
System is outlined in figure 2.2. 
       Briefly, the plasmid was first methylated using 100 ng of plasmid 
DNA, 1.6 µl of Methylation buffer, 1.6 µl of 10 X Sadenosylmethionine 
(SAM), 1.0 µl of DNA methylase (4 U/ul) and sterile water at 370C for 1 hour. 
Next the mutagenesis reaction was carried out using 2.5 µl	   of	   methylated	  plasmid,	   5	  µl	   of	   10X	  High	   Fidelity	   PCR	   buffer,	   0.3	  mM	  of	   dNTP,	   50	  mM	  Magnesium	   Sulphate,	   0.3	   µM	   each	   of	   the	   mutagenic	   forward	   and	  corresponding	   complementary	   reverse	   primer	   and	   0.3	   µl	   of	   Platinum® 
Taq High Fidelity polymerase (5 U/µl) and sterile water added to a final 
volume of 50 µl. The amplification reaction was carried out as depicted Table 
2.17. 
Table 2.17: PCR conditions for mutagenesis reaction. 
Step Temperature (0C) Time  Number of 
Cycles 
    













Final Extension 68 10 mins 1 
    
       After the reaction, 10 µl of the product was analyzed using 0.8% 
agarose gel to check of mutagenesis efficiency. 
2.2.8.2. Gel Extraction 
       To improve on transformation efficiency, mutagenesis product was 
resolved in 0.8% agarose gel and the DNA band of interest was excised under 
UV light with a clean scalpel. This was followed by the removal of excess gel 
to reduce gel size and purified using the QIAGEN	  QIAquick®Gel	  Extraction	  Kit.	  	  	  	  	  	  	  	   The	  gel	  slice	  was	  weighed	  and	  3	  volumes	  of	  buffer	  QG	  was	  added	  to	   1	   volume	   of	   gel	   and	   solubilized	   at	   500C	   for	   10	  minutes.	   1	   volume	   of	  isopropanol	  was	  then	  added	  to	  the	  solubilized	  DNA.	  The	  mixture	  was	  then	  added	   to	   the	  QIAquick	  spin	  column.	  After	  binding	   to	   the	  resin,	   the	  resin	  was	   washed	   with	   ethanol	   containing	   wash	   buffer	   PE.	   Bound	   DNA	   was	  eluted	  with	  15µl	  of	  sterile	  water	  and	  used	  for	  transformation.	   
2.2.8.3. Transformation. 	  	  	  	  	  	  	   One	   vial	   of	  DH5ά™-T1® E. Coli	   competent	   cells	   (provided	   with	  the	   mutagenesis	   system)	   for	   each	   reaction	   was	   thawed	   on	   ice	   for	   5	  minutes.	  Purified	  DNA	  was	  pipetted	   into	   the	   competent	   cells	   and	  mixed	  by	  tapping	  gently.	  The	  vial	  was	  incubated	  on	  ice	  for	  7	  minutes	  and	  further	  incubated	  for	  exactly	  30	  seconds	  at	  42°C.	  The	  vial	  was	  immediately	  placed	  on	   ice	   for	   1	   minute	   before	   the	   addition	   of	   200	   µl	   of	   pre-­‐warmed	   SOC	  medium	   (2%	   bacto-­‐tryptone,	   0.5%	   bacto-­‐yeast	   extract,	   0.05%	   sodium	  chloride	  and	  20	  mM	  glucose)	  to	  each	  vial.	  The	  vial	  was	  placed	  in	  a	  shaking	  incubator	  at	  30°C	  for	  1	  hour	  at	  225	  rpm.	  100	  µl	  from	  each	  transformation	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vial	  was	  then	  spread	  onto	  separately	  labeled	  LB	  agar	  plates	  with	  50	  µg/ml	  of	   ampicillin.	   The	   agar	   plates	   were	   inverted	   and	   incubated	   at	   37°C	  overnight.	  The	  following	  day,	  a	  single	  and	  well-­‐isolated	  colony	  was	  picked	  and	   inoculated	   into	   5	   ml	   of	   LB	   broth	   (1%	   bacto-­‐tryptone,	   0.5%	   bacto-­‐yeast	  extract	  and	  1%	  sodium	  chloride)	  with	  50	  µg/ml	  of	  ampicillin	  in	  14	  ml	  bacterial	  culture	  tubes.	  The	  inoculated	  culture	  was	  then	  incubated	  for	  14	  to	  16	  hours	  at	  37	  °C.	  0.5	  ml	  of	  overnight	  culture	  was	  used	  to	  prepare	  glycerol	  stock	  by	  addition	  of	  0.5	  ml	  of	  80%	  glycerol	  (v/v)	  and	  stored	  at	  -­‐800C	  while	  the	  remaining	  culture	  was	  used	  for	  plasmid	  purification.	  
2.2.8.4.	  Plasmid	  purification	  	  	  	  	  	  	  	   Plasmid	  purification	  from	  5	  ml	  overnight	  cultures	  was	  carried	  out	  using	  the	  QIAprep®	  Miniprep	  Kit.	  Bacterial	  cells	  were	  pelleted	  at	  6800	  g	  for	   3	   minutes	   at	   room	   temperature.	   Pelleted	   bacterial	   cells	   were	   then	  resuspended	  in	  250	  µl	  of	  RNase	  A	  containing	  buffer	  P1.	  250	  µl	  of	  the	  lysis	  buffer	   P2	  was	   then	   added	   to	   lyse	   the	   bacterial	   cells.	   350	   µl	   of	   the	   pre-­‐chilled	   neutralizing	   buffer	   N3	   was	   than	   mixed	   immediately	   and	   the	  mixture	  centrifuged	  for	  10	  minutes	  at	  17900	  g.	  The	  supernatant	  was	  then	  applied	  to	  the	  QIAprep	  spin	  column	  to	  allow	  for	  plasmid	  DNA	  binding	  to	  the	  resin.	  The	  resin	  was	  then	  washed	  with	  0.5	  ml	  of	  buffer	  PB	  to	  remove	  trace	   nuclease	   activity.	   The	   resin	   was	   washed	   again	   with	   0.75	   ml	   of	  ethanol	  containing	  buffer	  PE.	  Plasmid	  DNA	  was	  eluted	  with	  30	  µl	  of	  sterile	  water	  and	  subjected	  to	  analysis	  by	  restriction	  enzyme	  digestion.	  
2.2.8.5.	  Determination	  of	  successful	  mutants.	  	  	  	  	  	  	  	   Purified	   plasmid	   DNA	   was	   then	   subjected	   to	   restriction	   enzyme	  digestion	  by	  XbaI	  at	  370C	  for	  2	  hours	  to	  identify	  clones	  which	  display	  the	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correct	   fragment	   sizes	   after	   digestion	   (one	   11.3	   kbp	   fragment	   and	   one	  750	   bp	   fragment).	   Clones	   with	   the	   correct	   digestion	   pattern	  were	   then	  sent	  for	  DNA	  sequencing	  using	  the	  primers	  in	  Table	  2.12,	  section	  2.1.3.5.	  (Sequencing	   was	   done	   at	   the	   DNA	   sequencing	   service	   provided	   by	   AIT	  Biotech	  Singapore).	  	  2.2.8.6.	  Large	  Scale	  Plasmid	  purification.	  	  	  	  	  	  	  	   For	   large-­‐scale	  plasmid	  purification,	  glycerol	  stock	  prepared	  from	  colonies	  which	  carried	  successful	  mutants	  was	  first	  streaked	  onto	  LB	  agar	  plates	  with	  50	  µg/ml	  of	  ampicillin	  and	   incubated	  at	  370C	  overnight.	  The	  following	  day,	  a	  single	  and	  well-­‐isolated	  colony	  was	  picked	  and	  inoculated	  into	  5	  ml	  of	  LB	  broth	   (1%	  bacto-­‐tryptone,	  0.5%	  bacto-­‐yeast	  extract	  and	  1%	   sodium	   chloride)	   with	   50	   µg/ml	   of	   ampicillin	   in	   14	   ml	   bacterial	  culture	  tubes.	  The	  inoculated	  culture	  was	  then	  incubated	  for	  4	  to	  6	  hours	  at	  37°C	  with	  agitation	  at	  225	  rpm	  after	  which	  0.5	  ml	  of	   the	  culture	  was	  added	  to	  200	  ml	  of	  LB	  broth	  containing	  50	  µg/ml	  of	  ampicillin	  in	  a	  large	  conical	   flask.	   The	   culture	   was	   then	   incubated	   overnight	   at	   37°C	   with	  agitation	  at	  225	  rpm.	  Plasmid	  DNA	  was	   then	  prepared	   from	  the	   large	  culture	  using	   the	  QIAGEN®	   Plasmid	   Purification	  Maxi	   Kit.	   Bacterial	   cells	  were	   pelleted	   at	  6000	  g	  for	  15	  minutes	  at	  40C.	  The	  bacterial	  pellet	  was	  then	  resuspended	  in	  10	  ml	  of	  RNase	  A	  containing	  buffer	  P1.	  Cells	  are	  then	  lysed	  by	  adding	  10	  ml	  of	  the	  lysis	  buffer	  P2.	  10	  ml	  of	  pre	  chilled	  buffer	  P3	  was	  then	  added	  and	  the	  reaction	  incubated	  on	  ice	  for	  20	  minutes	  to	  allow	  genomic	  DNA,	  proteins	   and	   cell	   debris	   to	   precipitate.	   Precipitated	   contaminants	   were	  then	  removed	  by	  centrifugation	  at	  20000	  g	   for	  30	  minutes	  at	  40C.	   	   	  The	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Figure	  2.2:	  Workflow	  of	  the	  GeneTailorTM	  Site	  Directed	  Mutagenesis	  











3.1.  Akt induced N-CoR Phosphorylation is linked to its misfolded 
conformation dependent loss in Acute Monocytic Leukemia (AML)-M5 
subtype. 
3.1.1. N-CoR is processed by an APL-like aberrant protease activity in 
AML-M5 cells. 
Recently our laboratory reported a role for the misfolded conformation 
dependent loss (MCDL) of N-CoR protein in the malignant growth and 
transformation of APL cells58,62,63. However the molecular mechanisms 
underlying the misfolding of N-CoR and its implications in other AML 
subtypes are still unclear. Thus in an attempt to investigate if a similar 
mechanism contributed to the malignant growth and transformation of 
leukemic cells in other AML subtypes, the status of N-CoR protein in selected 
commercially available AML derived human leukemia cell lines was first 
determined.  
In this initial screening, an APL-like loss of N-CoR was observed in 
multiple leukemic cell lines derived from Acute Monocytic Leukemia, an 
AML subtype designated as AML-M5 in the FAB (French American and 
British) classification. As previously observed in the APL derived NB4 cell 
line, multiple AML-M5 derived leukemic cell lines contained a cleaved N-
CoR fragment of approximately 100kDa. This fragment was most likely 
generated from the proteolytic processing of full length N-CoR protein as no 
intact full length protein was detected in any of these AML-M5 cells (Fig. 
3.1). In contrast, an intact N-CoR protein of about 270 kDa was observed in 
U937, a monocytic cell line derived from histiocytic lymphoma; and in HL60, 
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an AML-M2 derived cell line (Fig. 3.1). This absence of full length N-CoR in 
AML-M5 derived cells was not a result of N-CoR mRNA down regulation as 
levels of N-CoR transcript in the AML-M5 derived cells was not significantly 
lower compared to the levels found in HL60 cells (Fig. 3.2A and B), 
suggesting that the lack of N-CoR expression in AML-M5 was due to post-
translational processing. 
Next, to determine if an APL-like aberrant protease activity was also 
involved in the processing of N-CoR protein in these AML-M5 cells, an 
optimized N-CoR cleavage assay was performed.  In this assay, cytosolic 
extracts of AML-M5 (THP-1 and Nomo-1) or non-AML-M5 (U937) cells was 
incubated with flag-tagged N-CoR protein ectopically expressed in HEK293T 
cells. The processing of N-CoR protein was thereafter determined using the 
anti-Flag antibody in western blotting assay. As shown in figure 3.3, 
incubation of flag-tagged N-CoR protein with the extract of THP-1 cells 
generated a cleaved 100kDa N-CoR fragment which was identical in size to 
the cleaved N-CoR fragment found in the endogenous N-CoR protein profile 
of THP-1 cells (Fig. 3.3A, lane 2). Similarly, Nomo-1 cell extract contained an 
activity which completely digested full length N-CoR protein, however in this 
instance no cleaved N-CoR fragment was generated (Fig. 3.3A, lane 4). This 
was consistent with the endogenous N-CoR protein profile observed in Nomo-
1 cells, where the 100kDa cleaved N-CoR band was not detected. In contrast, 
flag-tagged N-CoR incubated with the extract of U937 cells under identical 
assay conditions was not digested. This suggested that U937 cells lacked the 
N-CoR cleaving activity found in THP-1 or Nomo-1 cells (Fig. 3.3, lane 6). 
The N-CoR cleaving activity detected in the extracts of THP-1 and Nomo-1 
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cells was found to be completely deactivated by boiling, indicating the 
probable involvement of a heat-labile protease (Fig. 3.3A, lanes 3 and 5). A 
THP-1-like N-CoR cleaving activity was also found in three other AML-M5 
derived cells namely MM1, MV-4-11 and SigM5 (Fig. 3.3B). As observed in 
the AML-M5 derived cell lines, leukemic cells obtained from four out of five 
histologically confirmed primary human AML-M5 specimens contained an N-
CoR cleaving activity similar to that of either THP-1 or Nomo-1 cells (Fig. 
3.3C). In contrast, no N-CoR cleaving activity was detected in primary human 
leukemia cells derived from the AML-M1 subtype (Fig. 3.3C, third panel). 
The N-CoR loss in THP-1 cells was also observed to be effectively blocked by 
AEBSF, a broad spectrum protease inhibitor, and Kaletra, a clinical grade HIV 
protease inhibitor, resulting in the stabilization of full length N-CoR protein 
(Fig. 3.4A), while no N-CoR stabilization was observed with the proteasome 
inhibitor MG132 (Fig 3.4B). This suggested that N-CoR cleaving activity 





















Figure 3.1. Selective loss of N-CoR protein in AML-M5 derived cell lines. An 
aliquot of whole cell extract prepared from various AML derived cell lines as 
mentioned on the top of each lane was resolved in SDS-PAGE and stained with anti-
N-CoR antibody. N-CoR was found to be selectively loss in multiple cell lines 

















       
 
 
Figure 3.2. Loss of N-CoR protein in AML-M5 cells was a post transcriptional 
event. N-CoR loss in AML-M5 is not due to any significant down-regulation of N-
CoR transcript levels as determined via semi-quantitative PCR (A) and real time PCR 













   
 
                                             
                             
 
 
Figure 3.3. AML-M5 contained a heat-labile N-CoR cleaving activity. (A) AML-
M5 cells contain a N-CoR cleaving activity. An aliquot of flag-tagged N-CoR protein 
was incubated with the extract of THP-1 (lanes 2, 3), Nomo-1 (lanes 4, 5), or U937 
(lanes 6, 7) cells, and presence of N-CoR cleaving activity in the respective extract 
was determined by the generation of a 100 kDa cleaved N-CoR fragment (THP-1 
cells) or cleavage of full length N-CoR protein (Nomo-1 cells)  in western blotting 
assay with anti-Flag antibody. Cellular extract in lanes (3, 5 and 7) marked as 
“boiled” were pre-heated at 1000C for 10 minutes. In the lanes labeled as “buffer”, 
equal volume of buffer lacking cell extract was used. (B) AML-M5 cells of varied 
genetic background harbor identical N-CoR cleaving activity. N-CoR cleavage assay 
was performed using an aliquot of whole cell extract of various AML-M5 cells as 
mentioned on the top each lane. (C) Primary human AML-M5 specimens contain N-
CoR cleaving activity. Flag-tagged N-CoR protein was incubated with the extract of 
five independent primary AML-M5 specimens for the duration as mentioned at the 
bottom of each panel, and level of N-CoR digestion was determined in western 
blotting assay with anti-Flag antibody. In lane labeled as “buffer”, equal volume of 
buffer lacking cell extract was used. Extract of a primary AML-M1 specimen was 

















Figure 3.4. Cleaving activity found in AML-M5 was mainly protease mediated. 
(A) AEBSF and Kaletra abrogated N-CoR cleaving activity in AML-M5. Level of 
full length endogenous N-CoR protein in THP-1 cells after treatment with the broad 
spectrum protease inhibitor AEBSF or Kaletra for a duration of 48hours, as 
determined by western blotting assay. The doses of AEBSF used are indicated at the 
top of each lane.  AEBSF stabilized endogenous full length N-CoR in a dose 
dependent manner. (B) No stabilization of endogenous full length N-CoR was 






3.1.2. AML-M5 cells harbor the misfolded N-CoR protein.    
The N-CoR loss observed in AML-M5 cells was thought to be 
triggered by the misfolding of N-CoR protein as reported previously in APL 
derived cells58,63. In its native conformation, N-CoR is a detergent soluble 
protein which preferentially localizes to the nucleus in a majority of 
mammalian cells. In contrast, misfolded and unstable N-CoR protein found in 
APL cells was detergent insoluble, largely localized to the ER (endoplasmic 
reticulum) and linked to the amplification of ER stress 58,62,63. The misfolding 
of N-CoR protein was significantly inhibited by Genistein, a tyrosine kinase 
inhibitor from soy, but not by AEBSF, although both of these agents could 
block its loss in APL derived cells with equal efficiency 58. Given these 
findings, experiments were designed and carried out to explore if N-CoR 
degradation in AML-M5 cells was also due to a misfolded conformation. 
   First, to determine if Genistein was able to block N-CoR loss in AML-
M5, THP-1 cells was treated in the same manner as described previously in 
APL58. Here, it was observed that, Genistein stabilized N-CoR protein in a 
dose dependent manner (Fig. 3.5A). In THP-1 cells, the Genistein-stabilized 
N-CoR was mostly detergent soluble (S), suggesting a return of misfolded N-
CoR to its native conformation after treatment (Fig. 3.5B, lane 5). In contrast, 
a significant portion of N-CoR stabilized by AEBSF appeared as a high 
molecular weight (HMW) N-CoR protein band which was detergent insoluble 
(I) (Fig. 3.5B, lane 4), suggesting that AEBSF stabilized N-CoR was largely 
misfolded. The HMW detergent resistant N-CoR band observed in AEBSF 
treated THP-1 cells was most likely resulted from post-translational 
modifications and covalent linkages of other cellular proteins to the misfolded 
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N-CoR. Under identical assay conditions, the relative solubility or insolubility 
of beta actin, a reference protein, was hardly affected (Fig. 3.5B, middle 
panel). Consistent with the findings of the solubility assay, a significant 
portion of N-CoR in the AML-M5 derived cell lines THP-1, MV-4-11 and 
MM1 was found to be localized in the cytosol; while in U937 and HL60 cells, 
N-CoR was mostly confined to the nucleus (Fig. 3.6A). Flag-tagged N-CoR, 
which was preferentially localized to the nucleus of HEK293T cells when 
expressed alone, was found to be translocated to the cytosol when co-
expressed with MLL1-AF9, the fusion oncogene linked to the transformation 
of THP-1 and MM1 cells (Fig. 3.6B). After Genistein treatment, the cytosolic 
N-CoR was observed to be re-localized to the nucleus of THP-1 cells (Fig. 
3.6C). These data indicate that in AML-M5 cells, N-CoR displayed distinctive 
signs of misfolding. 
    Next to investigate if this misfolded N-CoR resulted in the 
amplification of ER stress in AML-M5, ER localization and the effect of 
misfolded N-CoR on the expression level of the ER stress marker PDI was 
analyzed. It was observed that in the cytosol of THP-1 cells, a significant 
portion of N-CoR protein co-localized with the ER resident proteins PDI and 
GRP78/BiP (Fig. 3.7), and the level of ER stress in AML-M5 cells was also 
significantly higher as indicated by the higher levels of PDI expressions across 
all AML-M5 cell lines when compared to non-AML-M5 derived cell lines 
(Fig. 3.8A). These observations indicated a role of ER localized misfolded N-
CoR in the amplification of ER stress. Moreover, AEBSF effectively increased 
HMW PDI levels, indicating an amplification of ER stress after AEBSF 
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treatment. In contrast, Genistein treatment caused a noticeable reduction in ER 
stress levels (Fig. 3.8B).  
    Taken together, these findings suggested that N-CoR degradation in 
AML-M5 leukemic cells was most likely due to a misfolded protein 
conformation which was linked to the selective amplification of ER stress in 




















                
 
 
Figure 3.5. Native N-CoR conformation could be rescued by Genistein but not 
by AEBSF. (A) Level of full length and cleaved N-CoR protein in THP-1 cells 
treated with Genistein in a dose dependent manner was determined in western 
blotting assay using N-CoR antibody. (B) Relative solubility/insolubility of N-CoR 
protein in AEBSF or Genistein treated THP-1 cells was determined by protein 
solubility assay. Soluble (S) and insoluble (I) fractions of AEBSF- or Genistein-
treated THP-1 cells were separated by high speed centrifugation and N-CoR level in 
each fraction was determined by western blotting assay using anti-N-CoR antibody. 
A HMW (high molecular weight) variant of N-CoR protein, which was part of 
insoluble fraction, was detected only in AEBSF treated cells. The relative 
solubility/insolubility of β-actin in each fraction was used as control. The level of 


















Figure 3.6. N-CoR localization was mainly cytosolic in AML-M5 cells and 
nuclear localization was restored by Genistein. (A) Subcellular distribution of N-
CoR (red signals) in AML-M5 derived cell lines (THP-1, MV4-11 and MM1) and 
non-AML-M5 derived cell lines HL60 and U937 was determined by staining the cells 
with anti-N-CoR antibody and florescence labeled secondary antibody. Nucleus was 
stained with DAPI (blue signals). The signals were analyzed by confocal microscopy. 
(B) Subcellular distribution of Flag-tagged N-CoR (red signal) expressed alone 
(upper panel) or with MLL1-AF9 (green, lower panel) in HEK293T cells was 
determined by confocal microscopy. DNA was stained with DAPI (blue signal). (C) 
Subcellular distribution of N-CoR (red signal) in THP-1 cells treated with vehicle or 

















Figure 3.7. N-CoR in AML-M5 was preferentially localized to the ER. 
Localization of N-CoR in THP-1 cells were evaluated by confocal microscopy after 
staining with Anti-N-CoR antibody (Red Signal) and  the ER resident proteins 
GRP78 /BiP (top panel) or PDI (bottom panel) (both Green Signals). Yellow signal in 
Overlay indicate almost complete N-CoR co-localization with the ER resident 


















Figure 3.8. Misfolded N-CoR in AML-M5 led to the accumulation of ER stress. 
(A) Selective accumulation of ER stress was observed in AML-M5 derived cell lines. 
Relative level of ER stress in AML-M5 derived cell lines was compared to that of 
non-AML-M5 derived cell lines (HL60 and U597) by determining the level of native 
and HMW (high molecular weight) PDI protein. (B) AEBSF amplifies ER stress in 
THP-1 cells while Genistein reduces HMW PDI levels. Relative level of ER stress in 
THP-1 cells treated with AEBSF or Genistein in a dose dependent manner was 







3.1.3. Misfolded N-CoR exhibits aberrant serine/ threonine 
phosphorylation.  
The conformation of a protein is defined by the free energy of its 
amino acid residues and minor alterations in the amino acid sequence can 
significantly alter the folding landscape of whole polypeptide sequences 
promoting misfolding 64,90. Besides genetic modifications, the natural folding 
landscape of the polypeptide sequence can also be altered by aberrant post-
translational modifications.  
    Previously, our laboratory reported a role for aberrant serine/threonine 
phosphorylation in PML-RARα induced misfolding of N-CoR protein in 
APL58. To investigate if N-CoR misfolding was also caused by a similar 
aberrant post-translational modification in AML-M5, the relative level of 
serine/threonine phosphorylated N-CoR in the total N-CoR protein stabilized 
by AEBSF or Genistein in THP-1 cells was first determined. N-CoR 
immunoprecipitated from the whole cell extract of AEBSF or Genistein 
treated THP-1 cells was resolved, transferred onto PVDF membrane and 
probed with a generic phospho-serine/threonine antibody. To quantify the 
amount of immunoprecipitated N-CoR protein, the membrane was reprobed 
with N-CoR antibody. Here, it was observed that N-CoR immunoprecipitated 
(IP) from AEBSF treated THP-1 cells displayed significantly higher levels of 
serine/threonine phosphorylation when compared to N-CoR 
immunoprecipitated from Genistein treated cells (Fig. 3.9, left top panel), with 
the total amount of N-CoR immunoprecipitated from both types of cells 
almost identical (Fig. 3.9, left lower panel).   
86	  
	  
After AEBSF treatment, the level of phosphorylated N-CoR protein 
increased most likely due to the inhibition of the protease responsible for its 
degradation. Genistein, on the other hand, may block the loss of N-CoR 
indirectly by inhibiting its aberrant phosphorylation. Although more 
commonly known for its strong anti-tyrosine kinase activity, Genistein’s 
potent inhibitory effect on serine/threonine kinase activity was not entirely 
unexpected given its recently documented role as a serine/threonine kinase 
inhibitor 58. Hence, with the data obtained thus far, it was hypothesized that 






























Figure 3.9. Misfolded N-CoR in AML-M5 displayed aberrant serine/threonine 
phosphorylation. Levels of serine/threonine phosphorylated N-CoR in THP-1 cells 
treated with AEBSF or Genistein was determined by staining the immunoprecipitated 
N-CoR protein with a generic phospho serine/threonine antibody (upper left panel). 
An aliquot of immunoprecipitated N-CoR was also stained with N-CoR antibody 
(lower left panel). Moreover, level of total N-CoR protein in each treated sample was 











3.1.4 Identification of Akt as a mediator of N-CoR misfolding in AML-M5 
cells. 
 In order to validate the hypothesis, identification of potential kinases 
which may be hyper-activated in AML-M5 was carried out by employing the 
proteome ProfilerTM Human Phospho-kinase antibody array system from R&D 
Systems. Complete analysis of all kinases available in the array was performed 
using cell lysates prepared from the N-CoR intact U937, HL60 and K562 
(reported to contain full length native N-CoR63) cell lines and the five N-CoR 
negative AML-M5 cell lines. Expression analysis via densitometric 
quantification of all spots on the array blots (the list of kinases and their 
positions on the array is appended in Appendix 1) revealed that only Akt 
phosphorylated at the Serine 473 residue was preferentially up-regulated in all 
the five AML-M5 derived cell lines when compared to the other non AML-
M5 derived cell lines (Fig. 3.10). The phosphorylation event by mTORC2 at 
this site facilitates the activating phosphorylation of Threonine 308 in Akt 
resulting in the full activation of Akt kinase activity. To validate the results of 
the array, western blotting assay was performed on lysates prepared from the 
cell lines used in the array as well as on multiple AML-M5 patient specimens 
to determine the levels of phospho-Akt (Ser473).  The western blotting 
analysis corroborated with that of the array indicating that phospho-Akt 
(Ser473) levels were indeed higher in the AML-M5 cell lines (Fig. 3.11A) as 
well as in multiple AML-M5 patient specimens where N-CoR was loss (Fig. 




    Next, in order to identify if Akt kinase was indeed involved in the 
accumulation of misfolded N-CoR in AML-M5, the ability to stabilized N-
CoR in THP-1 cells after loss of Akt kinase activity was accessed. Two 
approaches were taken, one via siRNA mediated knockdown of Akt in THP-1 
cells and two, via the inhibition of Akt kinase activity by inhibiting its 
activating phosphorylation using the commercial Akt kinase specific inhibitor 
Akti-X which inhibits the phosphorylation of Akt (Merck, Darmstadt, 
Germany)190,191. Both siRNA mediated Akt knockdown and inhibition of Akt 
kinase activity by Akti-X were able to stabilize full length N-CoR in THP-1 
cells (Fig. 3.12A and B). Since inhibition of Akt kinase activity by both 
siRNA mediated Akt knockdown and Akti-X treatment were able to stabilize 
N-CoR in THP-1 cells, the detergent solubility of this stabilized N-CoR was 
next accessed. Solubility assay as previously described was performed and it 
was observed that the N-CoR stabilized by both methods was found mainly in 
the soluble fraction (Fig. 3.13A). When N-CoR localization was analyzed via 
immunofluorescence assay, it was observed that N-CoR displayed a 
predominantly nuclear localization after Akt inhibition by both methods in 
THP-1 cells (Fig 3.13 B). This indicated that by blocking the activity of Akt in 
THP-1 cells, native properties of N-CoR were restored (a phenomenon similar 
to that observed when THP-1 cells were treated with Genistein) strongly 
implicating the involvement of Akt kinase activity in the misfolding of N-CoR 
found in AML-M5 cells. 
    To prove the concept that Akt activation was crucial in the induction of 
N-CoR misfolding, a constitutively activated,	  NH2-terminally myristoylation 
signal-attached Akt (myr-Akt) mutant was co-expressed with flag-tagged N-
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CoR in HEK293T cells. This ectopically expressed N-CoR was then similarly 
tested for detergent solubility. In this assay, it was observed that only in the 
presence of the myr-Akt mutant was N-CoR found to accumulate in the 
insoluble fraction (Fig. 3.14A). Another indication that Akt kinase activity 
was indeed important in the misfolding of N-CoR was its ability to induce N-
CoR cytosolic localization. Immunofluorescence assay performed in 
HEK293T cells revealed that in the presence of the mry-Akt mutant, N-CoR 
displayed a predominantly cytosolic localization (Fig. 3.14B, lower panel) 
while in the absence of the mutant N-CoR localization was predominantly 
nuclear (Fig. 3.14B, upper panel).  
Taken together these data indicated that Akt kinase activity was indeed 
important in the misfolding of N-CoR and could be the common factor that 















Figure 3.10. pAkt at serine 473 was selectively up-regulated in AML-M5. Level 
of activated kinases in five AML-M5 and three non-AML-M5 (HL60, U937 and 
K562) derived cell lines were determined by the Proteome ProfilerTM Human 
Phospho-kinase antibody array system. The level of activity of each kinase in these 
two subsets of cells was quantified and presented as bar graphs. Results presented are 
the averages of 3 independent experiments (upper panel). Raw blots used in the 
quantification and coordinate markers for each spot on the blot are annotated. The list 





                                                                                
             












Figure 3.11. Akt activity was selectively up regulated in AML-M5 derived cell 
lines and primary  specimens. (A) Level of activated Akt (pAkt (Ser473)) in various 
AML-M5 and non-AML-M5 cell lines was determined by western blotting. (B) Level 
of activated Akt (pAkt (Ser473)) and N-CoR protein in six primary human AML-M5 







           




                                
 
 
Figure 3.12. Loss of Akt activity resulted in the stabilization of N-CoR in THP-1. 
(A) N-CoR was stabilized after siRNA mediated Akt knockdown as determined via 
western blotting assay with anti-N-CoR antibody. Level of knockdown was 
determined by western blotting assay with anti-Akt antibody. (B) The specific 
inhibitor of Akt kinase activity Akti-X was able to stabilize N-CoR at 2.5 µM 
concentration as determined via western blotting with anti-N-CoR antibody. 
Inhibition of Akt kinase activity was determined by examining the levels of pAkt 





     
 
 
Figure 3.13. Native N-CoR conformation was rescued by loss of Akt kinase 
activity. (A) Relative solubility/insolubility of N-CoR protein in Akt silenced or 
Akti-X (a specific inhibitor of Akt kinase activating phosphorylation) treated THP-1 
cells was determined by protein solubility assay. Soluble (S) and insoluble (I) 
fractions of treated THP-1 cells were separated by high speed centrifugation and N-
CoR level in each fraction was determined by western blotting assay using an anti-N-
CoR antibody. N-CoR stabilized by AEBSF and Genistein in THP-1 cells was used 
as controls for N-CoR solubility/insolubility. The relative solubility/insolubility of β-
actin in each fraction was determined as control. The level of total of protein in each 
fraction was determined by coomassiee blue staining. (B) Subcellular distribution of 
N-CoR (red signal) in THP-1 cells treated with Control or Akt siRNA (upper panel) 
or with vehicle or Akti-X at 2.5 µM concentration (lower panel) was determined by 

















Figure 3.14. Constitutively active Akt can induce N-CoR misfolding in 
HEK293T cells. (A) Relative solubility/insolubility of flag-tagged N-CoR protein in 
HEK293T cells when expressed with a constitutively active Akt kinase (myr-Akt) 
was determined by protein solubility assay. Soluble (S) and insoluble (I) fractions 
were separated by high speed centrifugation and N-CoR level in each fraction was 
determined by western blotting assay using an anti-Flag antibody insoluble N-CoR 
was detected only in the presence of a constitutively active Akt kinase. The relative 
solubility/insolubility of β-actin in each fraction was determined as control. The level 
of total of protein in each fraction was determined by coomassiee blue staining. (B) 
Subcellular distribution of N-CoR (Red Fluorescence) protein in HEK293T cells after 
co-expression with the constitutively active Akt mutant, myr-Akt (Green 
Fluorescence) as determined using the anti-Flag anti-body followed by a red 
fluorescence tagged antibody. Preferential localization of N-CoR to the cytosol was 
observed after co-expression with myr-Akt while N-CoR was localized mainly in the 





3.1.5. N-CoR is a direct substrate of Akt.  
Data obtained thus far suggested that Akt kinase activity was essential 
for the accumulation of misfolded N-CoR in THP-1 cells. However it was still 
unclear as to whether N-CoR was directly phosphorylated by Akt kinase or 
was the effect indirect. Thus, to establish if N-CoR was a direct substrate of 
Akt and if this phosphorylation event was indeed critical in the initiation of N-
CoR misfolding in AML-M5, the following series of experiments were carried 
out. 
    It had been established that Akt kinase preferentially phosphorylates 
serine/threonine residues after the Akt kinase recognition motif RxRxx S/T- 
bulky hydrophobic (where X represents any amino acid). Thus the first step 
was to identify if there were any potential sites in the N-CoR sequence which 
fit this consensus motif. Using the Human Protein Reference database website, 
two putative Akt phosphorylation sites in the human N-CoR sequence was 
identified at moderate stringency. In the scan, a Serine residue at position 1450 
and a Threonine residue at position 1925 in the human N-CoR amino acid 
sequence were found after the putative Akt consensus motif (Fig. 3.15A upper 
panel). Multiple sequence alignment performed using ClustalW revealed that 
these two Akt substrate consensus motifs and its surrounding regions were 
highly conserved in both the mouse and human sequence (Fig. 3.15B lower 
panel).  
    Next to identify if the inhibition of Akt kinase activity was able to 
abrogate serine/threonine phosphorylation in the Akt kinase consensus motif 
of N-CoR, THP-1 cells was treated with AEBSF or Akt siRNA and full length 
N-CoR was immunoprecipitated. The immunoprecipitated N-CoR obtained 
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from each treatment was accessed for Akt mediated serine/threonine 
phosphorylation via western blotting with a phospho-Akt substrate (RxRxx 
pS/pT) antibody which specifically recognizes serine/threonine residues 
phosphorylated at the RxRxx S/T motif in western blotting assay.  In this 
assay it was observed that in AEBSF stabilized N-CoR, the serine/threonine 
residue at the Akt consensus motif site was phosphorylated. In contrast, N-
CoR stabilized via siRNA-mediated loss of Akt activity did not display RxRxx 
pS/pT phosphorylation (Fig. 3.16). Similarly, when flag-tagged N-CoR was 
ectopically expressed in HEK293T cells in combination with the constitutively 
active myr-Akt mutant and subjected to the same immunoprecipitation assay, 
it was also noted that only in the presence of Akt kinase activity was the N-
CoR phosphorylated at the Akt substrate motif (Fig. 3.17A). In vitro 
phosphorylation performed using purified flag-tagged N-CoR and Akt kinase 
also revealed that Akt kinase was able to directly phosphorylate N-CoR at the 
RxRxx S/T motif (Fig 3.17B). These data clearly showed that N-CoR was 
indeed a direct substrate of Akt. 
 Next, it was hypothesized that the loss of phosphorylation in native N-
CoR stabilized by Genistein observed previously was most likely due to the 
drug’s activity on Akt. Thus to validate this thought, the status of Akt activity 
after AEBSF and Genistein treatments in THP-1 cells were compared. Here, it 
was observed that while Genistein treatment resulted in a dose dependent loss 
of Akt kinase activity as indicated by the dose dependent loss of 
phosphorylation at the Serine 473 residue essential for full activation of Akt 
kinase activity, AEBSF treatment did have any significant effect on Akt kinase 
activity (Figure 3.18A). Thereafter, phosphorylation assay as performed 
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previously was carried out on AEBSF and Genistein treated cells and 
immunoprecipitated N-CoR was probed with the Akt substrate RxRxx pS/pT 
specific antibody. In Genistein treated cells, a loss of RxRxx pS/pT 
phosphorylation was observed implying that the loss of phosphorylation of 
native N-CoR stabilized by Genistein observed previously was partly due to 
the loss of Akt kinase activity in these cells (Figure 3.18B). 
   Taken together, these observations indicated that in AML-M5, N-CoR 
































Figure 3.15. Two putative Akt substrate motifs were identified in the human N-
CoR sequence. (A) Screen captures of results obtained during the motif scan 
searching for kinase substrate motifs using the Human Protein reference database 
where only the sites which showed up as putative Akt kinase substrate motifs are 
shown. (B) The Akt substrate consensus sequence and it surrounding sequences are 





























Figure 3.16. Inhibition of Akt kinase activity inhibited the phosphorylation of N-
CoR in THP-1.  Phosphorylation of immunoprecipitated full length N-CoR at the 
Akt consensus site in AEBSF treated cells versus that of Akt siRNA treated cells as 
determined by western blotting using a Phospho-Akt substrate (RxRxx pS/pT) 
specific antibody (left panel). Crude amounts of N-CoR loaded for 
immunoprecipitation as determined via western blotting using anti-N-CoR antibody 











      
 
                         
 
Figure 3.17. Akt kinase activity directly phosphorylates of N-CoR at the RxRxx 
S/T site. (A) Phosphorylation of immunoprecipitated flag tagged N-CoR at the Akt 
consensus site in HEK293T cells as determined via western blotting assay using a 
Phospho-Akt substrate (RxRxx pS/pT) specific antibody (left panel). Crude amounts 
of N-CoR loaded for immunoprecipitation as determined via western blotting using 
anti-Flag antibody (right panel). (B) Active Akt Kinase directly phosphorylates N-
CoR in vitro. Active Akt Kinase directly phosphorylates N-CoR in vitro. Purified 
flag-tagged N-CoR was subjected to in vitro kinase assay with purified active Akt 
kinase and subjected to western blotting assay with phospho-Akt substrate (RxRxx 














Figure 3.18. Loss of N-CoR phosphorylation after Genistein treatment was due 
to the loss of Akt kinase activity in THP-1. (A) Genistein treatment resulted in the 
dose dependent loss of Akt kinas activity as indicated by the loss of pAkt (Ser473) 
expression after treatment (left panel). AEBSF treatment did not have a significant 
effect on Akt kinase activity (right panel). (B) Phosphorylation of 
immunoprecipitated N-CoR at the Akt consensus site in THP-1 cells after AEBSF 
and Genistein treatment as determined via western blotting assay using a Phospho-
Akt substrate (RxRxx pS/pT) specific antibody (left panel). Crude amounts of N-CoR 
loaded for immunoprecipitation as determined via western blotting using anti-Flag 





3.1.6. Phosphorylation at the Serine 1450 residue by Akt was essential for 
the misfolding of N-CoR protein. 
  The data obtained in the above sets of experiments strongly suggested 
the importance of Akt mediated phosphorylation in the induction of the 
misfolded conformation of N-CoR. Thus in a proof of concept approach, 
mutagenesis of the Akt kinase consensus motifs in N-CoR to a non-
phosphorable Alanine residue was performed to access the ability of Akt 
kinase activity to induce the accumulation of misfolded N-CoR in these 
mutants. Based on the data obtained in figure 3.15, two mutants of N-CoR 
were created, one single mutant for each of the identified Akt substrate 
consensus sites. The location of the mutated sites on N-CoR and sequencing 
results of the two successful mutants and are shown in figure 3.19A and B. 
The mutants were next tested for their ability to be phosphorylated by Akt via 
ectopic expression with the myr-Akt mutant in HEK293T cells followed by 
immunoprecipitation assay as carried out previously to identify the true Akt 
substrate site in the N-CoR sequence. As observed in figure 3.20, only the 
single S1450A mutant showed a loss of phosphorylation in the presence of 
Akt kinase activity while the ability of the single T1950A mutant to become 
phosphorylated by Akt activity was not affected. This suggested that the 
Serine 1450 residue after the Akt substrate consensus motif in the N-CoR 
sequence was the actual Akt substrate site subjected to phosphorylation in Akt 
mediated misfolding of N-CoR. 
    Next to validate that this phosphorylation at Serine 1450 was indeed 
crucial for the induction of N-CoR misfolding, the HEK293T system was 
utilized and solubility assay was performed as described previously. As 
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depicted in figure 3.21, only the S1450A mutant was unable to accumulate in 
the insoluble fraction in the presence Akt kinase activity. Under the same 
assay conditions, the ability of myr-Akt to induce N-CoR misfolding of the 
T1950A mutant and wild-type N-CoR in HEK293T cells was not affected. 
This suggested the importance of the phosphorylation event by Akt at Serine 





























Figure 3.19. Site directed mutagenesis of Serine 1450 and Threonine 1925 in the 
N-CoR sequence to a non-phosphorable Alanine residue. (A) Successful Serine to 
Alanine mutation was created at position 1450 and 1925 of pAct-N-CoR-Flag. 
Locations of these mutations in N-CoR are depicted. (B) Successful mutants were 
determined via sequencing analysis and the chromatograms of the successful mutants 



















                                  
       
Figure 3.20. Serine 1450 after the Akt consensus motif was the true phospho-
acceptor site in the N-CoR sequence. (A) Serine to Alanine mutagenesis at 
position1450 in the Akt consensus site in N-CoR resulted in the inability of Akt 
kinase to phosphorylate immunoprecipitated N-CoR as determined via the a Phospho-
Akt substrate specific antibody while the Threonine to Alanine mutation at position 
1925 did not affect N-CoR phosphorylation by Akt kinase (top panel). Crude amounts 
of N-CoR loaded for immunoprecipitation as determined via western blotting using 



















                







Figure 3.21. Phosphorylation of N-CoR by Akt at Serine 1450 was essential for 
the induction of N-CoR misfolding. Relative solubility/insolubility of flag tagged 
N-CoR protein (WT or mutants, S1450A or T1925A) in HEK293T cells when 
expressed with a constitutively active myr-Akt was determined by protein solubility 
assay. Soluble (S) and insoluble (I) fractions were separated by high speed 
centrifugation and N-CoR level in each fraction was determined by western blotting 
assay using an anti-Flag antibody. Insoluble N-CoR was detected only when 
Serine1450 in N-CoR was mutated. The relative solubility/insolubility of β-actin in 
each fraction was determined as control. The level of total of protein in each fraction 










3.1.7. The negative charge conferred by the phosphorylation event 
initiates N-CoR misfolding in AML-M5. 
 A phosphorylation event results in a change in protein conformation 
by conferring a negative charge to the residue it phosphorylates. Thus to 
determine if by conferring a negative charge at position 1450 in N-CoR, 
misfolding could be induced, a phosphomimetic mutant was created by 
mutating the Serine at position 1450 to a Glutamic acid residue which carries a 
native negative charge due to the -COOH group. Successful site directed 
mutagenesis was determined via DNA sequencing (Fig 3.22). Detection of 
protein misfolding in this mutant (designated S1450E) was accessed using 
protein solubility assay and immunofluorescence assay. When ectopically 
expressed in HEK293T cells in the absence of any Akt kinase activity, the 
phosphomimetic mutant S1450E was observed to accumulate in the insoluble 
fraction when compared to the wild type N-CoR which only accumulated in 
the soluble fraction (Fig. 3.23A). The mutant was also observed to 
preferentially localize to the cytosol (Fig. 3.23B) in contrast to the 
predominantly nuclear localization of wild-type N-CoR in 
immunofluorescence assay. These results showed that the S1450E mutant 
displayed hallmark signs of misfolding. 
    Next, to determine if cytosolic localization of the mutant N-CoR 
induced ER stress (a key feature of misfolded proteins) in the cells which are 
expressing it, immunofluorescence assay was performed to look for the up-
regulation of the ER stress marker GRP78/BiP in these cells. As observed in 
figure 3.24, HEK293T cells which expressed the mutant N-CoR S1450E had 
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elevated GRP78/BiP levels while surrounding cells which were not transfected 
with the mutant expressed basal GRP78/BiP levels.  
    Collectively, the observations indicated that a negative charge 
conferred by the phosphorylation event mediated by Akt kinase activity at 
position 1450 in the N-CoR protein was critical for the initiation of its loss 
































Figure 3.22. Successful Serine to Glutamic acid mutation was determined via sequencing. Sequencing chromatogram of successful Serine to Glutamic 




















Figure 3.23.The phosphomimetic N-CoR S1450E displayed properties of 
misfolded N-CoR. (A) N-CoR phosphomimetic mutant S1450E accumulates in the 
insoluble fraction. Relative solubility/insolubility of flag tagged N-CoR protein (WT 
or mutant S1450E) in HEK293T cells was determined by protein solubility assay. 
Soluble (S) and insoluble (I) fractions were separated by high speed centrifugation 
and N-CoR level in each fraction was determined by western blotting assay using an 
anti-Flag antibody. S1450E was found to accumulate in the insoluble fraction while 
under the same conditions N-CoR (WT) accumulated only in the soluble fraction. The 
relative solubility/insolubility of β-actin in each fraction was determined as control. 
The level of total of protein in each fraction was determined by coomassiee blue 
staining. (B) Subcellular distribution of N-CoR (WT) and S1450E (Red 
Fluorescence) protein in HEK293T cells was determined using the anti-Flag anti-
body followed by a red fluorescence tagged antibody. Preferential localization of 























Figure 3.24. Expression of the phosphomimetic N-CoR S1450E resulted in the 
accumulation of ER stress. Accumulation of ER stress levels in cells transfected 
with S1450E (Red Fluorescence) protein in HEK293T cells was determined using the 
anti-Flag anti-body followed by a red fluorescence tagged antibody. Elevated 
GRP78/BiP levels as indicated by the increase in GRP78/BiP immunofluorescence 
(Green Fluorescence) as detected after staining with anti- GRP78/BiP antibody 
followed by a green fluorescence tagged antibody indicated the accumulation of ER 







3.2. Role of misfolded N-CoR mediated transcriptional deregulation of 
Flt3 in the pathogenesis of Acute Monocytic Leukemia (AML)-M5 
subtype.  
3.2.1. N-CoR loss correlates with the up-regulation of Flt3 expression. 
   N-CoR being a generic transcriptional co-repressor had been 
documented to be essential in the repression of many developmental genes. 
Thus, the most critical effect of Akt mediated N-CoR MCDL in AML-M5 
cells would be the transcriptional deregulation of genes which were normally 
repressed by N-CoR. This was particularly so for genes which are associated 
with the normal growth and development of hematopoietic cells. Therefore, in 
an attempt to identify hematopoietic genes which expressions were 
deregulated owing to the MCDL of N-CoR protein, the levels of selected 
hematopoietic genes in N-CoR negative AML-M5 derived cell lines and cell 
lines which contained intact N-CoR were analyzed. The goal was to identify 
genes which expressions would reflect an inverse correlation to the N-CoR 
status of these two groups of AML derived cell lines.  
    RT-PCR and qRT- PCR analysis of 21 genes reported to be important 
in normal hematopoiesis and lineage commitment 192 using the previously 
characterized N-CoR positive cell lines, HL60 (a AML-M2 derived cell line) 
,U937 (a monocytic cell line derived from histocystic lymphoma) and N-CoR 
null AML-M5 derived cell lines THP-1, Nomo-1, Mono-Mac-1 (MM1), MV-
4-11 and SigM5 revealed that only the Flt3 gene was observed to be highly up 
regulated in the N-CoR negative cell lines when compared to those expressing 
N-CoR (Fig. 3.25 and Fig. 3.26). Further analysis of more N-CoR positive and 
negative cell lines revealed that this inverse relationship between N-CoR and 
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Flt3 expression seemed to hold true (Fig. 3.27).  The inverse relationship 
between N-CoR and Flt3 expressions was also found to be translated to the 
protein level in the all the AML-M5 cell lines (Fig 3.28A) as well as in 
multiple histologically confirmed primary AML-M5 patient specimens (Fig 
3.28B), with both the 130 kDa intracellular non–glycosylated and the 160 kDa 
membrane bound glycosylated forms observed to be highly expressed. 
Furthermore, siRNA mediated N-CoR knockdown performed on N-CoR 
positive HL60 revealed that after N-CoR ablation, Flt3 transcript levels was 
significantly up-regulated while the levels of two other genes which did not 
have a correlation with N-CoR status was not altered (Fig. 3.29 left panel). 
Successful N-CoR knockdown in HL60 cells was determined via western 
blotting and RT-PCR (Fig. 3.29 middle and right panel). Conversely, over-
expression of flag- tagged N-CoR in THP-1 cells brought about a down 
regulation of Flt3 levels (Fig. 3.30). This inverse correlation between N-CoR 
loss and Flt3 expression suggested that N-CoR might have role in the 

















Figure 3.25. N-CoR loss was associated with Flt3 up-regulation in semi-
quantitative PCR analysis. Relative expression of N-CoR protein in HL60, NB4 and 
THP-1 as determined via western blotting assay using anti-N-CoR antibody (top 
panel). RT-PCR analysis of selected hematopoietic genes in AML-M5, APL and N-
CoR expressing HL60 cells. Only the Flt3 gene expression showed an inverse 











Figure 3.26. N-CoR loss was associated with up regulation of Flt3 in qRT-PCR analysis. Relative expression of selected hematopoietic genes in AML-
M5 and non-AML-M5 (HL60 and U937) cells were determined by qRT-PCR analysis. Data was analyzed using the comparative Ct method using the 
expression level of each gene in HL60 cells as the reference value, and the level of expression of the HPRT gene was used as control. The graph was plotted 
on a log scale with a base of 10. Expression levels in HL60 cells for all genes were set to 0 while genes which were up-regulated relative to their expression 
levels in HL60 cells were given positive values, and those which were down-regulated relative to expression level in HL60 cells were given negative values. 


















Figure 3.27. Flt3 expression was inversely related to N-CoR protein status. N-
CoR and Flt3 levels in various human leukemic cell lines were determined in western 




























Figure 3.28. The inverse relationship between N-CoR and Flt3 was translated to 
the protein level. Flt3 and N-CoR levels in AML-M5 derived cell lines (A) and in 
multiple histologically confirmed human primary AML-M5 specimens (B) were 
determined through western blotting assay using the respective antibodies. Levels of 






















Figure 3.29. siRNA mediated N-CoR knockdown in HL60 up regulated Flt3 
levels. Levels of Flt3, HoxA9 and Scl/Tal in HL60 cells transfected with N-CoR or 
control siRNA were determined by RT-PCR analysis (left panel). N-CoR knock 
down efficiency at protein (middle panel) and transcript level (right panel) in HL60 
cells transfected with anti-N-CoR or control siRNA was determined through western 
blotting assay and RT-PCR analysis. 
















                       
 
 
Figure 3.30. Over-expression of flag-tagged N-CoR in N-CoR null THP-1 cells 
resulted in the down-regulation of Flt3 levels. Ectopic expression of flag-tagged N-
CoR in THP-1 cells resulted in the loss of Flt3 expression as determine via western 
blotting assay with anti-Flt3 antibody. Levels of ectopic N-CoR expression were 












3.2.2. Flt3 is a transcriptional target of N-CoR.  
The observation of reduced Flt3 levels in cells which expressed N-CoR 
suggested that this could be due to a direct repression of the Flt3 gene by N-
CoR. Therefore, to show that N-CoR was actually involved in the repression 
of Flt3, the activity of a luciferase reporter driven by the full length Flt3 
promoter (up to 901 base pairs upstream of the transcriptional start site) was 
compared in N-CoR positive and negative leukemic cell lines. The Flt3-
luciferase reporter [Flt3 (-901)] activity was significantly lower in N-CoR 
intact HL60, K562 and U937 cells; whereas in THP-1 cells which lacked an 
intact N-CoR protein, reporter activity was significantly higher (Fig. 3.31). 
Introduction of ectopic N-CoR in THP-1 cells (Fig. 3.32A) resulted in a dose 
dependent reduction of Flt3 promoter activity (Fig. 3.32B).  
To further prove that the Flt3 promoter was repressed by N-CoR, the 
effect of ectopic N-CoR expression on Flt3 promoter activity was determined 
via luciferase assay performed in HEK293T cells. In the initial experiments, it 
was noted that despite repeated attempts, no significant reduction in the Flt3 
reporter activity by ectopic N-CoR was observed in HEK293T cells (data not 
shown). Thinking that this lack of reduction in the Flt3 reporter activity by 
ectopic N-CoR could be a result of the high levels of endogenous N-CoR 
protein present in HEK293T cells, the experiment was next repeated using N-
CoR ablated HEK293T cells. N-CoR ablation by N-CoR siRNA increased the 
basal Flt3 reporter activity in HEK293T cells when compared to its activity in 
non-ablated cells (Fig. 3.33). Moreover, ectopic restoration of N-CoR in N-
CoR ablated HEK293T cells down regulated this augmented Flt3 promoter 
activity in a dose dependent manner, and its value came down to a level which 
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was lower than the basal value (Fig. 3.33). The degree of Flt3 promoter 
inhibition by ectopic N-CoR was only two fold in N-CoR intact HEK293T 
cells irrespective of dose; while in N-CoR ablated cells, a seven fold reduction 
was observed when N-CoR was introduced at a maximum concentration of 
1µg (Fig. 3.34). All these observations strongly indicated a role for N-CoR in 
the direct regulation of the Flt3 promoter. 
In AML-M5, N-CoR repressive function was thought to be loss due to 
Akt mediated N-CoR misfolding. Thus to test the effect of misfolded N-CoR 
conformation on N-CoR mediated repression of the Flt3 promoter, the S1450E 
phosphomimetic mutant of N-CoR was utilized. It was observed that while 
wild-type N-CoR induced a 8 fold increase in the repression of Flt3 promoter 
activity, the phosphomimetic S1450E displayed a significant loss of N-CoR 
repressive effect on the Flt3 promoter (Fig. 3.35). These observations further 
suggested the active role of functional N-CoR in the repression of the Flt3 
promoter.  
 To identify the region in the Flt3 promoter which was essential for N-
CoR mediated repression, the luciferase reporter driven by various fragments 
of the Flt3 promoter region were utilized. The various constructs driven by the 
various fragments of the Flt3 promoter are depicted in figure 3.36A. Ectopic 
expression of N-CoR in HEK293T cells with the luciferase reporter constructs 
driven by the different Flt3 promoter regions revealed that the region more 
than 226 base pairs (bps) upstream of the Flt3 transcriptional start site was 
required for optimal N-CoR mediated Flt3 expression repression (Fig. 3.36B). 
This suggested that N-CoR and its associated co-repressor complex may bind 
somewhere in this region to repress Flt3 gene expression. Thus, to validate 
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that N-CoR suppression of Flt3 expression was via its binding to the Flt3 
promoter region, association of N-CoR protein with the promoter of Flt3 was 
analyzed by chromatin immunoprecipitation (ChIP) assay.   To better map the 
region of the Flt3 promoter specifically associated with N-CoR, chromatin 
extracts of HL60 or NB4 cells were immunoprecipitated with anti-N-CoR 
antibody. The DNA co-precipitated with N-CoR was amplified with primers 
flanking various regions of the Flt3 promoter. Primers were designed to 
amplify DNA in each of the following regions within the Flt3 promoter 
sequence, between 614 bps to 814 bps and between 75 bps to 272 bps, 
upstream of the transcriptional start site. Only the primers located in the 614 
bps to 814 bps region upstream of the transcriptional start site in the Flt3 
promoter region (Chapter 2, Fig. 2.1) was able to amplify the DNA co-
precipitated with N-CoR antibody (Fig. 3.37), while the primers which 
amplify the 75 bps to 272 bps upstream region failed to do so (data not 
shown). This further suggested that N-CoR and its associated repressor 
complex may have bound to the Flt3 promoter through a region located in the 
614 bps to 814 bps upstream region of the promoter sequence. CD36, a known 
N-CoR target gene, was used as a positive control in this assay.  
    Taken together, the data obtained thus far indicated that Flt3 repression 
may be brought about by the recruitment of the N-CoR repressor complex to 
its promoter region and loss of N-CoR in AML-M5 results in the subsequent 














Figure 3.31. Flt3 promoter activity was up regulated in N-CoR negative cells. 
Relative activity of a luciferase reporter driven by the Flt3 promoter was determined 
in various leukemic cell lines. The cells were transfected with reporter and reference 
plasmids using electroporation. The values presented in each bar represent the 























Figure 3.32. Ectopic expression of N-CoR in THP-1 cells down regulated Flt3 
promoter activity in a dose dependent manner. (A) Effect of ectopic N-CoR on the 
activity of the Flt3 promoter in THP-1 cells electroporated with flag-tagged N-CoR 
plasmid in a dose dependent manner was determined via luciferase assay. The values 
presented in each bar represent the average of three independent experiments. (B) In 
parallel, levels of ectopic N-CoR protein in THP-1 cells used in the luciferase assay 







Figure 3.33. Ectopic expression of N-CoR in N-CoR ablated HEK293T cells 
down regulated Flt3 promoter activity in a dose dependent manner. Effect of 
ectopic N-CoR on the activity of the Flt3 promoter in HEK293T cells transfected 
with N-CoR or control siRNA was determined using luciferase assay. In pGL3-Flt3 (-
901) reporter plasmid, luciferase reporter was placed under the control of the full 
length Flt3 promoter. The values presented in each bar represent the average of three 
independent experiments (upper panel). N-CoR knockdown efficiency in experiments 













Figure 3.34. Dose dependent fold of repression of Flt3 promoter activity by 
ectopic N-CoR in N-CoR ablated or non-ablated cells. The dose dependent fold 
repression by ectopic N-CoR in N-CoR ablated or non-ablated HEK293T cells was 
calculated by dividing the mean relative luciferase activity in N-CoR siRNA 






































Figure 3.35. Loss of N-CoR repressive function on the Flt3 promoter due to a 
misfolded conformation. The dose dependent fold repression by ectopic wild type 
N-CoR (WT) or the N-CoR phosphomimetic S1450E on the Flt3 promoter as 
determined by luciferase assay (top panel). The amount of N-CoR transfected as 

























Figure 3.36. The region more than 226bps upstream of the transcriptional start 
site in the Flt3 promoter was required for optimal repression of the promoter 
activity by N-CoR. The various luciferase constructs driven by the different regions 
in the Flt3 promoter (A). Fold of repression of luciferase activity of the various 
constructs by N-CoR in HEK293T cells. The values presented in each bar represent 
































Figure 3.37. N-CoR was associated with the Flt3 promoter. Relative amounts of 
Flt3 promoter sequence associated with N-CoR protein in HL60 or NB4 cells were 
determined through ChIP assay. The antibody used in the ChIP assay is mentioned at 
the bottom. N-CoR association with CD36 promoter, a known N-CoR target gene, 














3.2.3. N-CoR loss promoted IL-3 independent growth potential of BA/F3 
cells via the up-regulation of Flt3. 
Given the importance of Flt3 in the maintenance of survival and 
proliferative capabilities of HSCs as well as leukemic blasts, it was 
hypothesized that aberrant expression of the receptor due to N-CoR loss may 
be crucial in providing AML-M5 cells with a survival and proliferative 
advantage. Thus in a proof of concept approach, BA/F3 cells, an IL-3 
dependent murine bone marrow-derived cell line which expressed 
undetectable levels of the Flt3 receptor and a high level of endogenous N-CoR 
was utilized in an attempt to analyze the effects of N-CoR loss and Flt3 
expression, on the IL-3 independent growth properties of these cells. 
     First N-CoR level was ablated in BA/F3 cells via siRNA mediated 
gene knockdown and the level of Flt3 protein expression accessed via western 
blotting with an antibody which was capable of detecting the murine form of 
the Flt3 receptor. It was observed that in N-CoR ablated BA/F3 cells; there 
was an increase in the level of expression of the Flt3 protein (Fig. 3.38A). 
Next, the IL-3 independent growth properties of this N-CoR intact and N-CoR 
ablated BA/F3 cells was accessed, in the presence and absence of Flt3 ligand 
stimulation. It was observed that in the absence of IL-3 stimulation, N-CoR 
ablated BA/F3 cells had a slight proliferative advantage over non-ablated 
cells, with a proliferative index of about 2 times that of the non-ablated cells. 
When stimulated with the Flt3 ligand, this proliferative advantage was greatly 
enhanced to about 4 fold. This suggested that N-CoR loss promoted the IL-3 
independent growth potential of BA/F3 cells and this growth capacity was 
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greatly potentiated by the activation of the Flt3 signaling pathway via Flt3 


























   




Figure 3.38. N-CoR loss promoted IL-3 independent growth potential of BA/F3 
cells, potentiated by Flt3 ligand stimulation. (A) Levels of N-CoR and Flt3 protein 
in Ba/F3 cells transfected with control or anti-N-CoR siRNA were determined via 
western blotting assay with an anti-Flt3 antibody which recognizes the murine form 
of the receptor and N-CoR (C-20) antibody. (B) N-CoR loss mediated Flt3 expression 
enhanced the IL-3 independent growth potential of BA/F3 cells. Effect of IL-3 
independent growth of Ba/F3 cells transfected with control or N-CoR siRNA 
(population from A) with and without Flt3 ligand stimulation were determined by cell 
proliferation assay. The Y-axis of the graph represents the proliferation index of 
viable cells, and the duration of culture is plotted on the X-axis. The symbols used in 
the graph are as follows: Control siRNA transfected cells treated with vehicle ( ), 
Control siRNA transfected cells stimulated with Flt3 ligand ( ), N-CoR siRNA 
transfected cells treated with vehicle ( ) and N-CoR siRNA transfected cells 
stimulated with Flt3 ligand ( ). The values presented in each graph are average of 





3.2.4. N-CoR loss was potentiated by Flt3 signaling activation.  
With the observations in BA/F3 cells and findings which linked Akt 
activity to misfolded conformation dependent N-CoR loss, it was thought that 
Flt3 signaling activation by the Flt3 ligand might have resulted in the 
potentiation of N-CoR loss. This may result in the amplification of the growth 
advantage mediated by N-CoR loss in AML-M5. Therefore, to test this 
hypothesis, the effect of Flt3 ligand stimulation on the level of N-CoR protein 
in HEK293T cells in the presence or absence of the Flt3 receptor was 
accessed. As shown in figure 3.39A, Flt3 ligand stimulation down-regulated 
N-CoR protein levels in HEK293T cells in a Flt3 receptor dependent manner. 
Down regulation of the 160 kDa membrane bound form of the Flt3 receptor 
due to receptor internalization after ligand binding was used to access for Flt3 
signaling induction by the Flt3 ligand. 
    To investigate whether N-CoR loss in AML-M5 cells was potentiated 
by Flt3 activation, it was hypothesized that the blockade of Flt3 ligand binding 
to the Flt3 receptor would result in some stabilization of the N-CoR protein in 
THP-1 cells. Thus, selective blockade of Flt3 receptor with Flt3 antibody in 
THP-1 cells followed by Flt3 ligand stimulation was conducted. In this 
experiment it was observed that the inability of the Flt3 ligand to bind to the 
Flt3 receptor as indicated by the loss of receptor internalization resulted in the 
stabilization N-CoR protein in THP-1 cells in a dose dependent manner (Fig. 
3.39B).  These data suggested that an oncogenic stimulus which promotes 
cellular growth through Flt3 activation could amplify Flt3 mediated survival 



















Figure 3.39. N-CoR loss promoted growth potential which was amplified by Flt3 
signaling activation.  (A) Flt3 stimulation leads to N-CoR loss. Levels of N-CoR and 
Flt3 proteins in HEK293T cells treated with vehicle or Flt3 ligand (30 ng/ml) was 
determined by western blotting assay. (B) Blocking Flt3 stimulation leads to N-CoR 
stabilization in THP-1 cells. Effect of Flt3 antibody on the levels of N-CoR and Flt3 
proteins in THP-1 cells treated with vehicle or Flt3 ligand (30 ng/ml) was determined 








3.2.5. A potential tumor suppressive role for N-CoR via Flt3 expression 
regulation.  
The data collected thus far suggested that N-CoR may have a tumor 
suppressive role in normal hematopoiesis by restricting the proliferative 
capabilities of HSCs and its multi-potential progenitors via its regulation of 
pro-survival signaling receptors such as Flt3. Its resulting loss of function due 
to MCDL of N-CoR protein may contribute to the acquisition of 
tumorigenicity in AML-M5 by enhancing the survival and growth potentials 
of the leukemic cells. Therefore, in an attempt to validate this hypothesis, the 
expression levels of N-CoR and Flt3 during the progression of normal 
hematopoiesis was first accessed. qRT-PCR analysis of N-CoR and Flt3 
transcript levels in mouse HSCs/progenitor cells and committed cells of 
various lineages purified using multi-parametric Flow Cytometry was 
conducted. Here, N-CoR transcript levels was observed to be up-regulated in a 
progressive manner as the fractions were purified for the more matured 
myeloid cell phenotype when compared to levels expressed in total bone 
marrow. The lowest expression levels were found in the c-kit+ stem 
cell/progenitor cell population and the highest in the mature monocyte/ 
granulocyte and erythrocyte populations. This observed N-CoR transcript up-
regulation was accompanied by the concurrent down-regulation of Flt3 mRNA 
expression in these populations (Fig. 3.40). 
    Next, to investigate the effects of this increased N-CoR expression on 
the commitment of HSCs/ progenitor cells towards the myeloid lineage, the 
effect of enforced N-CoR expression on the growth and maturation of c-Kit+ 
HSC/progenitor cells was determined. Mouse bone marrow (BM) cells were 
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first transduced with either the MSCV-IRES-GFP-N-CoR or control vector 
MSCV-IRES-GFP and FACS purified GFP positive c-Kit+ cells were isolated 
and accessed for their growth and differentiation properties. In methylcellulose 
colony formation assay, it was observed that MSCV-IRES-GFP-N-CoR 
infected c-Kit+ cells made significantly fewer colonies when compared to 
MSCV-IRES-GFP infected cells (Fig. 3.41, right upper panel). Moreover, 
when the morphology of cells present in these colonies was analyzed by 
Wright-Giemsa staining, cells derived from the MSCV-IRES-GFP-N-CoR 
infected colonies displayed morphological feature of matured myeloid cells 
(Fig. 3.41, right lower panel). To better identify the phenotypes of cells after 
enforced N-CoR expression, long-term culture initiating cell assay (LTC-IC) 
was employed. In this assay it was observed that a relatively higher percentage 
of granulocyte (G), macrophage (M), and granulocyte-macrophage (GM) 
colonies were found in MSCV-IRES-GFP-N-CoR infected cells compared to 
cells infected with MSCV-IRES-GFP (Fig. 3.42A and B). This suggested that 
enforced N-CoR expression in immature hematopoietic cells led to their 
maturation towards the myeloid lineage.  
To access the effect of N-CoR on the re-populating capacity of HSCs 
in vivo, around 5x105 BM MNCs infected with MSCV-IRES-GFP-N-CoR or 
control vector were implanted intravenously into sub-lethally irradiated 
recipient mice and the number of GFP positive cells in the peripheral blood of 
the recipient mice was analyzed by FACS 3, 6 and 10 weeks after 
implantation. At all time points, the percentage of GFP positive cells in the 
peripheral blood of MSCV-IRES-GFP-N-CoR transplanted mice was 
significantly lower when compared to those of mice transplanted with the 
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control vector (Fig. 3.43) indicating that N-CoR expression in the HSCs 
inhibited their re-populating capacity.  
    These findings collectively suggested a role for N-CoR in the 
suppression of growth and survival potentials required for the maturation and 
commitment of HSCs/ progenitor cells toward the myeloid lineage probably 
through the loss of expression of pro-survival receptors such as Flt3. Thus it 
was hypothesized that N-CoR loss in AML-M5 possibly disrupts this tumor 































Figure 3.40. Stepwise up-regulation of N-CoR transcript levels as HSCs mature 
towards the myeloid lineage, accompanied by the concurrent down regulation of 
Flt3 transcript levels. Levels of N-CoR and Flt3 transcripts in purified mouse 
hematopoietic cells were determined by qRT-PCR analysis. The values presented in 























Figure 3.41. Enforced N-CoR expression in c-Kit+ stem cell/progenitor cells inhibits their self-renewal potential. Growth and self-renewal potentials of 


















Figure 3.42. Enforced N-CoR expression in c-Kit+ stem cell/progenitor cells 
induced myeloid lineage differentiation. Morphology of purified mouse bone 
marrow cells transduced with MSCV-IRES-GFP-N-CoR or control vector was 
determined with Wright-Geimsa staining where Eosinophils (Eos), mast cells (MC), 
meta-myelocytes (Met), monocytes (Mono), Myelocytes (M), neutrophils (N) and 
promyelocytes (PM) are labeled (A).   The phenotype of cells scored against total cell 














Figure 3.43. Enforced N-CoR expression inhibited the growth and repopulating 
potential of c-Kit+ stem cell/progenitor cells In vivo. 5 x 105 transfected BM cells 
were transplanted intravenously into sub lethally irradiated C57BL/6 mice (8 Gy). 
The recipient mice were examined at week 3, 6 and 10 for blood cell counts and GFP 





3.2.6. Restoration of N-CoR tumor suppressive function down-regulated 
Flt3 expression and induced terminal differentiation of AML-M5 cells.    
To validate the hypothesis, the effects of N-CoR function restoration in 
the AML-M5 cell line THP-1 on the growth and proliferative properties of the 
cells were tested. Utilizing Genistein, a drug which our laboratory had 
previously shown to restore N-CoR native properties in AML-M5 cells, the 
effect of Genistein induced restoration of N-CoR function on Flt3 expression 
in THP-1 was first accessed. It was observed that in THP-1 cells, Genistein 
down-regulated Flt3 expression at both the transcript and protein levels with 
maximum loss of expression occurring at 50 µM, the dose which most 
effectively restored N-CoR expression (Fig. 3.44). 
    Next the effect of N-CoR restoration and Flt3 down regulation on the 
proliferative properties of THP-1 cells was tested via MTT assay. Here, a dose 
dependent inhibition of the growth capacity of treated cells was observed. This 
inhibition was most pronounced again at the dose of 50 µM (Fig. 3.45). 
Morphological analysis via Wright-Giemsa Staining of treated cells, revealed 
that this growth inhibition was likely due to the relieve of differentiation arrest 
as a significant number of Genistein-treated THP-1 cells displayed 
characteristics of matured monocytic cells such as horseshoe-shaped nuclei 
(Fig. 3.46A). Genistein induced differentiation progression was further 
supported by the ability of Genistein to up-regulate the level of CD14, a 
marker for myeloid/monocytic lineage maturation in THP-1 cells in a dose 
dependent manner when analyzed by FACS and RT-PCR analysis (Fig. 3.46B 
and C). This suggested that Genistein induced growth arrest in THP-1 cells 
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was likely a due to the restoration of the ability of these cells to progress in 
myeloid/ monocytic lineage differentiation.  
    Next, in order to determine if the restoration of N-CoR function had a 
role in this progression in differentiation, siRNA mediated N-CoR knockdown 
in THP-1 cells was performed and the ability of these cells to differentiate 
after Genistein treatment was investigated. The expression level of the 
monocytic cell maturation marker CD14 at the transcript level was used as an 
indicator for progression of differentiation. It was observed that in the cells 
where N-CoR was knocked down, there was no restoration of N-CoR protein 
expression and Flt3 levels were not reduced compared to the non-ablated cells. 
CD14 transcript levels after Genistein treatment was also not significantly 
induced in the N-CoR ablated cells (Fig. 3.47), indicating that N-CoR function 
was necessary in Genistein induced Flt3 down regulation and the subsequent 
growth inhibition and differentiation progression of THP-1 cells.    
    Collectively, these observations suggested that N-CoR may have an 
essential role in the progression of myeloid cell maturation in normal 
hematopoiesis and its aberrant loss in AML-M5, contributes to disease 
pathogenesis by augmenting the survival and proliferative capacities of these 
cells via the aberrant re-expression of pro-survival receptors such as Flt3. 
   The dynamic role of natively folded and misfolded N-CoR protein in 
the growth promoting function of Flt3 has been presented schematically in 
figure 3.48. In the absence of N-CoR protein, Flt3 levels are maintained at a 
relatively higher level during the growth and self-renewal of immature 
hematopoietic cells. However, as these cells proceed towards maturation, N-
CoR levels are gradually up regulated, leading to the down regulation of Flt3 
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levels and suppression of cellular growth and self-renewal potentials (Fig. 
3.48, top panel). In AML-M5 cells, loss of N-CoR function due to Akt 
mediated misfolding abolishes its repressive control on the Flt3 gene, leading 
to the restoration of Flt3 expression and ectopic re-activation of cellular self-





























Figure 3.44. Flt3 levels were down regulated at both the protein and mRNA 
levels after Genistein treatment. Level of Flt3 expression was determined via 





































Figure 3.45. Genistein inhibited the proliferation of THP-1 cells. Genistein 
inhibited the proliferation of THP-1 cells in a dose dependent manner when 
determined via growth proliferation assay (MTT). Results are representative of 3 


















Figure 3.46. Genistein induced THP-1 differentiation progression. (A) Nuclear 
morphology of THP-1 cells treated with Genistein for the duration of 72 hours in a 
dose dependent manner was determined in Wright–Giemsa assay. The arrowheads 
mark the indented-shaped nucleus of differentiated cells. (B) & (C) CD14 levels in 
THP-1 cells treated with Genistein for 72 hours in a dose dependent manner was 






















Figure 3.47. N-CoR was required for Genistein induced THP-1 differentiation 
progression. N-CoR, Flt3 and CD14 levels in THP-1 cells transfected with N-CoR 
siRNA and treated with 50 µM Genistein for 72 hours was determined by western 



























Figure 3.48. Schematic representation of N-CoR-induced suppression of Flt3 in 
normal and leukemic cells. In the absence of N-CoR, Flt3 level is maintained at 
relatively higher level in immature hematopoietic cells, contributing to their increased 
growth and self-renewal potentials. However, as these cells proceed towards 
maturation, N-CoR level is gradually up regulated resulting in the suppression of Flt3 
level and down-regulation of cellular growth and self-renewal potentials. Due to the 
loss of misfolded N-CoR protein in AML-M5 cells, Flt3 level is up regulated and 








3.3. Targeting the N-CoR MCDL pathway as a therapeutic strategy in 
AML-M5. 
3.3.1. Targeting the clearing of misfolded N-CoR. 
 The data collected in the previous studies conducted in APL and in this 
thesis, suggested that the misfolded conformational loss of N-CoR was a two-
stage process. The first stage in the process of N-CoR loss was the aberrant 
post translational modification of N-CoR protein brought about by an 
oncogenic insult such as hyper-activation of Akt in AML-M5 or the 
expression of the fusion oncogene PML-RARα in APL62. This was followed 
by the activation of the proposed third arm of the unfolded protein response 
(UPR) - the ‘late’ cytoprotective UPR arm resulting in the subsequent 
proteolytic clearing of this misfolded N-CoR in the leukemic cells.  
The clearing of misfolded N-CoR during the activation of ‘late’ 
cytoprotective UPR in APL had been previously shown to prevent the 
accumulation ER stress brought about by misfolded N-CoR to a level which 
would trigger cell death63. A similar cytoprotective UPR mechanism was also 
thought to be present in AML-M5, allowing these cells to circumvent ER 
stress induced cell death due to the accumulation of misfolded N-CoR protein. 
The involvement of a heat liable protease in the clearing of misfolded N-CoR 
in AML-M5 was suggested in this thesis. It was shown that the inhibition of 
this protease activity by protease inhibitors were able to prevent misfolded N-
CoR clearing, resulting in the accumulation of ER stress in AML-M5 cells 
(Fig. 3.4A, 3.5B and Fig. 3.8B). It was thought that this inhibition would 
result in the accumulation of ER stress beyond the threshold level needed to 
initiate cell death.  
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Thus to validate this thought, the effects of AEBSF and Kaletra on the 
proliferation of THP-1 cells was carried out using MTT assay. In this assay, it 
was observed that both AEBSF and Kaletra were able to induce a dose 
dependent inhibition of cell proliferation in THP-1 cells; with the maximum 
inhibition occurring at the dose which most effectively prevented misfolded 
N-CoR clearing (Fig. 3.49). After both AEBSF and Kaletra treatment, treated 
cells displayed a distinct morphology characterized by fragmented nuclei and 
shrinkage of the cytoplasm, suggesting apoptotic cell death (Fig. 3.48). 
AEBSF treated THP-1 cells also displayed a clear dose dependent increase in 
apoptotic cells as indicated by Annexin V and Propidium Iodide (PI) staining. 
The percentage of apoptotic cells was the highest at the dose which most 
effectively stabilized N-CoR and displayed the highest ER stress levels (Fig. 
3.50). This indicated that the protease inhibitors blocked the clearing of 
misfolded N-CoR resulting in the accumulation of ER stress to levels beyond 
the survival threshold leading to cell death.  
 The selectivity of protease inhibitors for APL was previously reported 
and similarly, both the protease inhibitors tested showed a selective sensitivity 
to AML-M5 derived cell liines when cell proliferation after treatment was 





















Figure 3.49. Protease Inhibitors, AEBSF and Kaletra inhibited the proliferation 
of THP-1 cells. AEBSF (A) and Kaletra (B) inhibited the proliferation of THP-1 cells 
in a dose dependent manner when determined via growth proliferation assay (MTT). 
Results are representative of 3 independent experiments and asterisks represent 












Figure 3.50. Both AEBSF and Kaletra treated cells displayed morphological characteristics of apoptotic cell death. The morphology of THP-1 cells 













Figure 3.51. AEBSF treated cells displayed characteristics of apoptotic cell death. Annexin V and PI staining of THP-1 cells treated with AEBSF in a 
dose dependent manner for a total duration of 72 hours was determined by Flow cytometric analysis. There was a dose dependent increase in the percentage 














Figure	   3.52.	   Protease	   Inhibitors	   AEBSF	   and	   Kaletra	   promote	   selective	  
growth	   arrest	   of	   AML-­‐M5	   derived	   cell	   lines.	   Growth of AML-M5 (THP-1, 
Nomo-1, MM1, MV-4-11 and SigM5) and non-AML-M5 (U937, K562 and HL60) 
derived cell lines treated with AEBSF (A) or Kaletra (B) in a dose-dependent manner 
for a total duration of 72 hours was determined though MTT based cell proliferation 
assay. The value presented in each bar graph is average of three independent 






3.3.2. Targeting the misfolding of N-CoR. 
 In APL, N-CoR misfolding was brought about by its association with 
the fusion oncogene PML-RARα. Compounds which target this association 
such as All-Trans-Retinoic acid and Genistein disrupts the association thus 
resulting in the return of N-CoR native conformation and function58,62 which 
eventually results in terminal differentiation and cell death. 
 In AML-M5, it was observed that N-CoR misfolded conformation was 
initiated by the phosphorylation of N-CoR by Akt activity. Thus, drugs which 
inhibit this phosphorylation event would pose as good candidates for AML-
M5 therapy. Previously, it was observed that Genistein, a kinase inhibitor was 
able to restore N-CoR native properties (Fig. 3.5A and Fig 3.6C) and relieve 
the differentiation block in AML-M5 (Fig. 3.43 and Fig. 3.45). The blockade 
of N-CoR misfolding was thought to be through the inhibition of Akt kinase 
activity in AML-M5 and this was validated by western blotting assay. In THP-
1 cells, it was observed that Akt kinase activity was inhibited in a dose 
dependent manner as indicated by the dose dependent reduction of phospho-
Akt (Ser473) after Genistein treatment (Fig. 3.18A). Similarly, inhibition of 
Akt activity by the Akt specific inhibitor Akti-X was also observed to bring 
about the restoration of N-CoR native conformation (Fig. 3.13). Akti-X was 
observed to inhibit THP-1 cell proliferation in a dose dependent manner when 
its effect on cell growth was accessed via MTT assay (Fig. 3.53). After Akti-X 
treatment, treated cells displayed a distinct morphology characterized by 
fragmented nuclei and shrinkage of the cytoplasm, suggesting apoptotic cell 
death (Fig. 3.54).  This growth inhibition by Genistein and Akti-X was also 
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found to be selective to AML-M5 derived cell lines when compared to their 
effects on non-AML-M5 derived cell lines (Fig. 3.55). 
 The selectivity of protease inhibitors and agents which prevent Akt 
mediated N-CoR misfolding indicate a possible role of MCDL of N-CoR in 
the selective growth inhibition of AML-M5 leukemic cells.  This illustrates the 
































































Figure 3.53. Akti-X inhibited the proliferation of THP-1 cells. Akti-X inhibited 
the proliferation of THP-1 cells in a dose dependent manner when determined via 
growth proliferation assay (MTT). Results are representative of 3 independent 


























Figure 3.54. Akti-X treated cells displayed morphological characteristics of apoptotic cell death. The morphology of THP-1 cells treated with Akti-X in 




















Figure	   3.55.	   Kinase	   Inhibitors	   Genistein	   and	   Akti-­‐X	   promote	   selective	  
growth	   arrest	   of	   AML-­‐M5	   derived	   cell	   lines.	   Growth of AML-M5 (THP-1, 
Nomo-1, MM1, MV-4-11 and SigM5) and non-AML-M5 (U937, K562 and HL60) 
derived cell lines treated with Genistein (A) or Akti-X (B) in a dose-dependent 
manner for a total duration of 72 hours was determined though MTT based cell 
proliferation assay. The value presented in each bar graph is average of three 


















4.1 Misfolded Conformational Dependent Loss (MCDL) of N-CoR in 
AML-M5. 
4.1.1 Identification of APL-like N-CoR MCDL in AML-M5. 
 In our initial screening, we identified APL-like MCDL of N-CoR in 
multiple cell lines from AML of the M5 subtype, where the presence of the 
100 KDa N-CoR band and in vitro cleavage activity was consistant in all the 
cell lines derived from this subtype of AML. In the cell lines which were 
derived from the other FAB subclasses of AML (an average of 2 cell lines 
from each FAB subclass), the protein expression of full length N-CoR was not 
as uniform across cell lines derived from the each FAB subclass as that 
observed in AML-M5 (data not shown). Furthermore, the 100 KDa cleaved N-
CoR band and in vitro N-CoR cleaving activity was only observed in cell lines 
derived from the M3 (APL) and M5 subtype (data not shown). As we did not 
look at the N-CoR transcript levels in all these cell lines, it is unclear if the 
lack of N-CoR protein expression in some of these cell lines was due to the 
suppression of N-CoR transcript levels. More cell lines and primary patient 
specimens derived from the various FAB classes should be study to better 
identify the specificity of N-CoR MCDL to AML-M5 and APL. 
4.1.2. Processing of misfolded N-CoR in AML-M5 by aberrant protease 
activity. 
 Previously, it was reported that in APL, N-CoR was in a misfolded 
conformation as characterized by its detergent insolubility and aberrant 
cytosolic localization resulting in the amplification of ER stress62. This 
amplification of ER stress was kept below the threshold levels required to 
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initiate cell death by the processing of this misfolded N-CoR by an aberrant 
protease activity63.  In this study, it was reported that N-CoR was observed to 
display several characteristics of misfolding and was processed by an aberrant 
protease activity in AML-M5.  
In mammalian cells, there exists an efficient protein quality monitoring 
system known as the Unfolded Protein Response (UPR).  UPR is activated in 
response to the intracellular accumulation of misfolded proteins in the 
ER193,194. There are two arms to this UPR response, one which is 
cytoprotective and the other which is cytotoxic. The first response to the 
accumulation of misfolded protein is the activation of molecular chaperones in 
an attempt to refold these proteins. When this system fails to clear the 
misfolded proteins, a second defense mechanism, ER-associated degradation 
or ERAD is activated. This process promotes ubiquitin-proteasome mediated 
degradation of the misfolded proteins. When this cytoprotective UPR response 
fails, cytotoxic UPR takes over to eliminate cells which harbor these 
misfolded proteins.  
It was interesting to note that inhibition of proteasome activity in 
AML-M5 did not seem to have an effect on the clearance of misfolded N-CoR 
(Fig 3.4B). It is unclear if this was due to an inherent non-functional ubiquitin-
proteasome system in these cells or if the ERAD function was directly 
inhibited by the misfolded N-CoR itself. However, the failure of this system to 
clear misfolded N-CoR in AML-M5 cells did not seem to have affected the 
cells’ ability to escape the cytotoxicity brought about by the accumulation of 
misfolded N-CoR. Instead, there seemed to be a selective induction of a third 
proposed arm of the UPR pathway, the ‘late’ cytoprotective arm (which was 
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first suggested in APL cells) in AML-M5 cells63. This third arm which was 
associated with increased aberrant protease activity seemed to negate the 
negative effects of the accumulation of misfolded N-CoR on cellular growth in 
AML-M5. The involvement of aberrant protease activity in AML pathogenesis 
was first reported in APL. Cleavage of PML-RARα by neutrophil elastase was 
shown to be important for the pathogenesis of APL in mice 195,196. 
Subsequently, our laboratory reported the role of aberrant processing of 
misfolded N-CoR by the protease O-Sialoglycoprotein-Endopeptidase 
(OSGEP) in APL’s resistance to Unfolded Protein Response (UPR) - induced 
apoptosis63. 
 The findings reported in this thesis suggested that a similar aberrant 
protease activity in the processing of N-CoR in AML-M5. The degree and 
pattern of N-CoR loss across all AML-M5 derived cells was more or less 
comparable despite the differences in their genetic backgrounds. Although all 
AML-M5 derived cells displayed almost complete loss of full length N-CoR 
protein, the cleaved 100 kDa N-CoR fragment was less pronounced in Nomo-
1 cells when compared to other AML-M5 derived cells. Consistent with this 
finding, incubation of flag-tagged N-CoR with Nomo-1 cell extract did not 
generate any 100 kDa N-CoR fragment despite complete digestion of full 
length N-CoR protein (Fig. 3.1 and 3.3). The lack of cleaved N-CoR in Nomo-
1 cells could be due to the higher potency of N-CoR cleaving activity in 
Nomo-1 cells which could have further digested the cleaved N-CoR in 
addition to digestion of full length N-CoR. It is also likely that Nomo-1 cells 
posses an N-CoR cleaving activity which is distinct from the activity found in 
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other AML-M5 derived cell lines, and cleaved N-CoR protein in a distinct 
manner.     
    The generation of the 100 kDa N-CoR fragment in most of the AML-
M5 derived cell lines which was identical in size to that found in APL 
suggested that the cleaving activity in AML-M5 could possibly be mediated 
by OSGEP. However, despite the detection of OSGEP mRNA expression in 
AML-M5 cell lines, OSGEP was not identified in the N-CoR cleaving fraction 
of AML-M5 cell lysate after gel filtration chromatography in our attempt to 
identify the potential proteases involved in N-CoR processing in AML-M5 
(data not shown). Furthermore, it was observed that AML-M5 derived cell 
lines displayed a complete loss of full length N-CoR protein while in the APL 
cell line NB4, the loss was not complete. Thus, it is possible that some other 
protease or a combination of proteases may be involved in the processing of 
N-CoR in AML-M5.  Despite this, the data suggested that N-CoR cleavage in 
all AML-M5 derived cell lines was probably triggered by an identical non-
regulated proteolytic mechanism which was selectively activated in AML-M5 
leukemic cells to circumvent the cytotoxicity associated with the misfolded N-
CoR protein.  
Normal mammalian cells possess a robust protein quality control 
mechanism regulated by the ubiquitin-proteasome system that promptly 
dispenses non-amenable misfolded proteins to refolding by molecular 
chaperones. However in protein misfolding diseases, the function of the 
ubiquitin-proteasome system is severely compromised, resulting in excess 
accumulation of misfolded proteins in the ER, creating a potentially life 
threatening situation for the host cells. Furthermore, an excessive 
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accumulation of misfolded proteins in the subcellular compartment can 
directly impair proteasome function, resulting in further accumulation of 
misfolded proteins and amplification of ER stress. This usually leads to cell 
death, which largely forms the pathogenic basis in various neurological 
disorders such as Alzheimer and Parkinson’s diseases. In tumor cells derived 
from APL or AML-M5, protease mediated degradation of misfolded N-CoR 
protein may constitute an alternative mechanism for the disposal of misfolded 
proteins, leading to the attenuation of ER stress and eventual protection of 
AML-M5 cells from ER stress-induced apoptosis. Thus, degradation of 
misfolded N-CoR protein through aberrant protease activity could represent a 
tumor cell specific adaptive protein quality control mechanism specifically 
activated to remove misfolded proteins that are non-amenable to traditional 
protein quality control mechanism. 
4.1.3. Involvement of Akt kinase activity in the misfolding of N-CoR. 
 Unlike APL where the expression of the fusion oncogene PML-RARα 
is found in almost all cases of the disease (> 95%), the occurrence of fusion 
oncogenes in AML-M5 is less homogenous. Although the MLL1-AF9 fusion 
oncogene was found in more than half of the AML-M5 cases, other diverse 
genetic anomalies were also frequently reported12. Thus unlike APL, the 
misfolding of N-CoR in AML-M5 could not be attributed to the fusion 
oncogene alone. In APL, misfolded N-CoR which was localized to the cytosol 
was reported to be aberrantly phosphorylated at the Serine/Threonine residues 
in the presence of PML-RARα 58,197. In AML-M5, the misfolded N-CoR was 
also found to be aberrantly phosphorylated at the Serine/Threonine residue 
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(Fig 3.9). Thus, the involvement of a common kinase activity in the uniform 
loss of N-CoR in genetic variants of AML-M5 could not be ruled out. 
The involvement of aberrant kinase activity in the loss of N-CoR 
nuclear function due to cytosolic export was first reported in neuronal cells. In 
that report, Akt induced phosphorylation of N-CoR was found to be linked to 
its aberrant cytosolic export in cytokine stimulated neuronal cells, suggesting 
that N-CoR function could be adversely affected by Akt activity48. In a more 
recent publication, phosphorylation of N-CoR by IKKα was also linked to its 
aberrant cytosolic export in colorectal cancer cells56. These reports suggested 
that aberrant phosphorylation of N-CoR by kinase hyper-activity could result 
in the loss of N-CoR nuclear function due to aberrant cytosolic export. 
The findings reported in this study identified Akt as the kinase 
involved in the misfolding of N-CoR in AML-M5. This was not surprising, as 
Akt phosphorylation of N-CoR had been reported previously. A recent study 
by Yu et al198 and  the results obtained in figure 3.11 revealed that Akt was 
hyper-activated in AML-M5 cell lines and multiple AML-M5 patient 
specimens. This strongly suggests Akt kinase as the common factor which 
contributed to the misfolding of N-CoR across all AML-M5 variants. 
4.1.4. Akt phosphorylation of N-CoR at Serine 1450 was essential in the 
initiation of the misfolded conformation. 
Based on the data obtained, it appeared that N-CoR misfolding in all 
AML-M5 derived cells was primarily caused by an identical phosphorylation 
event by Akt kinase activity at the Serine residue at position 1450 triggered by 
the various forms of oncogenic alterations associated with the transformation 
of AML-M5 cells. The phosphorylation at Serine 1450 could alter the local 
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free energy and destabilized the core of N-CoR protein, leading to its 
conformational change and subsequent degradation in AML-M5 cells. The 
change in three-dimensional structure due to the phosphorylation at Serine 
1450 might have led to the exposure of the hydrophobic residues in the N-CoR 
protein normally buried in the core. This could result in the facilitation of N-
CoR’s interaction with molecular chaperones, ultimately targeting the 
misfolded N-CoR to the ER. The ER targeting of misfolded N-CoR could 
initially trigger ER stress; however, its subsequent degradation could have 
attenuated ER stress, eventually protecting AML-M5 cells from ER stress-
induced apoptosis. Interestingly, an important role of Akt in protecting cells 
from ER stress-induced apoptosis by attenuating cellular ER stress has 
recently been identified 199. The AEBSF-induced ER stress amplification in 
THP-1 cells was due to the net ER accumulation of misfolded N-CoR protein 
as a result of the inhibition of its degradation by proteases. Conversely, 
Genistein induced N-CoR stabilization could have resulted from the 
restoration of native N-CoR conformation due to inhibition of Akt activity. 
This resulted in the inhibition of serine 1450 phosphorylation, thus facilitating 
its transport back to the nucleus from the ER eventually reducing ER stress 
levels and restoring N-CoR nuclear function. 
 
4.2 Functional Consequence of MCDL of N-CoR in AML-M5. 
4.2.1. Flt3, a transcriptional target of N-CoR. 
 The main function of N-CoR as a transcriptional co-repressor is 
achieved in the nucleus. Thus Akt mediated aberrant cytosolic export would 
result in the loss of N-CoR transcriptional function. Small-scale genetic 
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screening conducted via comparative real time PCR analysis identified the 
pro-survival signaling receptor Flt3 as a transcriptional target of N-CoR. 
 Promoter studies indicated that N-CoR and its associated co-repressor 
complex exerted its control on Flt3 expression by binding to the promoter 
region of the Flt3 gene (Fig. 3.31 to 3.37). Although N-CoR acts as a co-
repressor for multiple transcription factors, there are no reports of N-CoR 
itself binding to any known specific DNA sequences. Thus it is unclear if the 
association of N-CoR with the Flt3 promoter region is direct, or mediated 
indirectly by other DNA binding transcription factors. Using the luciferase 
reporter driven by various truncated fragments of the full length Flt3 promoter 
as well as ChIP assay performed with primers encompassing the truncated and 
full length Flt3 promoter, the putative region which was associated to N-CoR 
was identified. This N-CoR binding site on the Flt3 promoter identified 
through luciferase and ChIP assay was located between 614 to 814 bps 
upstream of the Flt3 transcriptional start site. This putative N-CoR binding site 
was upstream of the Flt3 promoter region where most of the transcriptional 
factor binding sites had been identified.  
 Computational analysis using the TRANSFAC database (a database 
about eukaryotic transcription regulating DNA sequence elements and the 
transcription factors binding to and acting through them) revealed several 
putative transcription factor binding sites such as PPARα, RXR and RAR, all 
of which are known to utilize N-CoR for their function as transcriptional 
repressors. However more work is required to confirm the identity of the 
transcription factor that tethers N-CoR to the Flt3 promoter. This identification 
will be crucial for the complete understanding of N-CoR’s role in the 
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regulation of Flt3 expression and its implication in hematopoiesis and 
leukemogenesis.  
4.2.2. Effect of misfolded N-CoR on the regulation of Flt3 expression. 
 In this study, it was identified that N-CoR misfolding in AML-M5 was 
due to its phosphorylation at the Serine 1450 residue by Akt kinase activity. 
This observation was further supported by the spontaneous misfolding of the 
phosphomimetic N-CoR S1450E (where the serine 1450 residue was replaced 
with a glutamic acid residue to mimic the phosphorylation event). The 
phosphomimetic N-CoR was shown to have a weaker repressive action on the 
Flt3 promoter when compared to wild type N-CoR via luciferase assay (Fig 
3.35). To test if the misfolded N-CoR exerts any dominant negative effects on 
wild-type N-CoR, the same promoter assay was performed with the co-
expression of wild-type N-CoR in combination with increasing doses of 
phosphomimetic N-CoR. In this set of experiments, no dominant negative 
effect of the phosphomimetic N-CoR was observed over the wild-type N-CoR 
(data not shown). Previously, it was reported that Akt phosphorylation of the 
Foxhead family of transcription factors inhibit their nuclear function by 
sequestering them in the cytosol145,146. This prevented the binding of these 
factors to the promoter regions of the genes they regulate. Thus Akt mediated 
N-CoR misfolding may have a similar mode of action on N-CoR’s 
transcriptional role in AML-M5. The phosphorylation may have resulted in 
the re-localization and degradation of N-CoR, preventing the binding of N-
CoR to its transcriptional targets ultimately resulting in the loss of repression 




4.2.3. Tumor suppressive role of N-CoR in AML-M5. 
The ultimate goal of the work presented here was to identify how the 
APL-like post-translational loss of N-CoR contributed to the pathogenesis of 
AML-M5. To that end, this study revealed that N-CoR mediated 
transcriptional control of Flt3 might be essential for the control of the cellular 
self-renewal and growth potentials of hematopoietic cells during normal 
hematopoiesis. When this control is abolished due to post-translational N-CoR 
loss, AML-M5 cells could reacquire the capacities of growth and survival, 
which ultimately led to leukemogenesis in conjunction with other factors 
involved in differentiation arrest. 
Flt3 is involved in the growth of early progenitor cells. Recent studies 
by Kikushige et al demonstrated that Flt3 expression in human HSCs, 
Granulocyte/Macrophage Progenitor could prolong their survival. This 
suggested that Flt3 plays a critical role in the survival of the stem and 
progenitor cells as well as in AML transformation 164.  The data presented in 
this study suggested that loss of N-CoR mediated Flt3 repression enhanced the 
IL-3 independent proliferative capacity of BA/F3 cells and this growth was 
potentiated by Flt3 ligand stimulation (Fig 3.38). It was also shown that in 
normal HSCs/ progenitor cells, expression of N-CoR inhibited the growth 
potential of these cells and induced myeloid lineage commitment (Fig 3.41 to 
3.43). It was also observed that as the cells progress towards maturation to the 
myeloid phenotype, N-CoR expression was up regulated while Flt3 level 
decrease proportionately (Fig 3.40). Physiologically, N-CoR is important in 
many developmental processes such as proliferation, differentiation and 
apoptosis. De-regulations of N-CoR function due to changes in expression or 
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loss of transcriptional function due to aberrant nuclear export contributed to 
carcinogenesis53-56.  As shown in this report, loss of N-CoR function due to 
misfolding conferred a proliferative advantage to AML-M5 cells via the up-
regulation of the pro-survival Flt3 receptor and therapeutic restoration of N-
CoR function effectively inhibited this growth capacity and induced terminal 
differentiation. This observation illustrated the putative tumor suppressive 
function of N-CoR via its regulation of Flt3 at least in AML-M5. 
 The tumor suppressive effect of N-CoR might not be limited to its 
regulation of Flt3. N-CoR being a component of the generic co-repressor 
complex might also be involved in the repression of other oncogenes which 
work in combination with Flt3 to elicit the leukemic phenotype. Furthermore, 
there had been reports suggesting that the expression of Flt3 and its mutants 
alone were not able to induce the complete leukemic phenotype162. This 
implies that Flt3 has to work with other oncogenic factors for leukemogenesis 
to occur. Thus a more comprehensive screening using genome wide micro 
array analysis would give a better picture of the tumor suppressive effect of N-
CoR via the genes it regulates and the other factors which work in tandem 
with Flt3 to bring about the leukemic phenotype. 
4.2.4. Akt, N-CoR loss and Flt3 over-expression, a possible positive 
feedback mechanism in the amplification of survival signals. 
 The PI3K/Akt survival pathway and its non-regulated activation by 
cell surface receptors such as EGFR200 and Flt3201,202 had been widely 
implicated in carcinogenesis. Akt had been reported to be a downstream 
molecule of Flt3 ligand mediated Flt3 signaling202. In the data obtained in 
figure 3.39, Flt3 activation was found to enhance N-CoR loss. This suggested 
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a possible positive feedback mechanism where the aberrant expression of the 
Flt3 receptor and its subsequent activation via Flt3 ligand stimulation or 
activating mutations could result in the enhancement of N-CoR loss through 
Akt activation. It was also of interest to note that N-CoR was reported to be a 
negative regulator of PI3K and loss of N-CoR function in thyroid cancer cells 
contributed to the activation of Akt dependent survival pathway in these 
cells53. This same mechanism may also contribute to the enhancement of the 
survival advantage of AML-M5 leukemic cells as a consequence of N-CoR 
loss. 
 
4.3. Targeting the N-CoR MCDL pathway as a therapeutic strategy in 
AML-M5. 
 Despite the advances in our knowledge of the mechanisms involved in 
leukemogenesis and the quest for constant improvements in therapeutic 
strategies used in the clinics for AML treatment, AML to date remains a 
difficult disease to treat. This could be attributed to the vast genetic 
aberrations which play major roles in disease pathogenesis. Although Flt3 
activating mutations have been widely associated with the poorer prognosis of 
AML patients, the fact that more than 70% of AMLs express the wild-type 
Flt3 receptor implies that the native receptor is also important in the 
enhancement of survival and proliferation of leukemic blasts165-167. Current 
therapies for AML in clinical practice include aggressive multi-drug 
chemotherapy, radiotherapy and allogenic bone marrow transplantations. 
However these current strategies have severe side effects and widespread 
cytotoxicity.The use of tyrosine kinase inhibitors especially Flt3 kinase 
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inhibitors in AML treatment has recently gained prominence as an effective 
non-invasive strategy for disease management. However, most of these agents 
exhibit positive outcomes only in a subset of patients as their efficacy largely 
depend on the expression of the Flt3 mutants or the constitutively active forms 
of the receptor kinases found in the leukemic blasts. For example, most Flt3 
kinase inhibitors have been evaluated solely in in vitro cell culture systems 
which express the mutant Flt3 receptors but not the wild-type. It had been 
reported that wild-type Flt3 signaling affected the efficacy of the Flt3 
inhibitors203. In many patients, especially in the newly diagnosed AML cases 
which are heterozygous for both the mutant and wild-type receptors204, there is 
a need to find new strategies which are effective against both the wild-type 
and mutant Flt3 receptor. Furthermore, resistance against these inhibitors is a 
major drawback that limits the effectiveness of such tyrosine kinase inhibitor 
based therapy206. Thus a stategy, which targets the expression of the receptor 
regardless of its mutational status and activity, could possibly address these 
issues.  
 Based on the results obtained in this study, it was postulated that N-
CoR regulates the expression of the Flt3 promoter regardless of its mutational 
status. N-CoR loss and the reciprocal up-regulation of Flt3 expression were 
evident across cells which express the wild-type Flt3 receptor (THP-1 and 
Nomo-1) and those which express the activating mutants (MV-4-11: Flt3-ITD, 
MM1: Flt3-TDK at position 592). There are no known reports on the 
mutational status of the Flt3 receptor in SigM5 cells (Fig. 3.28A). This 
relationship was also observed across all the AML-M5 primary patient 
specimens used despite the heterozygosity of Flt3 receptor mutational status 
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across the specimens (Fig. 3.28B). Thus, therapeutic targeting of the N-CoR 
MCDL pathway could be a useful strategy in AML-M5 therapy irrespective of 
Flt3 receptor mutational status.   
In this study, it was proposed that N-CoR loss in AML-M5 was a two-
stage process. The first step was the change in conformation of native N-CoR 
to the misfolded form by the oncogenic insult. In the case of AML-M5, it was 
triggered by the hyper-activation of Akt kinase activity followed by the 
aberrant phosphorylation of N-CoR at the Serine 1450 residue. This misfolded 
N-CoR then accumulates in the ER.  In the normal non-permissive 
environment of most mammalian cells the accumulation of misfolded N-CoR 
in the ER leads to apoptotic cell death. However in the permissive 
environment of AML-M5 leukemic cells where there was the activation of the 
proposed ‘late’ cytoprotective arm of UPR, the misfolded N-CoR was 
processed by a non-regulated proteolytic process. This keeps the ER stress 
below the threshold levels needed to induce cell death.  In our laboratory, 
we have identified several agents with therapeutic potential which targeted 
either the mechanism of N-CoR misfolding or blocked the processing of 
misfolded N-CoR protein. Some of these agents such as the kinase inhibitor 
Genistein, the Akt specific inhibitor Akti-X and the protease inhibitors 
AEBSF and Kaletra displayed selective cytotoxic effects against AML-M5 
derived  cell lines (Fig. 3.52 and Fig. 3.55) and might have the potential to be 
used as effective therapeutic strategies for targeting the pathway of N-CoR 





4.4. Concluding Remarks. 
 In the work presented here, we demonstrated the existence of APL-like 
misfolded conformational dependent loss (MCDL) of N-CoR in AML-M5. 
The misfolding of N-CoR in AML-M5 was initiated by the aberrant 
phosphorylation of N-CoR at Serine 1450 by Akt hyper-activity. This 
subsequently led to the degradation of misfolded N-CoR by a non-regulated 
proteolytic mechanism that we termed as the cytoprotective third arm of the 
Unfolded Protein Response pathway or the ‘late’ cytoprotective pathway. The 
dynamics of the N-CoR MCDL pathway and how it may contribute to disease 
pathogenesis in AML-M5 is depicted on figure 4.1. 
 The pro-survival receptor Flt3 was identified as a direct target of N-
CoR mediated repression. Loss of functional N-CoR in AML-M5 resulted in 
the aberrant expression of the Flt3 receptor in leukemic blasts, thus conferring 
a survival advantage to these cells. The proposed action of N-CoR loss on Flt3 
expression is summarized in figure 4.2.  
 Finally, based on the evidence of uniform N-CoR MCDL across AML-
M5 derived cell lines of varied genetic backgrounds, blocking N-CoR MCDL 
with various agents was proposed as a promising therapeutic strategy for 
AML-M5. Figure 4.3 and figure 4.4 summarizes how this pathway could be 
blocked at certain stages and its end effect on the survival of AML-M5 
leukemic cells. 
 AML-M5 is defined as a group of malignant disorder characterized by 
an abnormal accumulation of immature cells of myelo-monocytic lineage in 
the bone marrow and peripheral blood. Although AML-M5 is caused 
primarily by a wide array of genetic defects, including chromosomal 
177	  
	  
translocation involving the MLL-1 gene, the leukemia cells in all AML-M5 
variants display almost identical phenotype characterized by differentiation 
arrest and increased self-renewal capacity. Despite significant progress in the 
understanding of diverse genetic anomalies associated with AML-M5, it is 
still unclear as to how these diverse genetic anomalies could possibly create an 
indistinguishable and almost uniform cellular and clinical feature in the 
different variants of AML-M5. Interestingly, Yu and colleagues had recently 
reported a relevant mouse model for human monocytic leukaemia through 
Cre/lox controlled myeloid specific deletion of PTEN. In this study, PTEN 
knockout mice were observed to have Akt hyper-activation and 11 out of 18 of 
these mice develop leukemia. Analysis of the leukemic blasts confirmed 
monocytic differentiation in the blasts198.  Given the relationship between Akt 
hyper-activity and N-CoR MCDL identified in the work presented in this 
thesis, it is likely that these uniform phenotypic features could be manifested 
through the de-regulation of a common factor such as N-CoR, a critical 
regulatory factor in the normal growth and maturation of early myeloid cells. 
 Despite all these evidence, more work is required to fully understand 
the roles of normal and misfolded N-CoR in normal and malignant 
hematopoiesis. To that end, the creation of myeloid lineage cell specific N-
CoR knockout mice and the generation of the phosphomimetic and 
constitutively misfolded N-CoR knock in mice models are currently 
underway. Successful creation of these models will greatly enhance our 











Figure 4.1. Dynamics of the N-CoR MCDL pathway in AML-M5. An oncogenic 
insult such as Akt hyper-activation in AML-M5 blasts brings about the aberrant 
phosphorylation of N-CoR. This disrupts the natural folding landscape of N-CoR 
protein resulting in the production of N-CoR with a misfolded N-CoR. The misfolded 
N-CoR protein is then transported from the nucleus where it normally exerts it 
functions to the Endoplasmic Reticulum (ER) where it accumulates. The activation of 
the Unfolded Protein Response (UPR) first attempts to refold this misfolded protein 
however due to the high protein load, there is an excessive aggregation and 
accumulation of misfolded N-CoR protein in these cells. In the permissive 
environment of the AML-M5 leukemic blasts where there is an activation of non-
regulated proteolysis, this misfolded N-CoR is degraded through the proposed 
cytoprotective 3rd arm of UPR/ ‘late’ cytoprotective UPR, first identified in APL. 
This results in the attenuation of ER stress, thus bypassing the effects of the cytotoxic 
UPR arm. This leads to the continued survival and growth of the AML-M5 leukemic 












Figure 4.2. Mode of action of N-CoR MCDL on Flt3 receptor expression in 
AML-M5. In normal monocytes, the expression of functional N-CoR results in the 
recruitment of the N-CoR co-repressor complex to the Flt3 promoter region. This 
prevents the binding of the transcriptional activators to the Flt3 promoter thus 
inhibiting the transcription and expression of the Flt3 receptor (upper panel).  
In AML-M5, post-translational loss of functional N-CoR due to Akt mediated 
phosphorylation results in the dissociation of the co-repressor complex from 
the Flt3 promoter region. This gives transcriptional activators access to the 
Flt3 promoter region. Binding of the transcriptional activators activates Flt3 
gene transcription and subsequent receptor expression. The re-expression of 
this pro-survival signaling receptor provides the leukemic blasts with a 
proliferative advantage contributing to AML-M5 disease pathogenesis (lower 
panel). 









Figure 4.3. Mechanism of action of agents which block the clearing of misfolded 
N-CoR in AML-M5. Protease inhibitors such as AEBSF and Kaletra inhibit the 
proteases involved in the non-regulated proteolysis of misfolded N-CoR. This 
inhibition results in the excessive accumulation of the misfolded N-CoR protein in 
the Endoplasmic Reticulum (ER) activating the cytotoxic UPR arm in AML-M5 
















Figure 4.4. Mechanism of action of agents which prevent the misfolding of N-
CoR in AML-M5. Agents such as Genistein and Akt inhibitors can prevent the 
aberrant phosphorylation of N-CoR in AML-M5. This results in the maintenance of 
N-CoR in its functional native conformation. This restores nuclear functions of N-
CoR such as Flt3 repression. Due to the restoration of N-CoR function, the AML-M5 
leukemic cells lose the proliferative advantage conferred by the Flt3 receptor and 
revert to the pathway of normal myeloid cell maturation, in conjunction with cellular 
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